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Primary cutaneous lymphomas are malignant lymphoproliferative disorders presenting in 
the skin without evidence of extracutaneous disease at the time of diagnosis. A diagnosis of 
 primary cutaneous lymphoma can only be made after excluding extracutaneous localizations 
by adequate staging procedures, comprising physical examination, total blood count, bone 
marrow aspiration/biopsy and computed tomography (CT) scan. It is important to separate 
primary cutaneous lymphoma from nodal non-Hodgkin lymphoma (NHL) that  secondarily 
 involve the skin, as these usually have a different clinical behavior and prognosis, and 
therefore might require different treatment strategies. For that reason, primary cutaneous 
 lymphomas have been included as distinct disease entities in the recent classification systems 
for lymphoid malignancies, such as the World Health Organization (WHO)-European Organi-
zation for Treatment of Cancer (EORTC) classification1 and WHO classification.2
While nodal NHL are predominantly of B-cell origin, primary cutaneous B-cell lympho-
mas (CBCL) only constitute a minority (20-25%) of all primary cutaneous lymphomas, the 
 remaining 75-80% being primary cutaneous T-cell lymphomas (CTCL).1 According to the  latest 
WHO-EORTC classification, the group of CBCL encompasses primary cutaneous marginal 
zone B-cell lymphoma (PCMZBL), primary cutaneous follicle center lymphoma (PCFCL) and 
primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT).1  The main clinico-
pathologic, immunophenotypical and molecular features of PCMZBL, PCFCL and PCLBCL-LT 
are summarized in Table 1. Histologically, PCMZBL is composed of a mixed infiltrate con-
taining small malignant B-cells, morphologically resembling marginal zone cells, lymphoplas-
macytoid cells and plasma cells. The plasma cells typically show monotypic intracytoplasmic 
immunoglobulin staining by immunohistochemistry. PCMZBL is an indolent type of NHL, with 
a 5 year disease-specific survival (DSS) of approximately 98%.3 Histologically, the tumor cells 
of PCFCL show a predominance of medium-sized to large centrocytes (cleaved cells) and vari-
able numbers of centroblasts. They can show a follicular, follicular and diffuse, but in most 
cases a diffuse growth pattern, a feature not related to prognosis.3 Clinically, PCFCL com-
monly presents with localized skin lesions on the head, in particular the scalp, or the trunk, 
is highly responsive to radiotherapy and has an excellent prognosis (see Table 1). PCLBCL-LT 
 characteristically shows a diffuse infiltrate of centroblasts and/or immunoblasts (cells with 
round nuclear configuration), and generally few admixed reactive T-cells. PCLBCL-LT usually 
presents on one or both legs in elderly patients, has an aggressive clinical course (5 year 
overall survival (OS) approximately 37%3), and should be treated with R-CHOP (rituximab, 
cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone). However, new thera-
peutical targets are wanted. Differentiation between PCFCL with a diffuse growth pattern and 
PCLBCL-LT can sometimes be difficult.
Recent reports have described a novel type of B-cell lymphoproliferative disorder (B-LPD) 
associated with the chronic use of immunosuppression, and more specifically with the use 
of methotrexate (MTX).4 As there have only been a few reports on this type of lymphoma 
occurring in the skin,5-9 it is not well characterized, which may cause a delay in its recognition.
This thesis includes a number of clinicopathologic, immunophenotypical and molecular 
 genetic studies in different subtypes of CBCL. The aims were (1) to define additional diag-
nostic markers that could aid in the differential diagnosis of PCFCL with a diffuse growth 
pattern from PCLBCL-LT, (2) to investigate molecular and genetic alterations in PCLBCL-LT 
underlying the pathogenesis of this type of lymphoma, and (3) to better define the group 
of MTX-associated B-LPD presenting in the skin, in order to find clinicopathologic and/or 
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 immunophenotypical characteristics that can be helpful in the early recognition of this rare 
type of lymphoma and are separate from PCFCL and/or PCLBCL-LT.
For the understanding of B-cell NHL in general, knowledge of physiological B-cell develop-
ment is crucial to gain insight into the classification of these lymphomas and the  molecular 
pathways involved in their pathogenesis. Therefore, this introductory chapter starts with 
an overview of normal B-cell development, the molecular alterations involved, and its re-
lationship with the different subtypes of B-cell NHL, including CBCL. Next, the difficulties 
in  differentiating PCFCL with a diffuse growth pattern from PCLBCL-LT are discussed. This 
is followed by a short overview of the current treatment options for PCLBCL-LT and the nu-
clear factor (NF)-κB signaling pathway is summarized, as a potential pathway for upcoming 
 targeted treatments. Finally, the rare entity MTX-associated DLBCL presenting the skin is dis-
cussed along with outstanding diagnostic issues with regard to its separation from PCFCL with 
a diffuse growth pattern and/or PCLBCL-LT.
 
Normal B-cell development
The normal development of B-cells from hematopoietic stem cells in the bone marrow 
with multilineage potential to effector B-cells in the peripheral blood or lymphoid tissues is 
 characterized by the formation of clonally diverse cell surface and secreted immunoglobulin 
B-cell receptors (BCR) which bind with high affinity to a specific antigenic epitope. Many 
 molecular genetic processes to establish these diverse BCR take place in different stages of 
the developmental pathway of B-cells. These different stages are not only characterized by 
the processes involved in BCR generation and diversity, but also have an inherent morphology 
and a distinct protein expression profile. An overview of the different stages of normal B-cell 
development is depicted in Figure 1.
Antigen-independent B-cell development
Immature B-cells are produced in the bone marrow and arise from hematopoietic stem cells in 
coordination with transcription factors early B-cell factor (EBF) and the E box protein E2A. EBF 
and E2A activate the B-cell gene expression program and initiate the process of VDJ-recom-
bination,10 comprising extensive rearrangements of the variable (V), diversity (D) and joining 
(J) segments of the heavy chain gene on chromosome 14 (VDJ-recombination). This first step 
in B-cell development is amongst others coordinated by the expression of  recombination 
activation genes 1 and 2 (RAG1 and RAG2) which are required for VDJ-recombination.11 The 
human immunoglobulin heavy chain consists of several different V-gene segments, D-gene 
segments and J-gene segments. Recombination between any D- and J-gene segments occurs 
by excision of the non-coding DNA and gene segments in between, followed by joining of any 
one of the V-segments to the rearranged DJ-segment (see Figure 2A). All gene segments in 
between that are not involved in these rearrangements will be deleted during VDJ-recombi-
nation. These events will create a vast amount of diversity of the heavy chain gene, which is 
even more enhanced by terminal deoxynucleotidyl transferase (TdT), which adds nucleotides 




































































































































































































































































































































































































































































   


















































   










































   








































   

































































































































































































































































































Figure 1. Normal B-cell development
The normal B-cell development from hematopoietic stem cell (HSC) in the bone marrow to effector cells in the 
peripheral lymphoid tissue and/or blood is depicted (adapted from: Kuppers et al, Nat Rev Immunol 2005).
 
Following VDJ-recombination, a pre B-cell receptor will now be assembled at the B-cell 
membrane, consisting of a rearranged heavy chain, a not yet rearranged lambda light chain, 
and signaling molecules Igα and Igβ.13 After recombination of the heavy chain gene, the 
 produced mu chain will induce recombination of the light chain genes in a same manner, 
although these genes lack D segments, and therefore only undergo VJ-recombination, before 
 generating transcripts linking the VJ-segment to the kappa or lambda constant region (Cκ or 
Cλ). Firstly, the kappa light chain on chromosome 2 will be rearranged. If non-productive, 
the second allele of the gene will undergo the same process. The lambda light chain gene 
on chromosome 22 will only undergo VJ-recombination if VJ-recombination of both alleles 
of the kappa light chain gene is unproductive.14 After successful VJ-recombination the light 
chain is complete. At this stage the B-cell receptor will be assembled at the B-cell receptor 
membrane, defining the immature B-cell stage.15 From this moment on transcripts from the 
rearranged heavy gene region will have VDJ segments joined to both the constant mu and 
the constant delta chain (Cµ and Cδ). By alternative splicing this will lead to expression of IgM 
and IgD subtypes of the B-cell receptor on the B-cell membrane. At this developmental stage, 
the B-cells are negatively selected for autoreactivity, and then enter the peripheral blood to 
migrate to peripheral lymphoid tissue.
 
Antigen-dependent B-cell development
Reaching secondary or peripheral lymph nodes, in the mantle of the germinal center, the 
B-cells are still called naïve, as they have not encountered an antigen yet. Subsequently, 
 antigen is presented to the B-cells by follicular dendritic cells, aided by follicular helper T-cells 





inducing transcription of the enzyme activation-induced cytidine deaminase (AID)17 and 
germinal center protein B-cell lymphoma 6 (BCL6).18 The B-cells enter the primary  follicle, 
where they rapidly proliferate as centroblasts. BCL6 controls B-cell activation, differentiation, 
susceptibility to DNA damage and apoptosis during this proliferative phase of the germi-
nal center reaction.19 By proliferating, the centroblasts form germinal centers and push out 
the naïve, non-antigen triggered B-cells to the periphery of this germinal center, forming a 
mantle zone. Characteristic for this developmental stage, the centroblasts undergo somatic 
 hypermutation (SHM) during proliferation, leading to subclones of the immunoglobulin gene 
with increased affinity for the antigen. This process involves the introduction of point muta-
tions in the V gene segments of the heavy and light chain genes, leading to further diversity 
of the antigen receptor, coupled with selection of the B-cell with the highest affinity B-cell 
receptor for the presented antigen. The presence of AID is required for SHM to occur,20 and 
catalyzes the initiation of SHM by deaminating cytidines on DNA. Subsequently, error-prone 
repair mechanisms will introduce somatic mutations.21 After this proliferative phase and 
the process of SHM, the centroblasts differentiate into centrocytes, which migrate to the 
 opposite side of the germinal center. There, the antigen is again presented to the B-cells 
with help of TFH and follicular dendritic cells. Centrocytes with insufficient affinity matura-
tion for the selected antigen will undergo apoptosis, but centrocytes with high affinity will 
undergo class switch recombination (CSR). This is a process in which the entire VDJ gene 
segment of the immunoglobulin heavy chain gene is transferred to a constant region down-
stream of the Cµ, deleting all DNA in between. The VDJ gene segment is then linked to either 
the Cγ, Cµ, Cα, or Cε gene segment, finally leading to production of either IgG, IgM, IgA, or 
IgE,  respectively. Like for SHM, without the presence of AID CSR cannot occur,20 although 
 separate domains of AID are required for both processes.22 The activated and class-switched 
B-cells finally become effector B-cells (plasma cell or memory B-cell), either secreting these 
immunoglobulins  (plasma cells) or expressing immunoglobulins as surface receptor (memo-
ry B-cells). The transition from centrocyte to effector B-cell is coordinated by combined B-cell 
receptor signaling and CD40 triggering through immune cells in the germinal center. This 
activation induces transcription factors nuclear factor-κB (NF-κB) and interferon regulatory 
factor 4 (IRF4), which in turn inhibit transcription of BCL6.23 If transcription factor paired 
box protein 5 (PAX5) is not downregulated, centrocytes differentiate into memory B-cells.24 
On the other hand, downregulation of PAX5 by a not yet elucidated mechanism in activated 
centrocytes leads to the release of repression of X-box binding protein 1 (XBP1) and J chain 
and concomitant upregulation of PRDM1 (PR domain containing 1, with ZNF domain)/Blimp1 
(B-lymphocyte-induced maturation protein 1) and IRF4 that drives the B-cells further towards 
plasma cell differentiation.25 
Stages of B-cell development and corresponding non-Hodgkin lymphomas
At several stages of normal B-cell development, B-cells are at risk to acquire genetic  lesions 
that can facilitate malignant transformation, as the genetic mechanisms responsible for 
 generating BCR diversity also induce deleterious genetic events. The B-cell NHL usually 
shows morphological, immunohistochemical and molecular resemblance to a specific B-cell 
 developmental stage, which consequently is its normal counterpart (Figure 3). Therefore 
knowledge of normal B-cell development is crucial to understand B-cell lymphomagenesis 
and classification. 
22
1 Figure 2. V(D)J recombination and B-cell development  
(A) In VDJ rearrangement, joining of a D segment to a J segment (DJ-recombination) is the first to occur,  followed 
by joining of a V segment to this newly formed DJ-segment. (B) Heavy and light chain proteins are assembled 
from the late pro B-cell phase on, occurring after DJ-recombination has finished, and at the pro B-cell phase, 
these proteins reside in the cytoplasm. Pre B-cells express a pre B-cell receptor on the cell surface containing 
a germline light chain. The actual B-cell receptor with rearranged heavy and light chain is expressed from the 
stage of immature naïve B-cell. After antigen-activation, isotype switching of the B-cell receptor  occurs, leading 
to secretion of IgG, IgA, IgM or IgE in effector plasma cells, or expression of one of these four isotypes on the 




The presumed cell of origin is reflected in the neoplastic cells by tumor cell morphology, 
immunophenotype and gene expression profile. Consistently, PCFCL tumor cells have the 
morphology of large follicle center cells, express germinal center marker BCL626  and show 
the gene expression profile of a germinal center B-cell (GCB).27 PCLBCL-LT has the tumor 
cell morphology of an immunoblast (lymphocytes that are antigen-activated and will under 
normal circumstances further differentiate into effector B-cells), demonstrates immunohis-
tochemical expression of B-cell activation-related markers IRF4/multiple myeloma oncogene 
1 (MUM1) and forkhead box protein 1 (FOXP1)28 and has the gene expression profile of an 
 activated B-cell (ABC).27 The large group of nodal DLBCL can also be subdivided into two 
groups with the germinal center B-cell or the activated B-cell as postulated normal coun-
terpart (GCB-DLBCL and ABC-DLBCL, respectively).29 As in primary cutaneous large B-cell 
lymphoma, nodal GCB-DLBCL has a more favorable prognosis as compared to ABC-DLBCL, 
although this difference is less pronounced (80% versus 45% 5 year OS, respectively).30
 
Maturation arrest in primary cutaneous large B-cell lymphoma, leg type
The ABC-like genotype of both PCLBCL-LT and ABC-DLBCL implies that both types of NHL 
are derived from B-cells that are blocked in differentiation in the transitional stage between 
germinal center B-cell and plasma cell.27,29 In nodal DLBCL, several genetic mechanisms have 
been described that might (in part) be responsible for this differentiation arrest. In nodal 
ABC-DLBCL several inactivating genetic events occur in PRDM1, of which PRDM1 or Blimp1 
is the functional protein and which is essential for plasma cell differentiation, including 
 mutations and chromosomal deletions.31,32  Other molecules driving B-cells towards plasma 
cell differentiation include FOXP1 and IRF4, and sporadic genetic alterations, such as translo-
cations involving these genes, also occur in nodal DLBCL.33,34 
Previous immunohistochemical studies of PCLBCL-LT have shown that BCL6 is expressed 
in more than half of the cases, IRF4 and FOXP1 are nearly always expressed by the tumor 
cells, and that no substantial expression of Blimp1 could be detected.28 In the context of 
normal B-cell development, the expression of germinal center marker BCL6 together with 
post-germinal center/B-cell activation markers IRF4 and/or FOXP1 seems aberrant, and also, 
the  absence of Blimp1 expression despite expression of IRF4 and/or FOXP1 is unexpected, as 
it is normally induced by both transcription factors. However, knowledge of potential under-
lying genetic mechanisms explaining the aberrant immunohistochemical expression of these 
 transcription factors in PCLBCL-LT is limited.
24
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Figure 3. B-cell development and concordant (non) Hodgkin lymphomas, including primary 
cutaneous large B-cell lymphomas 
Adapted from: Kuppers et al, Nat Rev Immunol 2005.
Differentiation between PCFCL and PCLBCL-LT
Both PCFCL with a diffuse growth pattern and PCLBCL-LT show a diffuse population of 
large neoplastic B-cells, and differentiation between conditions, which is important from a 
 therapeutic and prognostic point of view, can sometimes be difficult. While in the EORTC clas-
sification distinction between PCFCL and PCLBCL-LT was primarily based on site (leg versus 
non-leg),35 in the WHO-EORTC classification1 and the WHO 2008 classification2 differentiation 
is mainly based on cell morphology, i.e. large cells with cleaved nuclei (centrocytes) in PCFCL 
and large B-cells with round nuclei (centroblasts and immunoblasts) in PCLBCL-LT.  
The anatomical location of the cutaneous lesions can still be a helpful characteristic, but is 
not decisive. However, the predominant morphological subtype is sometimes a matter of 
debate. In such difficult cases the presence of a considerable number of admixed T-cells, 
the presence of a stromal reaction, as well as demonstration of (remnants of) follicular 
 dendritic cell networks by staining with appropriate immunohistochemical antibodies (CD35 
or CD21) may serve as useful additional arguments suggesting a diagnosis of PCFCL. More-
over, as  PCLBCL-LT, unlike PCFCL, characteristically shows strong expression of B-cell lym-
phoma 2 (BCL2), IRF4/MUM1 and FOXP1, this phenotypic profile may be used as a helpful 
adjunct supporting a diagnosis of PCLBCL-LT.26,28 Still, as BCL2, MUM1 and FOXP1 are also 
expressed by a small minority of PCFCL, these markers cannot be used as a golden stan-
dard to  differentiate between both conditions. In Table 1 the differences between PCFCL 
and PCLBCL-LT in the current classification systems are summarized. In a minority of cases 




 distinguish the two subtypes of PCLBCL.36
Molecular genetic studies
Genetic differences between PCFCL and PCLBCL-LT have also been observed. Array-based 
comparative genomic hybridization (CGH) studies showed more frequent amplification of 
chromosomal region 2p16.1 and loss of 14q11.2-q12 in PCFCL, while deletion of complete 
chromosome arm 6q and of a region corresponding to chromosome region 9p21.3 were 
preferentially detected in PCLBCL-LT.37 Detailed molecular analysis of this region by multiplex 
ligation-dependent probe amplification (MLPA) in combination with promoter hypermethy-
lation assays in a relatively large cohort of PCLBCL-LT furthermore showed that inactivation 
of cyclin-dependent kinase inhibitor 2A (CDKN2A), situated on 9p21.3, was associated with 
an unfavorable 5 year disease specific survival.38 The gene expression profiles of PCFCL and 
 PCLBCL-LT are to a considerable extent concordant with normal germinal center B-cells/
GCB-DLBCL and activated B-cells/ABC-DLBCL, respectively. Differences in gene expression 
 between the two subtypes of PCLBCL include higher expression of immunoglobulin mu heavy 
chain enhancer and constant region (IGHM), proto-oncogenes Pim kinases 1 and 2 (PIM1 and 
PIM2), and transcription factors IRF4 and octamer transcription factor 2 (OCT2) in  PCLBCL-LT. 
Serine protease inhibitor, Kazal type 2 (SPINK2) showed higher expression in PCFCL.27 A 




Differences in microRNA profiles can be detected between various types of tumors and might 
therefore be helpful in the differential diagnosis between tumor subtypes.  MicroRNAs are 
 approximately 22 nucleotide long non-coding RNAs. They are transcribed from their DNA 
 locus by RNA polymerase II in a primary microRNA (pri-microRNA) complex consisting of a 
loop and two strands containing a regular and a complementary star microRNA  sequence. The 
RNase III enzyme Drosha subsequently recognizes and cleaves this structure,  forming a hair-
pin structure (pre-microRNA). Exportin 5 then exports the pre-microRNA to the  cytoplasm, 
where the RNase enzyme Dicer cleaves off the loop of the hairpin, releasing both microRNA 
sequences, which are now called mature microRNAs. Potentially, both microRNA variants 
of one locus can be functional, but usually one variant dominates. The mature microRNA 
is  finally incorporated into a RNA-induced silencing complex (RISC) to exert its function. 
Through this RISC, microRNAs have the potential to regulate gene expression of their target 
genes. They are known to be able to inhibit translational initiation by blocking ribosomes. 
They can also directly target mRNA at the 3 prime untranslated region leading to degrada-
tion of the molecule.39 These interactions usually rather lead to fine-tuning of protein levels 
than complete silencing of the target gene.40 An overview of the biogenesis of microRNAs is 
depicted in Figure 4. 
MicroRNAs play a role in normal human hematopoiesis, which was firstly demonstrated by 
the detection of three microRNAs (miR-142, miR-181 and miR-223) which were specifically 
encountered in hematopoietic tissues.41 In B-cell development, a crucial role is found for 
miR-150, which is not expressed in progenitor B-cells, but shows high expression levels in 
mature B-cells. MiR-150 controls B-cell differentiation by targeting transcription factor and 
proto-oncogene c-MYB,42 which, amongst others, is one of the critical master regulators of 
B-cell proliferation in germinal centers.43 The miR-17~92 cluster (containing miR-17, miR-18a, 
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miR-19, miR-20a and miR-92a) is also essential for B-cell development, as absence of these 
microRNAs in mice leads to a block of the differentiation from pro B-cell to pre B-cell phase.44
Figure 4. MicroRNA biogenesis
The potential role of microRNAs in oncogenesis is emphasized by reports of several cancer 
types showing microRNA profiles that are significantly different as compared to normal cells 
from the same tissue type, which also accounts for hematopoietic tumors (reviewed in 45). In 
nodal DLBCL, microRNA research has to a large extent been focused on the identification of 
microRNAs separating GCB-type from ABC-type DLBCL for diagnostic purposes. Although con-
flicting results have been reported, the most frequently encountered microRNA alterations 
are upregulation of miR-155, miR-21, miR-221 and miR-222 in ABC-type DLBCL as compared 
to GCB-type DLBCL as detected by microarray profiling and/or Real Time-polymerase chain 
reaction (RT-PCR).46-54 Furthermore, upregulated expression of miR-21 has been reported to 
have an adverse prognostic impact in nodal DLBCL.50
The microRNA profiles of PCFCL and PCLBCL-LT are to a large extent unknown. A recently 
published study did perform quantitative PCR (qPCR) for a limited set of microRNAs on a 
group of PCFCL with the focus on comparison with PCMZL. A trend of higher expression miR-




New therapeutic targets for PCLBCL-LT
For a long time, optimal chemotherapy treatment regime for all PCLBCL-LT patients has been 
the same: CHOP or CHOP-like chemotherapy, concordant with treatment of nodal DLBCL. A 
recent improvement in CHOP chemotherapy has been the introduction of rituximab (mono-
clonal anti-CD20 antibody) to the chemotherapy regimens since 2001. Overall survival of 
nodal DLBCL has since then improved with 15 percent.56 One study in PCLBCL-LT  con cer ning 
the addition of rituximab to polychemotherapy also showed an increase in complete re-
sponse rate and 3-year specific survival rate in patients receiving additional rituximab,57 and 
treatment with rituximab-CHOP (R-CHOP) has been widely accepted as first choice treatment 
option.36
For a large part, the unfavorable clinical outcome of PCLBCL-LT seems to be related to the 
 aggressive nature of the disease. Despite initial response to treatment with polychemo-
therapy, many patients have rapid recurrences, show progressive disease with secondary 
nodal and visceral involvement and eventually succumb to the disease. Unfortunately, due to 
age or age-related comorbidity, not all patients are eligible for polychemotherapy. Both the 
inadequacy of current chemotherapy treatment in some patients and the not being eligible 
for chemotherapy in others, urges for new, additional treatment options in PCLBCL-LT.
In general in cancer research, the majority of new potential targets for treatment are 
 elaborately tested in cell lines of the tumor type investigated. Unfortunately, no cell lines of 
 PCLBCL-LT are currently available, hampering research options for treatment improvement. 
Due to previously mentioned similarities between PCLBCL-LT and nodal ABC-DLBCL, treat-
ments that are experimentally investigated in this type of nodal lymphoma, might also be of 
interest in PCLBCL-LT. Therefore, it is of great interest to further investigate to what extent 
PCLBCL-LT actually resembles nodal ABC-DLBCL and whether therapeutic targets in ABC- 
DLBCL can also be targeted in PCLBCL-LT to optimize treatment outcome.
 
Nuclear factor-κB
Nuclear factor-κB (NF-κB) comprises a family of transcription factors controlling genes that 
play a critical role in B-cell activation, proliferation and resistance to apoptosis. The NF-κB 
family has five members: p65 (RelA), p50 (NF-κB1), p52 (NF-κB2), RelB and c-Rel. In non- 
stimulated cells, these NF-κB proteins and their precursor proteins reside in the cytoplasm in 
an inactive form bound to NF-κB inhibitory proteins (IκBs). The NF-κB pathway signals down-
stream after activation through various surface receptors, including the B-cell receptor. Two 
major signalling pathways account for the activation of NF-κB (Figure 5). In the  canonical 
 signalling pathway, signal transduction events lead to activation of the IκB kinase (IKK) com-
plex resulting in phosphorylation and proteasomal degradation of IκB. Heterodimers and ho-
modimers of p50, p65 and c-Rel can then be translocated to the nucleus to regulate gene 
transcription. The alternative pathway is characterized by IκB kinase complex activation 
through NF-κB induced kinase (NIK), eventually leading to processing of the p52 precursor 
subunit into active p52, which translocates to the nucleus and forms a heterodimeric com-
plex with RelB.58,59 
The NF-κB pathway has been implicated to play a role in the pathogenesis of different types 
of haematological malignancies, including nodal DLBCL. NF-κB activation is characteristic 
for ABC-DLBCL, although it is also encountered in a minority of GCB-DLBCL.60 Constitutive 
activation of the pathway is required for survival of ABC-DLBCL cells in vitro.61 ABC-DLBCLs 
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 preferentially express known NF-κB target genes,62 which amongst others include members of 
the anti-apoptotic families BCL263 and IAP,64 and proliferation-related genes such as c- MYC65 
and IRF4.61 Furthermore, a small molecule inhibitor of IκB kinase, an essential molecule in the 
activation of NF-κB, is selectively toxic to ABC-DLBCL cell lines.66 
Mutations of several of the genes involved in the NF-κB pathway cause activation of NF-κB 
in DLBCL.60  The genes most frequently affected by genetic aberrations are TNFAIP3 (A20), 
CD79B, CARD11 (CARMA1), and MYD88, which all can contribute to constitutive  activation of 
the NF-κB pathway. In two-third of investigated cases of nodal ABC-type DLBCL, one or more 
of these genes are affected.67 The NF-κB pathway inhibitor TNFAIP3 is commonly downregu-
lated by (chromosomal) homozygous deletion or hemizygous deletion and hypermethylation 
of the promoter region of the remaining allele,60,68 while the CD79B, CARD11, and MYD88 
genes are frequently targeted by mutations that lead to activation of the NF-κB pathway.67,69,70 
Figure 5. The nuclear factor-κB signaling pathway in diffuse large B-cell lymphoma
The activation of the NF-κB pathway in diffuse large B-cell lymphomas via the B-cell receptor and the Toll-like recep-
tor (TLR) and IL-1 receptor (IL-1R) is depicted. The genes that commonly show genetic aberrations in nodal DLBCL 
and lead to constitutive pathway activation are dark grey. Signaling proteins that are under investigation for thera-
peutical targeting and thereby inhibiting the NF-κB pathway are represented by gene names in bold and a selection 




Together, these results suggest that activation of the NF-κB pathway is involved in the patho-
genesis of ABC-type DLBCL and that this pathway can serve as a potential therapeutic target 
in DLBCL. Indeed, several signalling proteins in the NF-κB pathway have already been selec-
tively targeted in vitro and in vivo to explore potential new treatment strategies, including 
SYK (by fostamatinib),71 BTK (ibrutinib),72,73 PKCβ (enzastaurin/sotrastaurin),74,75 and MALT1 
(phenothiazines)76,77 (see Figure 5). Moreover, the mutational status of especially CARD11 
and CD79B and to a lesser extent MYD88 has been linked to sensitivity or resistance to 
drugs targeting the NF-κB pathway,74,78 and their role therefore seems essential in tumor cell 
 survival in nodal ABC-type DLBCL.
 
Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin
PCLBCL-LT should be differentiated not only from PCFCL with a diffuse proliferation of large 
B-cells, but also from DLBCL secondarily involving the skin and from immunodeficiency- 
associated B-cell lymphoproliferative disorders (B-LPD) with large tumor cell morphology, 
such as methotrexate (MTX)-associated B-LPD. The drug MTX was primarily developed as 
an inhibitor of the dihydrofolatereductase enzyme, thereby inhibiting cell cycle division, and 
therapeutically used in high doses in acute leukemias.79 Later on, it was discovered that low 
dose MTX therapy was effective in treating autoimmune diseases, such as rheumatoid arthritis 
and psoriasis.80 While MTX was first reported to be administered in patients with  rheumatoid 
 arthritis and psoriasis in 1951,80 specific MTX-associated B-LPD were not  described until 1985.4 
Since that time, several reports of MTX-related NHL have been  published, especially in pa-
tients with underlying rheumatoid arthritis. Most of these lymphomas were B-cell NHL, main-
ly DLBCL, that could be Epstein Barr virus (EBV)-related and -unrelated.81 Of interest, there 
are several reports of spontaneous regression of NHL after withdrawal of MTX,  underlining 
the potential pathogenetic role of MTX in these lymphomas.82 Furthermore, these reports 
of spontaneous regression warrant for a careful wait-and-see approach in these patients, 
before considering more aggressive treatment regimens containing polychemotherapy and/
or radiotherapy. 
Reports of MTX-therapy associated B-LPD primarily or secondarily involving the skin are very 
rare, in particular those presenting with only skin lesions.6-9,83 To ensure optimal management 
and avoid overtreatment, MTX-associated B-LPD presenting in the skin should be differen-
tiated from PCFCL with a diffuse growth pattern, and from PCLBCL-LT. However, not much 
is known about histomorphological and/or immunophenotypical features of these cases 
that might facilitate recognition of this rare type of lymphoma and separate them from the 
 ‘regular’ types of PCLBCL.
 
Thesis outline
As differentiation between PCFCL with a diffuse growth pattern and PCLBCL-LT can some-
times be difficult, in chapter 2 the previously described higher expression of IGHM by gene 
expression profiling in PCLBCL-LT as compared to PCFCL27 is validated on a large cohort of 
PCFCL and PCLBCL-LT, in search for an adjunct immunohistochemical diagnostic marker dis-
tinguishing the two subtypes of CBCL. Formalin-fixed and paraffin-embedded (FFPE) tumor 
biopsy specimens were immunohistochemically stained for heavy chain and light chains, 
 including immunohistochemistry for IgM.
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In chapter 3 the complete microRNA profiles of both PCFCL and PCLBCL-LT are determined 
by next generation high-throughput sequencing on frozen tumor biopsies and compared 
with the profile of in vitro activated B-cells, aiming to detect microRNA signatures associated 
with diagnosis and/or prognosis. The results are validated by qPCR on FFPE tumor biopsy 
specimens. Furthermore, this chapter explores whether these differences are similar to the 
 differences in microRNA profiles found between nodal GCB-DLBCL and ABC-DLBCL.
In chapter 4 the genes that show genetic aberrancies in nodal DLBCL and lead to constitu-
tive activation of the NF-κB pathway are explored for deletions, mutations and/or epigenetic 
 silencing in a set of PCLBCL-LT by fine-tiling comparative genomic hybridization (FT-CGH), 
DNA sequencing and/or methylation specific melt curve analysis (MS-MCA). The aim is to 
find out whether aberrant NF-κB pathway activation is a feature of PCLBCL-LT, and whether 
treatment targeting specific molecules in this pathway might be suitable for patients with 
PCLBCL-LT.
Chapter 5 investigates whether maturation arrest of PCLBCL-LT in the activated B-cell stage 
might be related to (genetic) aberrancies in transcription factors that are involved in matu-
ration of the B-cells beyond this stage, including FOXP1, PRDM1/Blimp1 and IRF4. We there-
fore assess alterations in these transcription factors in a set of PCLBCL-LT by FT-CGH, DNA 
sequencing, qPCR, and immunohistochemistry.
Chapter 6 explores the clinical, pathological and immunophenotypical characteristics of 
MTX- associated DLBCLs presenting in the skin and compares these features with those of 
PCFCL and PCLBCL-LT, aiming to find differences that could aid in the differential diagnosis of 
these NHL.
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Abstract 
In the World Health Organization (WHO) 2008 classification 2 main types of primary  cutaneous 
large B-cell lymphomas (PCLBCLs) are distinguished: primary cutaneous follicle center lym-
phoma (PCFCL) and primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT).  PCFCL 
has a 5-year overall survival rate of 95%, and PCLBCL-LT of approximately 50%. Expression 
profiling studies have shown higher RNA expression of the IgM heavy chain in  PCLBCL-LT 
compared with PCFCL. To find out whether this difference could also be demonstrated at the 
protein level, we performed immunohistochemical staining for B-cell receptor heavy and light 
chains on skin biopsies from 53 patients with PCFCL and 40 patients with PCLBCL-LT. All 40 
cases of PCLBCL-LT consistently showed cytoplasmic staining for IgM, in 18 of them with co-
expression of IgD. In contrast, only 5 of the PCFCL cases showed cytoplasmic staining for IgM 
and/or IgD, including all 3 PCFCLs presenting on the leg. Hence, staining for IgM on paraffin- 
embedded sections seems to be an additional tool for differentiating between the 2 entities in 
clinical pathology practice. Analogous to other nodal and extranodal large B-cell lymphomas, 
 expression of IgM in PCLBCL seems to be related to an activated B cell-like phenotype. Finally, 




Primary cutaneous large B-cell lymphomas (PCLBCLs) are a group of malignant lympho-
proliferative disorders presenting in the skin with no evidence of extracutaneous disease 
at the time of diagnosis.1 In the World Health Organization (WHO)-European Organization 
for  Research and Treatment of Cancer (EORTC) classification2 and the WHO 2008 classifica-
tion3 2 main types of PCLBCL are distinguished: primary cutaneous follicle center lympho-
ma (PCFCL) and primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT). 
PCFCL is considered an indolent type of lymphoma (5-y survival > 95%), predominantly 
 presenting with  localized skin lesions on the head or the trunk,4 whereas PCLBCL-LT has a 
more  aggressive clinical course (5-y survival approximately 50%) and most often presents on 
the legs.5  Distinction between the different subtypes of PCLBCL is important, as it dictates 
the first choice of treatment, that is, radiotherapy in PCFCL and the combination of anthra-
cyclin-based chemotherapy and rituximab in PCLBCL-LT.6 In the EORTC classification of 1997, 
the subdivision was made solely on the localization of the tumor (head/trunk versus legs).1 
In the WHO- EORTC classification of 2005 and WHO classification of 2008, distinction is pri-
marily based on  morphological criteria, namely the absence or presence of confluent sheets 
of centroblasts and/or immunoblasts, designated previously as cleaved cell versus round cell 
morphology.7 Differentiation on the basis of morphology is sometimes a matter of debate. In 
such difficult cases the presence of a considerable number of admixed T-cells, the presence 
of a stromal reaction as well as demonstration of (remnants of) follicular dendritic cell net-
works by staining with appropriate antibodies (CD35 or CD21) may serve as useful additional 
criteria suggesting a diagnosis of PCFCL. Moreover, as PCLBCL-LT, unlike PCFCL, characteris-
tically shows strong expression of BCL2, IRF4/MUM1 and FOXP1, this phenotype profile may 
be used as a useful adjunct supporting a diagnosis of PCLBCL-LT.2 However, as BCL2, MUM-1 
and FOX-P1 are also expressed by a small minority of PCFCL, these markers cannot be used as 
a golden standard to differentiate between both conditions.6,8
Although PCLBCLs are suggested to have a distinct relationship with different stages of 
normal B-cell development, surprisingly little is known about the composition of the B-cell 
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 receptor (BCR) of this type of lymphoma. Expression profiling studies of our group have 
shown higher RNA expression levels of the IgM heavy chain of the BCR in PCLBCL-LT as com-
pared with  PCFCL.9 The aim of our current study was to find out whether this difference in 
expression  level could also be detected at the protein level by immunohistochemical staining. 
 Differences in immunohistochemical IgM expression could be of additional diagnostic value, 




Forty patients with PCLBCL-LT and 53 patients with PCFCL were selected from the archive 
of the Dutch Cutaneous Lymphoma Group. Characteristically, 33 of 40 cases of PCLBCL-LT 
presented with skin lesions on one or both legs, whereas 7 patients presented with skin 
lesions at other sites including the trunk (3 cases), head (3 cases), and arm (1 case). In the 
group of PCFCL 44 patients presented with localized skin lesions on the head or trunk, 6 
had more generalized lesions, but without involvement of the leg, while 3 patients had skin 
lesions on 1 or 2 legs at presentation. All cases had been classified by a panel of hematopa-
thologists and dermato(patho)logists according to the criteria of the WHO-EORTC classifi-
cation.1 All patients were adequately staged; physical examination, blood count, computed 
tomography scan, and bone marrow biopsy were performed and showed no signs of extracu-
taneous disease  manifestation at the time of diagnosis. Of all the patients, formalin-fixed 
and  paraffin-embedded pretreatment biopsy or excision tumor tissue was collected from 
 different hospitals in the Netherlands.
 
Antibodies and immunohistochemistry
Immunohistochemical staining was performed on 4 μm sections using standard procedures. 
After antigen retrieval by boiling for 10 minutes in 1.0 mmol/L ethylenediamine tetra-acetic 
acid (pH 8.0) for IRF4/MUM1 and BCL6, and in 10 mmol/L citrate buffer (pH 6.0) for κ, λ, 
IgM, IgG, IgA, IgD, and BCL2, tissue sections were incubated overnight with the different 
antibodies, listed in Table 1. Sections were then incubated for 30 minutes with PowerVision 
Poly-horseradish peroxidase. Subsequently, a 10-minute incubation with diaminobenzidine 
(DAB) solution (Sigma-Aldrich, Zwijndrecht, The Netherlands) for IRF4/MUM1, Bcl2 and Bcl6 
was performed, whereas slides with κ, λ, IgM, IgG, IgA, and IgD were incubated with DAB+ 
chromogen (K-3468, DAKO, Glostrup, Denmark) for 10 minutes. Finally, all slides were coun-
terstained with Mayer’s haematoxylin.
Data analysis
The data were analyzed with SPSS version 16.0. Descriptive statistics were used to describe 
the characteristics of the study population. Differences in immunohistochemical positivity for 
IgM, Bcl2, and IRF4/MUM1 between the 2 diagnosis groups were calculated with the χ2 test. 
Binary logistic univariate and multivariate regression modeling was used to determine the 
extent to which patient characteristics (independent variables) could differentiate between 
the diagnosis of PCFCL or PCLBCL-LT (dependent variable). In the multiple regression analysis, 
gender, age over 70, tumor localization on the leg(s), and immunohistochemical positivity 
for BCL2, IRF4/MUM1 and IgM were entered in a forward stepwise method with likelihood 
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ratio test, to assort the most optimal and feasible combination of parameters to predict the 
final diagnosis in patients with PCLBCL. P-values lower than 0.05 were considered to indicate 
statistical significance.
Table 1. Antibodies used in this study
Protein Clone Source Dilution
κ rabbit polyclonal DAKO, Glostrup, Denmark 1:16000
λ rabbit polyclonal DAKO, Glostrup, Denmark 1:16000
IgM rabbit polyclonal DAKO, Glostrup, Denmark 1:8000
IgG rabbit polyclonal DAKO, Glostrup, Denmark 1:8000
IgA rabbit polyclonal DAKO, Glostrup, Denmark 1:8000
IgD rabbit polyclonal DAKO, Glostrup, Denmark 1:4000
BCL2 mouse monoclonal DAKO, Glostrup, Denmark 1:200
BCL6 mouse monoclonal DAKO, Glostrup, Denmark 1:50




A summary of relevant clinical and follow-up data of the different groups is given in Table 2. 
Table 3 summarizes the results of the immunohistochemical staining.
 
PCLBCL-LT
In all 40 cases of PCLBCL-LT there was moderate to strong cytoplasmatic staining for IgM 
of almost all tumor cells. Of these cases, 18 showed coexpression of IgD, mainly with weak 
staining intensity (Figs. 1A-C). Except for 1 case without any detectable light chain expression 
of the tumor cells, all cases showed either monotypic κ (n = 26) or λ (n = 13) expression. The 
7 cases classified as PCLBCL-LT with presentation on the head, trunk, or arm showed similar 
results as the PCLBCL- LT presenting on the legs (Table 3). Membranous expression of BCL2 
was detected in most cases of PCLBCL-LT (36/40), as was nuclear expression of IRF4/MUM1 
(35/40), both of which were independent of the site of presentation. Nuclear expression of 
BCL6 was detected in approximately half of the cases (18/40).
PCFCL
Out of 50 cases of PCFCL presenting on the head or trunk 2 cases showed moderately strong 
cytoplasmatic staining of virtually all of the tumor cells for IgM, combined with coexpression 
of IgD. Except for 4 cases showing questionable expression of IgG or IgA in combination with 
monotypic κ or λ light chain restriction, 43 cases showed no expression of heavy or light 
chains at all (Figs. 1D-F). One case showed monotypic κ light chain expression without ex-
pression of a specific heavy chain. The IgM and IgD-negative cases showed evident positive 
internal controls, as the remains of the mantle zone in between the neoplastic cells did show 
expression of these 2 markers, sparing the neoplastic cells. In contrast, all 3 cases presenting 
on one or both legs showed strong cytoplasmatic expression of IgM and of κ (n = 2) or λ (n = 
1) light chain (Figs. 1G-I). There was no coexpression of IgD in these cases. 
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Table 2. Characteristics of the study population
PCLBCL-LT PCFCL
leg head/trunk leg head/trunk
Number of cases 33 7 3 50
Sex
    - male 12 5 1 39
    - female 21 2 2 11
Age (years)
    - median 78 80 70 58
    - range 47-92 60-86 68-83 21-81
Initial therapy
    - radiotherapy 13 5 3 40
    - polychemotherapy 12 1 0 3
    - chemoradiation 4 0 0 3
    - none 3 0 0 1
    - other 1 1 0 3
Follow-up (months)
    - median 19 26 30 54
    - range 2-121 5-72 26-32 1-264
Current status
    - A0 7 5 0 32
    - A+ 5 2 0 11
    - D0 4 0 2 6
    - D+ 17 0 1 0
    - unknown 0 0 0 1
A+ indicates alive with disease; A0, alive without disease; D+, death with disease; D0, death without disease; 
PCLBCL-LT, primary cutaneous B-cell lymphoma - leg type; PCFCL, primary cutaneous follicle center lymphoma.
The 2 patients with tumors on the head or trunk that expressed IgM and IgD were  treated 
with radiotherapy and are still alive without evidence of disease activity after 102 and 161 
months, respectively. One of these patients had a cutaneous relapse after 46 months of 
follow-up that was treated with chemotherapy resulting in complete remission. Two of the 
3  patients with PCFCL presenting on the leg died 26 and 30 months after radiation of the 
 primary tumor due to causes unrelated to the disease. In one of these patients, a cutaneous 
relapse occurred after 9 months of follow-up, which was successfully treated with additional 
radiotherapy. The third patient with PCFCL presenting on the leg was treated with radio-
therapy resulting in complete remission. However, he died with disseminated lymphoma 32 
months after initial diagnosis.
Twenty-two cases of PCFCL showed a (partly) follicular growth pattern of the neoplastic cells, 
whereas the remaining 31 cases, including the ones presenting on the leg(s), exhibited a dif-
fuse growth pattern. Expression of IgM (and IgD) was not restricted to either growth pattern. 
Membranous expression of BCL2 was detected in 9/50 cases presenting on the head or trunk, 
but in none of the 3 cases presenting on the leg(s). Nuclear expression of IRF4/MUM1 was 
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detected in only 1 PCFCL, presenting on the leg. Nuclear expression of BCL6 was detected in 
almost all cases (51/53).
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For BCL2 and BCL6 cases were considered positive if more than 50% of the tumor cells showed expression, the 
cut-off point for positivity of IRF4/MUM1 was 30%.
Κ indicates kappa light chain; λ, lambda light chain; Mum1, IRF4/MUM1; PCLBCL-LT, primary cutaneous B-cell 
lymphoma, leg type; PCFCL, primary cutaneous follicle center lymphoma.
Discriminative characteristics
Expression of BCL2, IRF4/MUM1, and IgM was significantly different between PCFCL and 
 PCLBCL-LT (P = 0.000). These 3 factors were also indicative for diagnosis in a univariate logistic 
regression model, with an accurate prediction percentage of 94.6% for IgM, 93.5% for IRF4/
MUM1, and 86% for BCL2 in our series. The clinical parameter tumor localization on the leg(s) 
was also correlated with the final diagnosis (accurate prediction 89.2%). In a logistic multiple 
regression model, using both clinical features and immunohistochemical staining procedures, 
positive staining for IgM and BCL2 was the most optimal combination to correctly classify 
cases of PCLBCL, with an accurate prediction of 95,7% in our series, which was only slightly 
more predictive than positive staining for IgM alone.
Discussion
In this study, intracytoplasmic expression of IgM was demonstrated to be significantly  different 
between the 2 types of PCLBCL, which are, PCFCL and PCLBCL-LT. All PCLBCL-LT showed 
strong protein expression of IgM, whereas only a minority (5/53) of PCFCL  demonstrated 
detectable intracytoplasmic IgM. This is consistent with previous reports demonstrating a 
 notable difference in IgM heavy chain gene expression between both entities.9 Moreover, 
using array-based comparative genomic hybridization, our group has shown loss of chromo-
some 14q32.33 containing the immunoglobulin heavy chain locus in 13 of 19 PCFCL, but 
only in 3 of the 12 PCLBCL-LTs.10 In the present study, not only PCLBCL-LT presenting on the 
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leg, but also PCLBCL-LT presenting on the trunk or head, showed strong expression of IgM, 
 implying that for lesions on the trunk and head IgM expression might be used as an additional 
marker in differentiating between PCFCL and PCLBCL-LT. Of note, the 3 PCFCLs that presented 
on the leg(s) also expressed IgM. Therefore, IgM expression does not seem to discriminate 
between both PCLBCL entities when presenting on the leg. 
Because of these results, we considered the possibility that the 3 cases of PCFCL  p resenting 
on the leg were classified incorrectly, but are nonetheless convinced that a diagnosis of 
 PCFCL is justified. All cases showed a predominantly cleaved morphology, lacked cohesive 
sheets of centroblasts and/or immunoblasts, were negative for BCL2 (3/3) and MUM1/IRF4 
(2/3), and were admixed with a considerable amount of small reactive T-cells. Moreover, 
2 of the 3 cases showed (remnants of) follicular dendritic networks, which also supports a 
diagnosis of PCFCL.
We previously reported that PCFCLs presenting on the leg have a significantly worse prog-
nosis than their counterparts on the head or trunk, with a 5-year disease specific survival of 
approximately 46%.6 It can therefore be argued that the expression of IgM in these PCFCL on 
the legs is part of a phenotype that shows a more malignant behavior than PCFCL occurring 
on the head or trunk. Hence, as exact classification of the type of PCLBCL Over 50% of nodal 
DLBCLs show immunohistochemical expression of IgM in the tumor cells.11,12 Furthermore, 
IgM expression was reported as an independent adverse prognostic parameter in all patients 
with DLBCL.11 High levels of IgM RNA are more frequently encountered in activated B-cell 
(ABC)-type DLBCL than in germinal center B-cell (GCB)-type DLBCL,13 which might in part ex-
plain the prognostic impact of IgM expression, as ABC-type DLBCL has a worse overall survival 
compared with GCB-type DLBCL.14 Previous reports have shown immunoglobulin expression 
in primary extranodal large B-cell lymphomas at other sites than the skin. Primary central 
nervous system (CNS) large B-cell lymphomas showed transcripts of IgM and IgD, confirmed 
at protein level by immunohistochemical staining for IgM in 11 out of 11 cases, with consis-
tent absence of IgG.15 Primary testicular large B-cell lymphoma also showed consistent immu-
nohistochemical expression of IgM,16 although some cases were reported to coexpress IgA or 
IgG. Both primary CNS large B-cell lymphoma and primary testicular large B-cell lymphoma 
almost invariably have an ABC-like phenotype.17,18 In contrast, primary large B-cell lymphoma 
of the bone does not show immunohistochemical IgM expression, but rather expression of 
IgG.19 However, this type of lymphoma is known for its predominant GCB phenotype and 
favorable survival.20 So, expression of IgM is encountered in both ABC-type DLBCL as well as 
some extranodal large B-cell lymphomas at immunoprivileged sites, which are also known for 
an ABC-like phenotype and decreased survival as compared with other large B-cell lympho-
mas. This is consistent with our finding that IgM is expressed in PCLBCL-LT and not in PCFCL, 
as PCLBCL-LT shows an ABC-like phenotype9 and is a more aggressive type of PCLBCL.
In normal B-cell maturation the BCR characteristically shows stepwise alterations.21 Mature 
naive B cells express membrane-bound IgM and IgD molecules, composed of rearranged, 
but unmutated Ig variable heavy chain and light chain genes. In secondary lymphoid tissues, 
these B cells encounter antigens in the germinal centers of secondary follicles. During the 
subsequent cell divisions, somatic hypermutations (SHM) diversify the variable region of the 
Ig genes. This process of so-called affinity maturation finally leads to selection for B cells 
with high affinity for the recognized antigens. Subsequently, these selected B cells receive 
growth and differentiation signals that promote class switch recombination (CSR) of the Ig 
heavy chain constant region by deletional recombination, leading to Ig heavy chain isotype 
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 switching. This process, yielding different classes of immunoglobulins, determines the final 
effector functions of the secreted immunoglobulin. 
Figure 1. Primary cutaneous large B-cell lymphomas 
Primary cutaneous large B-cell lymphoma, leg type (A-C). High power view showing a dense infiltrate of large 
non-cleaved lymphoid cells (A) (haematoxylin and eosin). The neoplastic cells show strong staining intensity for 
IgM (B) and moderate strong staining intensity for IgD (C).
Primary cutaneous follicle center lymphoma (D-F). Low (D) and high (E) power view showing a diffuse infiltrate 
of large cleaved lymphocytes admixed with scattered small lymphocytes. Immunohistochemistry for IgM (F) 
shows strong staining of some of the small lymphocytes and negativity for the large, neoplastic cells.
Primary cutaneous follicle center lymphoma presenting on the leg (G-I). Low (G) and high (H) power view show-
ing a diffuse infiltrate of large cleaved lymphocytes admixed with a considerable amount of small lymphocytes. 
Immunohistochemistry for IgM (I) shows strong staining of the large, neoplastic lymphocytes, sparing most of 
the small lymphocytes in between.
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Gene expression profiling,9 the presence of SHM22 and expression of activation-induced 
 cytidine deaminase (AID)22 and BCL6 strongly imply a germinal center experience in  PCLBCL-LT. 
The coexpression of BCL2 and IRF4/MUM1 seems aberrant in this context. However, coex-
pression of BCL2, BCL6 and IRF4/MUM1 is also frequently encountered in ABC-type  DLBCL,23 
and may be part of a malignant deregulating phenotype. Given this presumed germinal 
 center experience, the absence of CSR in PCLBCL-LT is surprising and might indicate a defect 
in the CSR mechanism. Derivation of PCLBCL-LT from the recently described subpopulation 
of memory B cells expressing IgM and IgD24 seems unlikely as this subpopulation consistently 
expresses CD27 and the tumor cells of PCLBCL in our study did not (5 cases of PCFCL and 5 
cases of PCLBCL-LT, data not shown). Collectively, these data point to a germinal center origin 
of PCLBCL-LT and defective CSR.
The RNA-editing enzyme AID is essential for CSR and deficiency of the AID is associated 
with impairment of CSR.25 AID expression was demonstrated in PCLBCL and levels of AID in 
 PCLBCL-LT seem to be higher than in PCFCL and normal lymph node tissue,22 so the absence 
of CSR in PCLBCL-LT cannot be explained by shortage of AID. Moreover, AID is required for 
CSR as well as for SHM,25 so AID must at least be partly functional in PCLBCL-LT, as this type of 
lymphoma shows evidence of SHM.22 In ABC-type DLBCL as well as in primary CNS large B-cell 
lymphoma it was suggested that CSR was impaired due to the high frequency of mutations 
in the switch regions of the constant chain, comprising both intra-Sµ and intra-Sγ deletion/
recombination events.15,26
In summary, we reported immunohistochemical staining for IgM on paraffin-embedded 
sections to be an easy additional tool to differentiate between PCFCL and PCLBCL-LT in 
clinical pathology practice. Analogous to other nodal and extranodal large B-cell lympho-
mas, expression of IgM in PCLBCL appears to be related to an ABC-like phenotype.  Finally, 
the expression of IgM (and IgD) in this type of lymphoma might imply defective CSR. 
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Abstract
Aberrant expression of microRNAs is widely accepted to be pathogenetically involved in nodal 
diffuse large B-cell lymphomas (DLBCLs). However, the microRNAs profiles of  primary  cutaneous 
large B-cell lymphomas (PCLBCLs) are not yet described. Its two main subtypes, i.e., primary 
cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) and  primary  cutaneous follicle 
center lymphoma (PCFCL) are characterized by an activated B-cell  (ABC)-genotype and a ger-
minal center B-cell (GCB)-genotype, respectively. We performed high-throughput  sequencing 
analysis on frozen tumor biopsies from 19 cases of PCFCL and PCLBCL-LT to  establish microRNA 
profiles. Cluster analysis of the complete microRNome could not distinguish between the two 
subtypes, but 16 single microRNAs were found to be differentially expressed. Single microRNA 
RT-qPCR was conducted on formalin-fixed paraffin-embedded tumor biopsies of 20 additional 
cases, confirming higher expression of miR-9-5p, miR-31-5p, miR-129-2-3p and miR-214-3p 
in PCFCL as compared to PCLBCL-LT. MicroRNAs previously described to be higher expressed 
in ABC-type as compared to GCB-type nodal DLBCL were not differentially expressed between 
PCFCL and PCLBCL-LT. In conclusion, PCFCL and PCLBCL-LT differ in their microRNA profiles. In 
contrast to their gene expression profile, they only show slight resemblance with the micro-
RNA profiles found in GCB- and ABC-type nodal DLBCL. 
Introduction
Primary cutaneous large B-cell lymphomas (PCLBCLs) are a group of malignant lympho-
proliferative disorders presenting in the skin with no evidence of extracutaneous disease at 
the time of diagnosis.1 In the latest World Health Organization (WHO) 2008 classification 
two main types of PCLBCL are distinguished: primary cutaneous follicle center lymphoma 
(PCFCL) and primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT).2 PCFCL 
is considered an indolent type of lymphoma (5 year overall survival (OS) > 95%), whereas 
PCLBCL-LT has a more aggressive clinical course (5 year OS approximately 40%).3 The two 
subtypes also show marked differences at a molecular level by array comparative  genomic 
hybridization4 and gene expression profiling. PCFCL and PCLBCL-LT have gene expression 
profiles corresponding to germinal center B-cell (GCB)-type diffuse large B-cell lymphoma 
(DLBCL) and activated B-cell (ABC)-type nodal DLBCL, respectively.5 Clinical distinction at the 
time of first diagnosis between these different subtypes of PCLBCL is important, as the first 
choice of treatment differs between the two entities. PCFCL can be adequately treated with 
radiotherapy, but the more aggressive behavior of PCLBCL-LT warrants for treatment with 
anthracyclin-based chemotherapy combined with rituximab.6 
MicroRNAs are approximately 22 nucleotides long non-coding RNA molecules that can 
 regulate translation of several specific target messenger RNAs (mRNAs). The two major 
 responsible mechanisms are inhibition of translational initiation by blocking ribosomes and 
direct targeting of mRNA at the 3 prime untranslated region leading to degradation of the 
molecule.7 Alterations in the expression of microRNAs contribute to the pathogenesis of dif-
ferent types of malignancies, including malignant lymphomas, but are also involved in normal 
development of hematopoietic cells.8 Although a role for microRNAs in the pathogenesis of 
nodal DLBCLs is generally recognized, little is known about the presence and significance of 
microRNAs in PCLBCL. In one recently published study, a limited set of microRNAs was inves-
tigated in PCFCL.9 
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In nodal DLBCL, much effort has been given to differentiate between the two major mo-
lecular subtypes, i.e. GCB-type DLBCL and ABC-type or non-GCB-type DLBCL, by means of 
expression of specific microRNAs or microRNA profiles. However, conflicting results concer-
ning this topic have been published. The most frequently encountered microRNA alterations 
are upregulation of miR-155, miR-21, miR-221 and miR-222 in ABC-type DLBCL as compared 
to GCB-type DLBCL as detected by microarray profiling and/or Real Time quantitative PCR 
(RT-qPCR).10-19 To date, the prognostic value of expression levels of specific microRNAs in no-
dal DLBCL remains unclear. Although higher expression of miR-222 correlating to a shorter 
progression-free  survival (PFS) was reproduced in more than one study,12,15,20 a correlation 
was not consistently found for other microRNAs. In addition, reported microRNA profiles 
 generated by  complete microRNA profiling that would distinguish between the two  subtypes 
of nodal DLBCL have no substantial similarities (Supplemental Table 1).12,14-18,21 To some  extent, 
the  observed variations might be explained by the different techniques used to  quantify 
 microRNAs, i.e. different microarrays or varying reference RNAs in RT-PCR experiments. Fur-
thermore, the techniques used to distinguish the two molecular subtypes from each other 
are not uniform. The encountered differences might on the other hand also reflect the pro-
found tumor  heterogeneity within the group of nodal DLBCLs.
In search of differences in the pathogenesis of PCFCL and PCLBCL-LT we investigated the 
microRNA profiles in PCLBCL by performing microRNA high-throughput sequencing. Several 
single microRNAs that were differentially expressed between PCFCL and PCLBCL-LT in our 
high-throughput sequence data were validated by RT-qPCR. Furthermore, we were interes-
ted in comparing the microRNA profiles of PCFCL and PCLBCL-LT with the (known) microRNA 
profiles of GCB- and ABC-type nodal DLBCL, in search for common pathogenetical pathways 




Frozen skin biopsy or excision material from primary tumors was collected from 6 patients 
with PCFCL and 13 patients with PCLBCL-LT from the archives of the Leiden University 
 Medical Center (Leiden, The Netherlands). Formalin-fixed and paraffin-embedded (FFPE) 
skin  biopsy material was available from 5 of these patients (2 PCFCL and 3 PCLBCL-LT cases) 
and an  additional 8 patients with PCFCL and 7 patients with PCLBCL-LT.  The diagnosis was 
based on the criteria of the WHO-EORTC and WHO 2008 classifications,1,22 and confirmed 
by a panel of hematopathologists and dermatologists, aided by several additional immuno-
histochemical stainings. The clinical data and expression of relevant immunohistochemical 
markers are summarized in Table 1. In all cases physical examination, computed tomography 
scan, bone marrow examination and peripheral blood counts did not show extracutaneous 
disease. Furthermore, FFPE lymph node excisions of 34 cases of nodal DLBCL were collected 
from the Leiden University Medical Center, the Diaconessenhuis (Leiden, The Netherlands) 
and the Reinier de Graaf Hospital (Delft, The Netherlands). Of those, 19 were ABC-type and 
11 were GCB-type, according to both Hans and Choi immunohistochemical algorithms,23,24 
the four samples with discrepancy between the two algorithms were discarded from further 
analysis. The tumor cell percentage was at least 75% in every tumor specimen, as shown 
by immunohistochemistry for CD20 and CD3. All tissue samples were handled in a coded 
 fashion,  according to the Dutch National Ethical guidelines (Code for Proper Secondary Use of 
Human Tissue, Dutch Federation of Medical Scientific Societies), waving the need for specific 
55
MicroRNA profiling of PCLBCL
3
appro val of the study by the ethical committee and patient informed consent. 
Human B-cells were purified from peripheral blood mononuclear cells isolated from buffy 
coats obtained from anonymous blood donors (Sanquin Bloodbank, Nijmegen, The Nether-
lands) and were in vitro activated subsequently (details are given in Supplemental Materials 
and Methods). 
MicroRNA library preparation, high-throughput sequencing and data analysis
Total RNA was extracted from the frozen tumor samples and activated B-cells using TRIzol and 
according to the protocol described by the supplier (Invitrogen, Carlsbad, CA, USA). Library 
preparation was to a large extent based on the SOLiD Total RNA-Seq Kit protocol (SREK protocol, 
Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) as described  previously (Sup-
plemental Materials and Methods).25 Subsequently, 0.5 nM per sample of the cDNA clusters 
generated was loaded onto the flow cells for massively parallel high- throughput  sequencing 
using the Illumina Genome Analyzer II (Illumina) performing sequencing-by- synthesis tech-
nology.  The raw sequencing data were extracted through standard Illumina pipelines. The 
primary sequencing data and are publicly available through the Gene Expression Omnibus 
(GEO) archive through accession GSE51359. Illumina sequence reads were aligned to the 
human genome (GRCh37/hg19) using the miRDeep2.0 algorithm,26  which  predicts pre-
cursor sequences and matches them to precursor microRNAs enlisted in the miRBase 18.0 
 database (http://www.mirbase.org). Only sequences with a minimum sequence length of 17 
bases were analyzed, allowing for a maximum mismatch of one base. Samples with less than 
100.000 microRNA reads were discarded from further analyses.27 The different micro RNAs 
were only included in the analyses if in at least half of the samples of at least one of the three 
analyzed groups (PCFCL, PCLBCL-LT or activated B-cells) the single microRNA read  number 
exceeded 0,01% of the total number of microRNA reads (100 reads/million). The samples 
were then analyzed for differential expression between the groups by the Bioconductor 
 package EdgeR,28 considering only mature microRNAs. Differential expression was considered 
statistically significant when a p-value below 0.05 was reached after multiple testing cor-
rection according to the Benjamini-Hochberg method.29 EdgeR transformed, normalized 
microRNA expression (in counts per million reads) were used for unsupervised hierarchical 
 clustering, running under R 2.14.2 software (http://www.r-project.org). The Norm Finder 
version 0.953 algorithm30 was used on high-throughput sequencing data to identify the 




Total RNA was isolated from 10 μm sections of FFPE tumor samples. Approximately 300 ng 
of total RNA from each sample (FFPE or frozen, same isolation as for the high-throughput 
sequencing) was reverse transcribed using the microRNA reverse transcription kit (Applied 
Biosystems). RT-qPCR was performed in duplicate using Taqman microRNA and control assays 
(Applied Biosystems). The output data were analyzed using CFX Manager software (Bio-Rad). 
The expression of the different microRNAs was analyzed using the ΔΔCt method expressed 
relative to the most stably expressed endogenous controls according to GeNorm.32 For more 
details see Supplemental Materials and Methods. Statistical analyses were performed using 
the Mann Whitney U test in IBM SPSS version 20 (SPSS Inc., Chicago, IL, USA) and the data 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































From 19 tumor samples (13 samples of PCLBCL-LT and 6 samples of PCFCL) and 4 samples of 
activated B-cells, microRNA libraries were generated and sequenced. Of these, two  PCLBCL-LT 
samples yielded less than 100.000 total microRNA reads (7.302 and 55.383 reads) and were 
discarded from further analyses.27 Mean microRNA read number in the other samples was 
4.139.515 (standard deviation 9.348.501). After alignment of the sequence reads in miRDeep 
2.0, 1921 different known precursor microRNAs were identified to be expressed in at least 
one sample. 328 precursor loci were identified as putative novel microRNAs. After discarding 
precursor microRNAs that showed low expression levels (see Materials and Methods), a total 
number of 238 different precursor microRNAs were included for further analysis. 
 
MicroRNA profiles of PCFCL and PCLBCL-LT
The most abundantly expressed microRNAs of the analyzed subgroups are represented in 
Figure 1. In PCLBCL-LT, miR-19b-3p and miR-19a-3p show the highest expression levels, and 
comprise 12% and 11% of the total microRNome, respectively. In PCFCL, these microRNAs 
also constitute a substantial part of the microRNome (7% and 6%, respectively), but miR-
150-5p is most abundantly expressed. The activated B-cells are to a large extent represented 
by miR-150-5p, comprising approximately one-fifth of the microRNome. Using NormFinder, 
miR-148b-3p, miR-25-3p, let-7c and let-7e-5p were the most stably expressed microRNAs in 
our complete study cohort (Supplemental Figure 1).
Unsupervised hierarchical clustering analysis of all samples using the 238 mature microRNAs 
of the precursor sequences identified did not result into distinct clustering of the two tumor 
types and/or the activated B-cells (Supplemental Figure 2).
Differential microRNA expression in PCLBCLs
Table 2 shows an overview of mature microRNAs that showed statistically significantly dif-
ferential expression between PCFCL and PCLBCL-LT. Under the given conditions (allowing a 
mismatch of 1 base pair), MiRDeep 2.0 did not categorize miR-129-1-3p and miR-129-2-3p as 
separate microRNAs. Recounting of both variants in the aligned sequence data derived from 
miRDeep 2.0 showed a markedly higher expression of miR-129-2-3p in PCFCL as compared 
to PCLBCL-LT. Similarly, miRDeep 2.0 was not able to differentiate between miR-9-1, -2 and 
-3 variants, because of the relatively short aligned sequences (no sequences containing (part 
of) the precursor microRNA outside the mature microRNA region). For the 16 differentially 
expressed microRNAs, unsupervised hierarchical clustering analysis was applied (Figure 2). 
According to this analysis, two groups are separated from each other, one containing all cases 
of PCFCL and two cases of PCLBCL-LT, the other group comprising of the remaining cases of 
PCLBCL-LT. The two cases of PCLBCL-LT clustering with the PCFCL cases showed a clinical pre-
sentation, tumor cell morphology and immunohistochemical profile with classical features of 
PCLBCL-LT. One of the patients received polychemotherapy combined with radiotherapy and 
died of lymphoma after 38 months; the other patient was solely treated with radiotherapy 
and is still alive without disease recurrence after 50 months of follow-up.
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Table 2. High-throughput sequencing: differential expression of microRNAs between PCFCL 
and PCLBCL-LT
MicroRNA
Reads per million, mean (SD)
Adjusted p-valuea
PCFCL PCLBCL-LT
miR-129-2-3p b 1.668 (3.260) 4 (8) 5.74E-15
miR-129-1-3p 184 (269) 18 (21) 2.10E-14
miR-1246 0 (0) 26 (45) 1.42E-5
miR-214-3p b 8.620 (14.534) 1.174 (1.232) 7.24E-4
miR-574-3p b 12.079 (14.180) 1.951 (1.392) 0.00266
miR-4485 6 (8) 77 (127) 0.00321
miR-222-5p 16 (14) 142 (126) 0.0108
miR-31-5p b 1.729 (995) 346 (385) 0.0129
miR-486-3p b 196 (194) 40 (43) 0.0133
miR-363-3p b 37 (27) 288 (535) 0.0153
miR-99a-5p b 9.843 (9.113) 2.168 (1.155) 0.0184
miR-574-5p 289 (184) 1.996 (5.654) 0.0442
miR-100-5p b 8.849 (6.850) 2.318 (1.400) 0.0442
miR-205-5p b 11.492 (12.787) 3.059 (2.818) 0.0442
miR-342-3p b 22.775 (24.636) 6.079 (3.992) 0.0442
miR-9-5p b 273 (309) 73 (74) 0.0442
a p-values Benjamini-Hochberg corrected; b microRNA included in RT-qPCR validation; PCFCL: prima-
ry cutaneous follicle center lymphoma, PCLBCL-LT: primary cutaneous large B-cell lymphoma, leg type. 
MicroRNA RT-qPCR validation
A selection of 11 differentially expressed microRNAs (marked in Table 3) was used for valida-
tion in a novel group of test cases. MiR-129-1-3p, miR-1246, miR-4485 and miR-222-5p were 
not validated because of the relatively low counts in both PCFCL and PCLBCL-LT samples. Of 
miR-574-5p, no Taqman PCR primer assay was available, because of dinucleotide repeats 
in the microRNA sequence that could interfere with the PCR. Assays for miR-148b-3p, miR-
25-3p, let-7c and let-7e-5p were included as reference microRNAs, along with widely used 
 reference RNAs U6 and RNU48. Of these six, miR-148b-3p, let-7e-5p and miR-25-3p were 
most stably expressed in the RT-qPCR experiments (according to GeNorm) and therefore used 
for normalization of the data. The expression of U6 and RNU48 was very variable in this sam-
ple set. Comparison of RT-qPCR performed on both RNA of frozen tumor material isolated for 
high-throughput sequence analysis and RNA isolated from FFPE sections of the same tumor 
sample (2 cases of PCFCL and 3 cases of PCLBCL-LT) showed high concordance (Supplemental 
Figure 3). With inclusion of all 20 FFPE PCLBCL samples in the analysis,  including 10 PCFCL 
and 10 PCLBCL-LT cases, we confirmed higher expression of miR-129-2-3p, miR-214-3p, miR-
31-5p and miR-9-5p in PCFCL as compared to PCLBCL-LT (p<0.05) (Figure 3). For the  other 
seven microRNAs, no statistically significantly differential expression was found  between 
 PCFCL and PCLBCL-LT. In addition to these differentially expressed microRNAs  resulting from 
the deep sequence analysis, we tested whether four microRNAs frequently reported to show 
higher expression in ABC-type compared GCB-type nodal DLBCL (miR-21-5p, miR-155-5p, 
miR-221-3p and miR-222-3p) were higher expressed in PCLBCL-LT. 
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Figure 2. Unsupervised hierarchical clustering analysis in PCLBCL samples of high-throughput 
sequencing, using 16 differentially expressed microRNAs 
PCFCL and PCLBCL-LT tend to cluster together in two subgroups, with only 2 cases of PCLBCL-LT clustering 
 together with the PCFCL cases.
 
However, no differential expression between PCLBCL-LT and PCFCL of these four micro-
RNAs was observed (Figure 4). Above that, unsupervised hierarchical clustering analysis of 
the high-throughput sequence data of our PCLBCLs using microRNA signature profiles that 
should be able to distinguish GCB-type from ABC-type DLBCL12,14,17 did not set apart PCFCL 
from PCLBCL-LT.
MicroRNA RT-qPCR analysis of GCB- and ABC-subtypes of nodal DLBCLs
Because of the inconsistencies in literature concerning microRNA profiling of nodal DLBCL 
and the varying references used in these studies, a set of well-defined GCB- and ABC-subtype 
nodal DLBCLs was subjected to microRNA RT-qPCR analysis, using the same conditions as for 
our PCLBCL FFPE samples. As in PCLBCL, GeNorm analysis showed that miR-148b-3p, miR-25-
3p, let-7e-5p were most stably expressed, and these three microRNAs were therefore used 
as reference microRNAs. We evaluated the expression of the four microRNAs that showed 
significantly higher expression in PCFCL as compared to PCLBCL-LT in our nodal DLBCL sam-
ples. The expression of miR-129-2-3p was indeed higher in GCB-type DLBCL as compared 
to the ABC-type (p=0.00), while the expression of miR-214-3p, miR-31-5p and miR-9-5p did 
not show statistically significant differences between both nodal subtypes. Four microRNAs 
frequently reported to show higher expression in ABC-type than in GCB-type nodal DLBCL 
(miR-21-5p, miR-155-5p, miR-221-3p and miR-222-3p) were included in the RT-qPCR analy-
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sis. However, in our group of nodal DLBCLs, of these four microRNAs, we could only confirm 
higher expression levels of miR-155-5p (p=0.01) and miR-222-5p (p=0.05) in ABC-type as 
compared to GCB-type DLBCL (Figure 4). 
 
Table 3. MicroRNAs in RT-qPCR validation: predicted targets 
MicroRNA Locationa Upb Potential target(s) and function
miR-129-2-3p 11p11.2 PCFCL SOX4 (B-cell) transcription factor
CDK6 regulator of cell cycle 
 progression
miR-214-3p 1q24.3 PCFCL PTEN negative regulator of cell cycle 
progression
EZH2 polycomb group gene silencer
miR-574-3p 4p14 PCFCL IL6 involved in NF-κB signaling
miR-31-5p 9p21.3 PCFCL PIK3C2A PI3K pathway component
CXCL12 chemokine attractant
RhoA metastasis promoting gene
NIK NF-κB signaling
miR-486-3p 8p11.21 PCFCL PTEN negative regulator of cell cycle 
progression
E2F1 regulator of cell cycle 
 progression
miR-99a-5p 21q21.1 PCFCL mTOR PI3K family member
miR-100-5p 11q24.1 PCFCL mTOR PI3K family member
miR-205-5p 1q32.2 PCFCL PTEN negative regulator of cell cycle 
progression
E2F1 regulator of cell cycle 
 progression 
miR-342-3p 14q32.2 PCFCL BCL2L10 BCL2 family member
miR-9-5p 1q22/5q14.3/15q26.1 PCFCL PRDM1/BLIMP1 B-cell transcription factor
FOXP1 (B-cell) transcription factor
NFκB1 = p50 NF-κB signaling
miR-363-3p Xq26.2 PCLBCL-LT CDKN1A = p21 regulator of cell cycle progres-
sion
 
a chromosomal location microRNA gene; bhigher expression in subgroup of PCLBCL.; PCFCL: primary cutaneous 
follicle center lymphoma; PCLBCL-LT: primary cutaneous diffuse large B-cell lymphoma, leg type.
Discussion
This is the first study to report complete genome-wide microRNA profiles of PCLBCLs, and com-
paring PCFCL and PCLBCL-LT subtypes. By use of next generation high-throughput  microRNA 
sequence analysis, we provided microRNA profiles of these tumors on frozen  biopsy samples, 
accurately exploring both quantitative and qualitative aspects of all  microRNAs. The complete 
microRNomes of PCLBCL-LT and PCFCL did not allow their separation by unsupervised hierar-
chical clustering, and PCLBCL-LT did not cluster together with activated B-cells, its postulated 
normal counterpart (Supplemental Figure 1). The list of expressed and quantified microRNAs 
generated from this experiment was the basis for selecting specific microRNAs for RT-qPCR 
confirmation on FFPE tumor tissue of both lymphoma subtypes. The use of high-throughput 
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sequencing also enabled us to identify 328 putative novel microRNAs expressed in our sam-
ples, of which further validation was not performed and is warranted. Furthermore, these 
sequence data were also instrumental in selecting stably expressed reference microRNAs 
for subsequent confirmation experiments. We identified four microRNAs (miR-129-2-3p, 
miR-214-3p, miR-31-5p and miR-9-5p) of which statistically significantly higher expression 
in  PCFCL as compared to PCLBCL-LT in high-throughput sequencing could be confirmed by 
RT-qPCR on a new FFPE study cohort. 
Figure 3. RT-qPCR expression in FFPE samples (1) 
The expression of the 4 microRNAs showing statistically significantly higher expression in PCFCL as compared 
to PCLBCL-LT are represented in dot plots. ΔΔCq was calculated with miR-148b-3p, let-7e-5p and miR-25-3p as 
stably expressed reference microRNAs. *P-value < 0.05 (Mann Whitney U test).
MicroRNomes of PCFCL and PCLBCL-LT
Considering all samples analyzed, miR-19a-3p and miR-19b-3p constituted a significant part 
of the microRNA profile, up to 12% for miR-19b-3p of the complete profile of PCLBCL-LT. Both 
microRNAs are members of the miR-17~92 cluster, the presence of which is critical for nor-
mal B-cell development.33 It also acts as a potential oncogenic cluster in B-cell  non-Hodgkin 
lymphomas,34 with miR-19 components being essential in this oncogenic potential.35 The 
other members of this cluster, miR-17-5p, miR-18a-5p, miR-20a-5p and miR-92a-3p, only 
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made up a very small proportion of the complete microRNome (with a maximum of 1%). 
The relatively low expression of miR-92a-3p was most remarkable, as this microRNA was 
found to be one of the most abundantly expressed microRNA in a recent study on nodal 
 DLBCL and primary central nervous system DLBCL, an extranodal DLBCL with an ABC-like 
genotype.36 Although in PCFCL, miR-19a-3p and miR-19b-3p also made up a substantial part 
of the  microRNome, miR-150-5p was most abundantly expressed. MiR-150-5p is involved in 
normal B-cell  development, targeting transcription factor and proto-oncogene c-MYB.37 
Differentially expressed microRNAs
By performing RT-qPCR in an independent cohort of FFPE tumor samples, the higher 
 expression of miR-129-2-3p, miR-214-3p, miR-31-5p and miR-9-5p in PCFCL as compared to 
 PCLBCL-LT in high-throughput sequence data could be confirmed. 
MiR-129-2-3p targets transcription factor SOX4, which was validated in endometrial cancer.38 
SOX4 also has a critical function in normal B-cell development.39 Because of the dichotomy in 
expression of miR-129-2-3p (11 cases without and 9 cases with expression of this microRNA 
in RT-qPCR), immunohistochemical staining for SOX4 was performed. However, no inverse 
correlation between RT-qPCR expression of miR-129-2-3p and immunohistochemical expres-
sion of SOX4 was observed (data not shown). 
A previous array-based comparative genomic hybridization study performed by our group, 
showed low copy number gains of 1q23-q25 in PCFCL, but not in PCLBCL-LT cases.5 The miR-
214 gene is located in this chromosomal region and correspondingly, higher levels of miR-
214-3p were observed in PCFCL compared to PCLBCL-LT. MiR-214-3p has been reported as 
oncogenic microRNA in T-cells, negatively regulating tumor suppressor gene phosphate and 
tensin homolog (PTEN),40 and is involved in controlling cell cycle regulation. However, miR-
214-3p has also been described to exert a tumor suppressor function in breast cancer cell 
lines, where reduced levels of this microRNA result in increased proliferation and invasion 
and in accumulation of EZH2,41 a polycomb group protein with the potential to promote cell 
proliferation.42 
The miR-31 gene is located on 9p21.3. This chromosomal region is often targeted by mono-
allelic or biallelic deletions in PCLBCL-LT, but not in PCFCL.4,43 In accordance, the expression 
of miR-31-5p was lower in PCLBCL-LT in proportion to PCFCL. Correlation of previous multi-
plex ligation probe-dependent assay results of chromosomal location 9p21.343 to the current 
 results showed that two of the PCLBCL-LT samples tested here had deletions in this region and 
low expression of miR-31-5p, while four samples did not have deletions and showed higher 
expression of this specific microRNA. Well characterized genes involved in this deletion are 
CDKN2A and CDKN2B, tumor suppressor genes involved in cell cycle control.44 We previously 
reported that inactivation of CDKN2A in PCLBCL-LT is associated with inferior survival.4,43 It is 
however not clear whether the miR-31 gene is also part of the 9p21.3 deletion involved in 
this more aggressive behavior. Downregulation of miR-31-5p has been described in different 
types of T-cell non-Hodgkin lymphomas.45 In these lymphomas, miR-31-5p was shown to be 
associated with activation of the nuclear factor (NF)-κB pathway, a signaling pathway often 
deregulated in several types of malignancies, by targeting NF-κB inducing kinase.45 
MiR-9-5p is involved in normal B-cell development, negatively regulating transcription fac-
tor PRDM1, an essential driver of plasma cell differentiation. In accordance, this micro RNA 
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is more abundantly expressed in normal germinal center B-cells than plasma cells.21 As 
PCLBCL-LT is thought to be derived from B-cells in a stage just beyond the germinal center 
 reaction, tending towards plasma cell differentiation, the lower expression of miR-9-5p might 
reflect a normal biological stage in B-cell maturation. In ovarian cancer, miR-9-5p has been 
demonstrated to act as a tumor suppressor microRNA by targeting the NF-κB family member 
NFκB1/p50.46 Since the NF-κB pathway has a well-known oncogenic potential in ABC-type 
nodal DLBCL,47 it can be speculated that downregulation of miR-9-5p might have a pathoge-
nic effect in PCLBCL-LT through reduced inhibition of NF-κB signaling.
Figure 4. RT-qPCR expression in FFPE samples (2) 
The expression of the 4 microRNAs that are repeatedly reported in previous studies to be more abundantly 
expressed in ABC-type than GCB-type nodal DLBCL are represented in dot plots. ΔΔCq was calculated with miR-
148b-3p, let-7e-5p and miR-25-3p as stably expressed reference microRNAs. *P-value < 0.05; ** P-value = 0.05 
(Mann Whitney U test).
Correlation with nodal DLBCL subtypes 
PCFCL and PCLBCL-LT have a very distinct gene expression profile, corresponding with gene 
expression profiles of GCB- and ABC-type nodal DLBCL.5 We therefore were interested in 
comparing both subtypes of PCLBCL with their molecular counterparts of nodal DLBCL. 
 However, literature concerning microRNA expression in nodal DLBCL shows inconsistent 
 results. Taken together, the most frequently reported microRNAs showing higher expression 
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in ABC-type as compared to GCB-type nodal DLBCL are miR-155-5p, miR-21-5p and miR-
221-3p and miR-222-3p.11,12,15-19,48 In our PCLBCL samples, expression of these four micro-
RNAs did not show significant differences between the two subtypes in both high-throughput 
 sequencing and RT-qPCR. To accurately compare our PCLBCL samples with nodal DLBCL, and 
exclude external influences such as differing reference microRNAs, we performed RT-qPCR 
on well-defined subgroups of nodal DLBCL by using a set of three microRNAs (miR-148b-3p, 
let-7e-5p and miR-25-3p) that were stably expressed in our PCLBCL sequencing studies as 
a reference. These microRNAs were, in contrast to widely used references U6 and RNU48, 
stably expressed in our nodal DLBCLs. By using this approach of matching conditions, we 
confirmed higher expression of miR-155-5p and miR-222-3p in ABC-type as compared to 
GCB-type nodal DLBCL, but not of miR-21-5p and miR-221-3p. 
The absence of higher expression of miR-155-5p in PCLBCL-LT as compared to PCFCL was 
most noteworthy. The role miR-155-5p has been studied extensively in nodal B-cell non- 
Hodgkin lymphomas and is linked to activation of the intracellular signaling pathway PI3K-Akt 
pathway10 and increased lymphoma cell motility,49 and its expression is associated with NF-κB 
activity in nodal DLBCL.48 The finding that miR-155-5p was not elevated in PCLBCL-LT as com-
pared to PCFCL suggests at least partially different pathogenetic mechanisms in PCLBCL-LT as 
compared to its nodal molecular counterpart. 
In summary, we presented the first microRNA profiling results by next generation 
high-throughput sequencing and RT-qPCR comparing PCFCL and PCLBCL-LT. These two sub-
types of PCLBCL did not show entirely distinct microRNA profiles, but could be distinguished 
by differential expression of microRNAs miR-129-2-3p, miR-214-3p, miR-31-5p and miR-9-5p. 
We also showed that the hitherto described microRNA signature of GCB- and ABC-subtype 
nodal DLBCLs could not be extrapolated to PCFCL and PCLBCL-LT. Therefore, we conclude 
that although PCFCL and PCLBCL-LT show strong resemblance at gene expression level with 
GCB- and ABC-type nodal DLBCL, respectively, their microRNA profiles are at least partially 
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Supplemental Materials and Methods
B-cell selection and activation
Human B-cells were purified from the separate lymphocyte fractions of peripheral blood 
(buffy coats) obtained from four healthy individuals by positive selection with magnetic 
CD19 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The B-cells were cultured 
in RPMI 1640 with 10% FCS and incubated with CpG (5 μg/ml) (ODN 2006, Invivogen, San 
Diego, USA) and monoclonal antibodies to CD40 (0.1 μg/ml) (BD Biosciences Pharmingen, 
Heidelberg, Germany) for 24 hours. After harvesting, a B-cell purity of more than 97% was 
confirmed by flow cytometric analysis with a mixture of monoclonal antibodies against B-cell 
(CD20, APC-H7), T-cell (CD3, PE-H7) and monocytes (CD14, APC). Simultaneously, the acti-
vation status was determined using anti-CD80 (PE) and anti-CD86 (FITC)), respectively. All 
antibodies were obtained from BD Biosciences. Dead cells were excluded using 1 µM of DAPI. 
A BD Biosciences LSRII was used for acquisition. WinList 7 (Verity Software House, Topsham, 
ME, USA) was used for data analysis. Approximately 86% of the lymphocytes showed expres-
sion of these activation markers. 
 
MicroRNA library preparation for high-throughput sequencing
Sequencing adaptors were ligated to total RNA on both ends of the RNA molecules and 
reverse-transcribed. The cDNA was pre-amplified with PCR primers containing specific 
 sequence tags making the libraries compatible with the Illumina flow cells (Illumina, Son en 
Breugel, The Netherlands). Polyacrylamide gel electrophoresis size selection was performed, 
excising the 95-105 bp band containing the adaptor-ligated microRNA insert. Quantification 




Total RNA was isolated from 10 μm sections of FFPE tumor samples (number of sections 
varying from 4 to 20 sections, according to the size of the specimen) using the RecoverAll 
Total Nucleic Acid Extraction Kit according to manufacturer’s protocol (Ambion, Warrington, 
UK). Approximately 300 ng of total RNA from each sample (FFPE or frozen, same isolation as 
for the high-throughput sequencing) was reverse transcribed using the microRNA reverse 
 transcription kit (Applied Biosystems) combined with the stem-loop Megaplex primer pool 
A v2.1 (Applied Biosystems), which allowed for simultaneous reverse transcription of 377 
 microRNAs and 4 endogenous controls. The reverse transcription was conducted on the 
LightCycler480 (Roche, Almere, The Netherlands), running 40 cycles with the following con-
ditions: 2 minutes at 16oC, 1 minutes at 42oC and 1 second at 50oC, followed by 5 minutes 
holding at 85oC. RT-qPCR was performed using Taqman microRNA and control assays and 2x 
Universal PCR mastermix (Applied Biosystems). The reactions were run in duplicate on the 
CFX384 RT-qPCR Detection System, according to manufacturer’s protocol (Bio-Rad Labora-
tories, Veenendaal, the Netherlands), with the following cycle parameters: 10 min at 95 oC, 
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Abstract
Primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT) is an aggressive cutaneous 
lymphoma with a 5-year overall survival of approximately 40%. At gene expression level, 
 PCLBCL-LT resembles the activated B-cell (ABC)type of nodal diffuse large B-cell lymphoma 
(DLBCL). In ABC-DLBCL, a role for constitutive Nuclear Factor (NF)-κB pathway activation in 
tumor cell survival is generally recognized. We screened 10 cases of PCLBCL-LT for genetic 
alterations potentially leading to aberrant NF-κB activation. Tumor suppressor gene TNFAIP3 
was heterozygously deleted in four cases. No additional promoter hypermethylation was 
detected. A CD79BY196 mutation was found in 2 cases. The coiled-coil domain of CARD11 
contained a D415E and a R423W mutation in one sample. At genomic level, the oncogenic 
MYD88 L265P mutation was found in 4 cases, of which 3 showed the same mutation at trans-
criptional  level. Combined, seven out of 10 cases of PCLBCL-LT showed genetic alterations in 
genes that regulate NF-κB activation. The percentages of mutations were highly concordant 
with those encountered in nodal ABC-DLBCL. Together, these findings strongly suggest a role 
for constitutive activation of the NF-κB pathway in PCLBCL-LT and provide the rationale to 
explore using new treatment modalities targeted at components of the NF-κB pathway.
 
Introduction
Primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT) is an aggressive cutaneous 
lymphoma with a 5 year overall survival of approximately 40%.1 Due to its aggressive nature, 
the treatment of first choice is anthracyclin-based chemotherapy combined with rituximab.2 
However, patients often show a progressive disease course despite treatment with polyche-
motherapy. Furthermore, due to age and (age-related) comorbidity, not all patients are eligi-
ble for this treatment. Therefore, new and additional therapies for PCLBCL-LT are necessary, 
with a focus on more specific, targeted therapies with fewer side effects than conventional 
chemotherapy.
At mRNA expression level, PCLBCL-LT resembles activated B-cell (ABC) type of nodal diffuse 
large B-cell lymphoma (DLBCL), including strong expression of known targets of the Nuclear 
Factor (NF)-κB pathway, such as interferon regulatory factor 4(IRF4).3-5 In nodal ABC-type/
non-germinal center-type DLBCL, increased NF-κB activity likely plays a role in its patho-
genesis, by acting as a transcription factor involved in several cellular survival mechanisms. 
In line with this role, in nodal ABC-type DLBCL cell lines, constitutive activation of NF-κB is 
required for tumor cell survival.3,6 Studies on the molecular background of NF-κB pathway 
activation have demonstrated that mutations in multiple genes can cause deregulation of 
NF-κB signaling in nodal ABC-type DLBCL.7 The genes most frequently affected by genetic 
aberrations are TNFAIP3 (A20), CD79B, CARD11 (CARMA1), and MYD88, which all can con-
tribute to constitutive activation of the NF-κB pathway. In two-third of cases nodal ABC-type 
DLBCL, one or more of these genes are affected.8 The NF-κB pathway inhibitor TNFAIP3 is 
commonly  affected by (chromosomal) deletion and hypermethylation of the second allele,7,9 
while the CD79B, CARD11, and MYD88 genes are frequently targeted by mutations that lead 
to activation of the NF-κB pathway.8,10,11 Together, these results suggest that activation of 
the NF-κB pathway is involved in the pathogenesis of ABC-type DLBCL and that this pathway 
can serve as a potential therapeutic target in DLBCL. Indeed, several molecules in the NF-κB 
pathway have already been selectively targeted in vitro and in vivo to explore potential new 
treatment  strategies, including SYK (fostamatinib),12 BTK (ibrutinib),13,14 PKCβ (enzastaurin/
sotrastaurin),15,16 and MALT1 (phenothiazines).17,18 Moreover, the mutational status of espe-
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cially CARD11 and CD79B and to a lesser extent MYD88 has been linked to sensitivity or re-
sistance to drugs targeting the NF-κB pathway,15,19 and their role therefore seems essential in 
tumor cell survival in nodal ABC-type DLBCL. We performed a comprehensive investigation of 
genetic aberrancies in PCLBCL-LT leading to pathological NF-κB pathway activation, to evalu-




Frozen biopsy primary tumor material of 10 PCLBCL-LT cases was available from the archive 
of the Leiden University Medical Center (Leiden, The Netherlands). A diagnosis of PCLBCL-LT 
was made according to criteria of the WHO-EORTC20 and WHO classification,21 and confirmed 
by a panel of hematopathologists and dermatologists, aided by several routinely performed 
immunohistochemical stainings. Cases were only included when frozen biopsy material 
contained a tumor cell percentage of at least 75%, as assessed by immunohistochemical 
 stainings for CD20 and CD3.  In all cases physical examination, total blood count, computed 
tomography scan, and bone marrow did not show extracutaneous disease at inclusion. Pa-
tient characteristics are summarized in Supplemental Table 1.
 
Activated B-cells
Human B-cells were purified from the separate lymphocyte fractions of peripheral blood 
(buffy coats) obtained from four healthy individuals by positive selection with magnetic 
CD19 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The B-cells were cultured 
in RPMI 1640 with 10% FCS and incubated with CpG (5 μg/ml) (ODN 2006, Invivogen, San 
Diego, USA) and monoclonal antibodies to CD40 (0.1 μg/ml) (BD Biosciences Pharmingen, 
Heidelberg, Germany) for 24 hours. After harvesting, a B-cell purity of more than 97% was 
confirmed by flow cytometric analysis with a mixture of monoclonal antibodies against B-cell 
(CD20, APC-H7), T-cell (CD3, PE-H7) and monocytes (CD14, APC). Simultaneously, the acti-
vation status was determined using anti-CD80 (PE) and anti-CD86 (FITC)), respectively. All 
antibodies were obtained from BD Biosciences. Dead cells were excluded using 1 µM of DAPI. 
A BD Biosciences LSRII was used for acquisition. WinList 7 (Verity Software House, Topsham, 
ME, USA) was used for data analysis. Approximately 86% of the lymphocytes showed expres-
sion of these activation markers.
 
DNA and RNA isolation
Genomic DNA was extracted using the Genomic-tip 20/G method, according to the protocol 
supplied by the provider (Qiagen, Hilden, Germany). RNA was isolated by the TRIzol method 
(Life Technologies, Carlsbad, CA, USA). 0,5 μg of total RNA was treated with RQ1 DNase I 
(Promega, Madison, WI) and reverse-transcribed by use of the iScript cDNA Synthesis kit (Bio-
Rad, Veenendaal, The Netherlands).
TNFAIP3 gene expression
mRNA expression of TNFAIP3 was analyzed by quantitative PCR (qPCR). Candidate reference 
genes were selected by analysis of gene expression data of two sets of (extra)nodal DLBCLs,22,23 
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online accessible in GENEVESTIGATOR (https:// www.genevestigator.com) and supplemented 
with three additional stably expressed reference genes, previously used by our group. Opti-
mal reference genes were selected and tested as previously described.24 The combination 
of TMEM222, ZDHCC5, and ARF5was identified as most optimal and used as reference gene 
set in all subsequent experiments. The qPCR reactions were run in triplicate with the use of 
iQ SYBR Green SuperMix (Bio-Rad) on the CFX384TM Real-Time System (Bio-Rad). The output 
data were analyzed using Bio-Rad CFX Manager software applying the ∆∆Cq method. Relative 
expression was normalized to the determined reference gene set. Cycle parameters for all 
transcripts analyzed were as follows: denaturing for 15 seconds at 95 oC, and annealing and 
extension for 20 seconds at 60 oC, for 40 cycles. Specificity of the PCR products was confirmed 
by melting curve analysis. Primer sequences are listed in Supplemental Table 2.
 
TNFAIP3 copy number variation 
A custom designed high-density fine-tiling DNA array with a resolution of 10 kB was set up for 
the genomic region of TNFAIP3 (situated at chr6: 138,188,581-138,204,445; array coverage: 
chr6: 137,200,000 - 139,200,000), according to the human genome, built 19 (February 2009; 
Humane Genome Browser, University of California, Santa Cruz, CA, USA). The array was pre-
pared using Maskless Array Synthesizer Technology (NimbleGen Systems, Reykjavik, Iceland). 
The mean fluorescence was normalized to reference DNA (healthy donor DNA from blood, 
Promega, Madison, USA) and analyzed using SignalMap software (NimbleGen Systems) in 
order to detect copy number alteration in the chromosomal region containing the TNFAIP3 
locus.
 
TNFAIP3 promoter methylation assay
Using the EZ Methylation Kit (Zymo Research Corporation, Orange, CA), extracted tu-
mor sample DNA was treated with sodium bisulfite. PCR primers annealing to sodium 
bisulfite- modified DNA, 5’- ATTGAAACGGGGTAAAGTAGATTG - 3’ forward and 5’- CAAAATC-
CCAAATCCTAATCAAAACA - 3’ reverse, were designed. Primers were developed in such a way 
that both methylated and unmethylated sequences are amplified using the same bisulfite 
treated DNA as PCR template. These primers amplified a 236 bp genomic region (-211 bp to 
+26 bp from the transcription start site (ENST00000237289)) and covering the middle part of 
the  promoter CpG island of TNFAIP3. Twenty-four CpGs were situated in this amplicon. PCR 
amplification was performed on the CFX384TM Real-Time System (Bio-Rad), and afterwards 
melting curves were acquired in the presence of iQ SYBR Green Supermix (Bio-Rad) during 
a linear temperature transition from 65 to 90 oC with increments of 0,2 oC per 10 seconds. 
The presence of methylated DNA in the samples was detected through a peak with a higher 
melting curve temperature (84.2 °C) as compared to unmethylated DNA (79.6 °C), using bi-
sulfite converted unmethylated human semen DNA and methylated human DNA (Chemicon, 
Hampshire, UK) as references as described before.24
TNFAIP3 alternative transcript analysis
For isolated tumor sample DNA, the genomic region containing exons 3 and 4 and intron 3 of 
TNFAIP3 was amplified. Forward primer 5’ - TTGCTGGGTCTTACATGCAG - 3’ and reverse primer 
5’ - GCTGAAAGCATTTAAGTACAGATCC - 3’ were designed for PCR amplification in the  presence 
of Advantage GC Genomic LA Polymerase Mix (Clontech, Heidelberg, Germany). PCR  products 
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were sequenced by the 3730XL/3130XL Genetic Analyzer (LGC Genomics, Berlin, Germany). 
The nucleotide alterations of each gene were analyzed using Mutation  Surveyor software 
(Softgenetic, State College, PA). 
For cDNA amplification of TNFAIP3 exon 3 to 5, 5’ - ATTTGTTGAAACGGGGCTTT - 3’ forward 
and 5’ - GGCGAAATTGGAACCTGAT - 3’ reverse primers were designed. Amplification was per-
formed on the C1000 TouchTM Thermal Cycler (Bio-Rad) using a touchdown PCR protocol 
with the following parameters: denaturing at 95oC for 30 seconds, followed by 40 cycles of 
annealing at 65 oC to 58 oC for 20 seconds (with a 1 oC decrement per cycle in the first 7 cycles) 
and extension at 72 oC for 30 seconds. The purified PCR products were subjected to Sanger 
sequencing both with forward and reverse primers on the ABI 3730 (Applied Biosystems, Fos-
ter City, CA). The sequenced PCR fragments of each gene were aligned to the corresponding 
normal sequences (Ensembl Genome Browser 70, http://www.ensembl.org).
 
Mutational analysis of CD79B and CARD11, and MYD88
PCR was performed to amplify exon 5 of CD79B, exons 5 to 10 of CARD11, and exon 5 of 
MYD88 for both DNA and cDNA (primer pairs listed in Supplemental Tables 2 and 3), on the 
C1000 TouchTM Thermal Cycler (Bio-Rad) using the touchdown PCR protocol as described 
above. The PCR products were completely sequenced in both directions on the ABI 3730 





mRNA expression of TNFAIP3 varied substantially among the tumor samples (Figure 1) as 
measured relative to stably expressed reference genes TMEM222, ZDHCC5, and ARF5. The 
high-density fine-tiling DNA array showed decreased mean fluorescence in the TNFAIP3 chro-
mosomal region in four tumor samples. The mean log2 transformed fluorescence levels of 
these samples varied from -0,315 to -0,382 and were concordant with heterozygous deletion 
of the gene region. Above that, in all 4 samples the complete region investigated (1 MB up-
stream and downstream of the gene) was heterozygously deleted, confirming this deletion 
targeted a larger chromosomal area than the TNFAIP3 locus alone.
Mutational analysis CD79B, CARD11, and MYD88
Two tumor samples showed a nucleotide substitution in the first immunoreceptor tyro-
sine-based activation motif (ITAM) of CD79B, the first one a c.680A>T missense mutation 
leading to substitution of tyrosine by phenylalanine (Y196F), the second one a c.679T>C mu-
tation in which tyrosine will be substituted by histidine (Y196H). Both mutations were detec-
ted at genomic and transcriptional level (Supplemental Figure 1a and b). 
One tumor sample showed both a c.1649C>A and a c.1671C>T mutation in CARD11 in DNA 
and cDNA (Supplemental Figure 1c), leading to a substitution of aspartic acid by glutamic acid 
(D415E), and of arginine by tryptophan (R423W), respectively. Two additional tumor samples 
showed alterations in codon 415 of CARD11, concerning a similar silent mutation (c.1649C>T) 
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(Supplemental Figure 1d). One of these samples displayed this mutation in DNA and cDNA 
sequences. For the other sample, only cDNA was analyzed.
Figure 1. TNFAIP3 mRNA expression (quantitative PCR)
Mean ΔΔCq for PCR with two primer sets for  TNFAIP3 relative to reference genes TMEM222, ZDHHC5 and 
ARF5 for 9 of 10 tumor samples and 4 samples of in vitro activated peripheral blood B-cells (ABCs). The error 
bars  represent the standard deviation. The underlined tumor samples showed heterozygous deletion of the 
 complete  TNFAIP3 gene region.
Methylation-specific melting curve analysis of the TNFAIP3 promoter region showed melt 
curves at the temperature of unmethylated control DNA in all 9 tumor samples tested. No 
TNFAIP3 intron 3 mutations or gene conversions affecting the intronic c.487-2A to c.487-1G 
acceptor splicing site were detected. In cDNA, PCR amplification of exon 3 to 5 of TNFAIP3 
using cDNA showed normal transcripts with a length of 212 base pairs and without replace-
ment any of these exons.
 
In of four cases, a c.794T>C mutation in MYD88 was detected in DNA (Supplemental figure 
1e and f), leading to a substitution of leucine by proline (L265P). This specific mutation was 
also present in cDNA in 3 of these cases, but one of these four showed an unchanged cDNA 
sequence.
An overview of all results is given in Table 1, showing that 7 out of 10 cases contained ge-
netic alterations involved in the regulation of the NF-κB pathway that could lead to consti-
tutive  activation of this signaling pathway. Off note, one of the three cases without genetic 
 alterations showed relatively low levels of TNFAIP3, suggesting that NF-κB pathway activation 
is also present in these tumors. In this relatively small cohort of PCLBCL-LT cases, no correla-




We generated a comprehensive overview of NF-κB-activating genetic aberrancies in 
 PCLBCL-LT. Evident genetic alteration were encountered in 7 out of 10 samples, strongly sug-
gesting that constitutive activation of the NF-κB pathway plays a role in the pathogenesis 
and/or tumor cell survival in PCLBCL-LT.
TNFAIP3
TNFAIP3 (A20) is a tumor suppressor gene, downregulating the NF-κB signaling pathway by 
deubiquitination of several target proteins involved in activation of this pathway. The  TNFAIP3 
protein consists of an ovarian tumor (OTU) domain and seven Zinc finger domains, both 
 necessary for optimal functioning.25 In both nodal ABC-type DLBCL and PCLBCL-LT, chromo-
somal arm 6q, on which the TNFAIP3 gene is situated, is frequently deleted.26,27 
Table 1. Overview of genetic aberrancies 
 












mut. splice variant DNA cDNA
exon
5-8 & 10 exon 9 DNA cDNA
1 no no 0,50 no no no no no no L265P L265P
2 no no 0,51 no no no no no no no no
3 no no 0,08 no no no no no no no no
4 +/- no 0,11 no no no no no no L265P L265P
5 +/- no 0,13 no no no no no D415E, R423W no no
6 no no N/A N/A N/A no no no no1 no no
7 no N/A 0,03 no no Y196H Y196H no no L265P no
8 no no 0,17 no no Y196F Y196F no no L265P L265P
9 +/- N/A 0,01 no no N/A no no no N/A no
10 +/- no 0,01 no no no no no D415D no no
del: deletion; mut: mutation; +/-: heterozygous deletion; N/A: not assessed; 1 A silent mutation (D415D) was 
detected.
 
As the mRNA expression levels of TNFAIP3 varied amongst the tumor samples of PCLBCL-LT, 
we were interested in potential underlying mechanisms for these variations in PCLBCL-LT. 
Four cases showing heterozygous deletion of the gene region indeed showed relatively low 
mRNA expression levels of TNFAIP3. These heterozygous deletions were concordant with our 
previous results of conventional array comparative genomic hybridization studies in primary 
cutaneous large B-cell lymphomas.26 Homozygous deletions that are observed in 10% of  nodal 
ABC-type DLBCL,7 were not found in PCLBCL-LT. In cases with two gene copies of TNFAIP3 
and relatively low levels of mRNA, we could not establish a negative regulatory mechanism. 
Epigenetic silencing through promoter hypermethylation was not detected in PCLBCL-LT, as 
was encountered in approximately 40 percent of nodal ABC-type DLBCLs.9 Furthermore, we 
investigated whether the TNFAIP3 transcripts present could give rise to functional proteins. 
In one-third of cases of nodal ABC-type DLBCL, intron 3 splice site mutations or gene conver-
85
NF-κB pathway-activating gene aberrancies
4
sions disrupting the intron 3 splice site are encountered, leading to transcripts with an intro-
duced premature stop codon. These transcripts will give rise to a truncated protein without 
the essential OUT and Zinc finger domains. Again we could not detect these alterations in 
PCLBCL-LT. As TNFAIP3 was demonstrated to influence proliferation and survival in normal 
B-cells in a gene-dose-dependent fashion,28 the relatively low expression of TNFAIP3 in most 
of the PCLBCL-LT samples still seems a relevant finding.
Altogether, the heterozygous deletions of TNFAIP3 and reduced mRNA expression in 
 PCLBCL-LT suggest a role for this tumor suppressor in the pathogenesis of this type of lym-
phoma, but the mechanisms of reduced expression of TNFAIP3 are different from the ones 
encountered in nodal ABC-type DLBCL.
 
CD79B, CARD11 and MYD88 activating mutations
CD79B (immunoglobulin-associated beta) is a component of the B-cell receptor, and has 
a combined function with CD79A in the assembly and membrane expression of the B-cell 
receptor. The CD79A/CD79B heterodimer also initiates downstream activation of different 
signaling pathways, including the NF-kB pathway.29 Somatic mutations affecting CD79B were 
 detected in 18% of nodal ABC-type DLBCLs, mainly comprising recurrent mutations in the 
first immunoreceptor tyrosine-based activation motif (ITAM) tyrosine Y196. These mutations 
lead to increased surface B-cell receptor expression and downregulated Lyn kinase, a feed-
back inhibitor of B-cell receptor signaling.10 The mechanism of activation of the NF-κB path-
way through these mutations is called chronic active B-cell receptor signaling, and occurs 
in cases with wild-type CARD11. In our series, concordant with nodal ABC-type DLBCLs, in 
20% an Y196 mutation was detected in the absence of mutations in CARD11, suggesting that 
chronic active B-cell receptor signaling is a mechanism involved in these cases of PCLBCL-LT.
CARD11 is a signaling scaffold protein involved in coordinating the activation of the NF-kB 
pathway,11 and a critical component involved in constitutive NF-κB activation in ABC-DLBCL,6 
downstream of the B-cell receptor (see Figure 2).Remarkably, in 3 out of 10 cases, we found 
point mutations in codon 415 of exon 9. In two of these cases, it concerned a silent muta-
tion. Although functional consequences may seem less apparent for silent mutations, there 
is increasing evidence that these do have physiological effects, for example through incorrect 
splicing and changes in RNA structure or by altering the rate of translation.30 However, as this 
mutation is a common single nucleotide polymorphism, the relevance of these mutations in 
PCLBCL-LT can be debated. The sample with a missense mutation in this codon (D415E) also 
showed a R423W mutation in the same exon in both DNA and cDNA. This CARD11 R423W 
mutation was previously described in nodal ABC-type DLBCL.7 In contrast to some known 
CARD11 mutations, the functional relevance of the D415E and R423W mutations has not yet 
been investigated. However, mutations in the coiled-coil domain are potentially relevant in 
constitutive activation of the NF-κB pathway, as changes in this domain have the potential to 
disrupt the autoinhibition of CARD11 signaling, leading to receptor-independent activation 
of the NF-κB pathway.31
Myeloid response gene 88 (MYD88) is a Toll-like receptor associated adaptor protein with 
many cellular functions. Amongst others, MYD88 is known to be involved in activation of 
different signaling pathways through the assembly of a complex containing IRAK1 and IRAK4.8 
Nodal ABC-type DLBCLs showed a L265P mutation in 29% of cases, and the consequent ami-
no acid substitution in the βD sheet of MYD88 has been shown to be oncogenically active, 
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leading to aberrant activation of NF-κB and JAK-STAT3 signaling pathways and lymphoma 
cell survival,8 a mechanism most likely not directly related to (chronic active) B-cell receptor 
signaling (see Figure 2). In primary central nervous system DLBCL, also an extranodal DLBCL 
of ABC-genotype, the L265P mutation was encountered in 36% of cases32 and 38% of cases33. 
Somatic MYD88 L265P mutations in PCLBCL-LT have been previously described in 69% of 
 cases.34 The 40% mutation rate we encountered in our series is therefore concordant with 
other (extra)nodal ABC-type DLBCLs. Furthermore, we showed that not all mutations in the 
DNA seem to be transcribed to RNA, as for one sample, the mutation was not detected in 
cDNA.
Table 2. Genetic aberrancies in PCLBCL-LT compared to nodal ABC-type DLBCL
PCLBCL-LT nodal ABC-type DLBCL
CD79B ITAM mutations 20% 20%
CARD11 coiled-coil domain 
mutations 10% 10%
MYD88 L265P mutation 30%* 40%
TNFAIP3
  - homozygous deletion 0% 10%
  - heterozygous deletion 40% 40%
  - epigenetic silencing 0% 40%
  - alternative transcripts 0% 33%
*30% in cDNA, 40% in DNA
PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg type; ABC-type DLBCL, activated B-cell-type diffuse 
large B-cell lymphoma
Mutational status and therapeutic targets
The above described specific mutations not only give more insight into the pathogenesis of 
(extra)nodal DLBCLs, but the relevance of these mutations for novel therapeutic stra tegies 
has also been explored. For example, sotrastaurin can interfere with NF-κB pathway activa-
tion, by inhibition of PKC-β, which is required for CARD11-dependent activation of the NF-κB 
pathway.35 Sotrastaurin was shown to be selectively toxic for CD79-mutant DLBCL in a mouse 
xenograft model15 as compared to unmutated DLBCL, but only in presence of wild-type 
CARD11. These findings strongly suggest that sotrastaurin is especially promising in cases 
of DLBCL with chronic active B-cell receptor signaling. An RNA interference screen revealed 
that a BCR signaling component, Bruton’s tyrosine kinase (BTK), is essential for the survival of 
nodal ABC-type DLBCL with wild-type CARD11 and in addition, knockdown of proximal B-cell 
receptor units, i.e. CD79B, was selectively toxic to wild-type CARD11 nodal ABC-type DLBCL, 
but not to other lymphomas.10 Furthermore, in a phase I trial, the BTK-inhibitor ibrutinib was 
well-tolerated and generated a clinical (partial) response in 40% of refractory nodal ABC-type 
DLBCL, both in patients with tumors bearing CD79 mutations or a combination of CD79 and 
MYD88 mutations. However, patients with only MYD88 mutations were refractory to this 
treatment, reflecting the B-cell receptor signaling-independency of these MYD88-mutated 
tumors and warranting assessment of the mutations status of these NF-κB related signaling 
molecules.19
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In conclusion, seven out of ten cases of PCLBCL-LT showed geneti c alterati ons in the NF-κB 
pathway. For pathway-acti vati ng mutati ons in the CD79B ITAM, MYD88 L265P mutati ons and 
CARD11 coiled-coil domain mutati ons, the percentage of tumors aff ected corresponds to the 
percentages in nodal ABC-type DLBCL (Table 2). However, although downregulated mRNA 
expression of TNFAIP3 in our samples was highly suggesti ve for a role of this tumor suppres-
sor in NF-κB acti vati on, the geneti c substrate for low expression is not completely evident 
in PCLBCL-LT, and therefore diff ers from the well-defi ned mechanisms downregulati ng the 
functi on of TNFAIP3 in nodal ABC-type DLBCL. Together, these fi ndings strongly suggest a role 
for consti tuti ve acti vati on of the NF-κB pathway in PCLBCL-LT, and provide the rati onale to 
explore the possibility of using specifi c therapy targeted at components of the NF-κB pathway 
in this type of lymphoma.
Figure 2. Pathway overview and geneti c aberrancies in primary cutaneous large B-cell lym-
phoma, leg type 
The suggested relati ons between the diff erent components of B-cell receptor signaling and MYD88 signaling 
are represented.14 The molecules aff ected by geneti c aberrancies in PCLBCL-LT are indicated in red and the 
 percentage of the cases aff ected by these aberrancies are indicated. Molecules that can be therapeuti cally tar-
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Supplemental Figure 1. Sequencing results of CD79B, MYD88, and CARD11
DNA (a) and cDNA (b) sequences of CD79B exon 5 in tumor sample 8, concordant with a Y196H mutation. 
Although in DNA, the dominant sequence of codon 196 is equal to the reference sequence, a clear C-peak is 
visible under the T-peak (arrow), indicating a nucleotide substitution. In cDNA of the same tumor, the C-peak 
is dominant, suggesting a predominant expression of the mutated allele. cDNA sequence of CARD11 exon 9 of 
tumor sample 5 showing a R423W mutation (c) and of tumor sample 6 with a silent mutation in codon 415 (d). 
DNA (e) and cDNA (f) sequences of MYD88 exon 5 in tumor sample 4 showing a L265P mutation.
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Supplemental Table 2. Primers for quantitative PCR
Gene Sequence 5’- 3’ Product size
TNFAIP3 (1)1   - forward CTGGGACCATGGCACAACTC
182 bp  - reverse CGGAAGGTTCCATGGGATTC
TNFAIP3 (2)   - forward CCATGGCACAACTCATCTCA
172 bp  - reverse GAAGGTTCCATGGGATTCTG
TMEM222   - forward CGCCTCTGAGGAGTACAAGC
92 bp  - reverse TGTAGCGCATCAGATTCAGG
ARF5   - forward TGCTGATGAACTCCAGAAGATGC
144 bp  - reverse CGGCTGCGTAAGTGCTGTAG
ZDHCC5   - forward TATCGGCCGGGTTACAGTAG
95 bp  - reverse GTTGGCTCCTTCAAGCTGTC
1. Braun FCM, Grabarczyk P, Möbs M, et al. (2011) Tumor suppressor TNFAIP3 (A20) is frequently deleted in 
Sézary syndrome. Leukemia 25: 1494-1501.
Supplemental Table 3. Primers for mutational analysis DNA
Gene Sequence 5’- 3’ Product size
CD79B  - forward TCTTGCAGAATGCACCTCAC
159 bp
 - reverse CCAACCACACCAGCAGATAG
MYD88 2  - forward CTGGGGTTGAAGACTGGGCT
276 bp


























2. Pham-Ledard A, Cappellen D, Martinez F, et al. (2012) MYD88 somatic mutation is a genetic feature of primary 
cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 132: 2118-20
3. Lenz G, Davis RE, Ngo VN, et al. (2008) Oncogenic CARD11 mutations in human diffuse large B-cell lymphoma. 
Science 319: 1676-9.
Supplemental Table 4. Primers for mutational analysis cDNA  
Gene Sequence 5’- 3’ Product size
CD79B   - forward AGTCATGGGATTCAGCACCT
218 bp  - reverse GCAGCGTCACTATGTCCTCA
MYD88   - forward AGGAGATGATCCGGCAACT
297 bp  - reverse CGCAGACAGTGATGAACCTC
CARD11 exon 9 - forward AATGTACAAGCACCGCATGA
295 bp- reverse GATGGTTACTGGCAGGTTCC
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Abstract
The postulated normal counterpart of primary cutaneous diffuse large B-cell lymphoma, leg 
type (PCLBCL-LT) is an antigen-activated post-germinal center B-cell. However, in contrast 
to post-germinal center B-cells, immunohistochemical studies have shown that PCLBCL-LT 
 expresses BCL6, FOXP1 and IRF4, and that Blimp1 (encoded by PRDM1) is not detected. To find 
out if these abnormal findings could be explained by genetic alterations, as is occasionally the 
case in nodal activated B-cell type diffuse large B-cell lymphoma (ABC-DLBCL), we generated 
an overview of genetic aberrancies of BCL6, FOXP1, PRDM1 and IRF4 combined with immu-
nohistochemistry in 10 well-defined cases of PCLBCL-LT. While immunohistochemistry showed 
positivity in 8 out of 10 cases for BCL6 and in all cases for FOXP1 and IRF4, no evidence of 
translocations or amplifications involving these genes by fine-tiling comparative genomic hy-
bridization (FT-CGH) combined with ligation-mediated PCR (LM-PCR) was encountered, that 
could explain high protein levels. However, high protein levels of FOXP1 are not only based on 
the detection of the full length protein, but most probably also comprise N-terminally trun-
cated proteins. This is partly based on small deletions in the FOXP1 gene and partly due to 
the presence of alternative isoforms 3 and 9. PRDM1, of which the protein Blimp1 is con-
sistently absent by immunohistochemistry, was heterozygously deleted according to FT-CGH 
analysis in 5 cases. No additional PRDM1 mutations were encountered in the heterozygously 
 deleted cases, and variations in mRNA levels were independent of the deletions. Together, 
these  results show that in PCLBCL-LT genetic alterations in BCL6, IRF4, FOXP1 and PRDM1 are 




Primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT) is the most aggressive type 
of primary cutaneous B-cell lymphoma, with a 5 year overall survival of approximately 40%.1 
This lymphoma is regarded as an extranodal variant of nodal diffuse large B-cell lymphoma 
(DLBCL) with activated B-cell (ABC) genotype, as both lymphoma subtypes are thought to 
be derived from B-cells that are blocked in differentiation in the transitional stage between 
germinal center B-cell and plasma cell.2,3 In nodal DLBCL, several mechanisms have been 
described that might (in part) be responsible for this differentiation arrest, for example trans-
locations involving B-cell lymphoma 6 (BCL6)4,5 and/or deletion and mutations of PR domain 
containing 1, with ZNF domain (PRDM1).4,6 Other molecules driving B-cells towards plasma 
cell differentiation include interferon regulatory factor-4 (IRF4) and forkhead box protein 1 
(FOXP1), and sporadic genetic alterations, such as translocations involving these genes, also 
occur in nodal DLBCL (see Figure 1).7,8
In normal B-cell development, BCL6 is expressed in germinal center B-cells in high levels to 
sustain the germinal center reaction, amongst others by downregulation of Blimp1 expres-
sion, the protein encoded by PRDM1.9 After a successful germinal center reaction, BCL6 is 
downregulated, leading to expression of Blimp1. This Blimp1 expression is sufficient to allow 
B-cells to undergo plasma cell maturation, and also induces other transcription factors, such 
as IRF4, which are also part of the plasma cell program.10 Furthermore, FOXP1 expression is 
inversely correlated to BCL6 expression, thereby occurring in a post germinal center stage, 
and FOXP1 is also able to upregulate the expression of Blimp1.11
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Figure 1. B-cell development and transcription factors
The normal germinal center reaction and antigen-dependent B-cell activation are depicted along with the 
immunohistochemical profile of the germinal center B-cell, activated B-cell and plasma cell concerning activa-
tion-related transcription factors. 
Previous immunohistochemical studies of PCLBCL-LT by our group have shown that BCL6 is 
expressed in more than half of the cases, IRF4 and FOXP1 are virtually always expressed by 
the tumor cells, and that no substantial expression of Blimp1 is detected.12 In the context of 
normal B-cell development, the expression of germinal center protein BCL6 together with 
post-germinal center activation proteins IRF4 and/or FOXP1 seems aberrant, and also, the ab-
sence of Blimp1 expression despite expression of IRF4 and/or FOXP1 is not what is expected 
(Figure 1). However, knowledge of potential underlying genetic mechanisms for the aberrant 
immunohistochemical expression of these transcription factors in PCLBCL-LT is limited.
We generated an overview of genetic aberrations of these transcription factors in 10 well- 
defined cases of PCLBCL-LT, in order to gain more insight into the pathogenesis of the pre-




Frozen biopsy primary tumor material and formalin fixed and paraffin embedded (FFPE) 
 tumor material of 10 PCLBCL-LT cases was available from the archive of the Leiden University 
 Medical Center (Leiden, The Netherlands). All tissue samples were handled in a coded  fashion, 
according to the Dutch National Ethical guidelines (Code for Proper Secondary Use of Human 
Tissue, Dutch Federation of Medical Scientific Societies). A diagnosis of PCLBCL-LT was made 
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according to criteria of the WHO-EORTC13 and WHO classification,14 and confirmed by a panel 
of hematopathologists and dermatologists, aided by several routinely performed immunohis-
tochemical stainings. Cases were only included when frozen biopsy material contained a tu-
mor cell percentage of at least 75%, as assessed by immunohistochemical  stainings for CD20 
and CD3.  In all cases physical examination, total blood count,  computed tomography scan, 
and bone marrow did not show extracutaneous disease at inclusion.  Patient  characteristics 
are summarized in Supplemental Table 4.
 
DNA and RNA isolation and cDNA synthesis
Genomic DNA was extracted from frozen biopsy specimens using the Genomic-tip 20/G 
method, according to the protocol supplied by the provider (Qiagen, Hilden, Germany). RNA 
was isolated from frozen biopsy specimens by the TRIzol method (Life Technologies, Carls-
bad, CA, USA). 0.5 μg of total RNA was treated with RQ1 DNase I (Promega, Madison, WI) 
and reverse-transcribed by use of the iScript cDNA Synthesis kit (Bio-Rad, Veenendaal, The 
Netherlands).
 
High-density fine-tiling DNA array 
A custom designed high-density fine-tiling oligonucleotide array with a resolution of 10 kB, 
oligonucleotide probes of 45-60 bp, and 15 bp median probe spacing was set up for the 
genomic regions containing BCL6, FOXP1, PRDM1, and IRF4 and dual specificity protein 
phosphatase 22 (DUSP22) (for details see Supplemental Table 1), according to the human 
genome, built 19 (February 2009; Human Genome Browser, University of California, Santa 
Cruz, CA, USA). The array was prepared using Maskless Array Synthesizer Technology (Nim-
bleGen Systems, Reykjavik, Iceland). The mean fluorescence signal intensity was normalized 
to  reference DNA (healthy donor DNA from blood, Promega, Madison, USA) and analyzed 
using SignalMap software (NimbleGen Systems) in order to detect copy number alteration in 
the investigated chromosomal regions.
 
Confirmation of deletions in the FOXP1 gene
PCR amplification of tumor DNA flanking the regions of FOXP1 that were deleted as was 
 detected by FT-CGH was performed using forward and reverse primers (listed in Supplemen-
tal Table 2) on the C1000 TouchTM Thermal Cycler (Bio-Rad) using a touchdown PCR protocol 
as previously described.15 The purified PCR products were subjected to Sanger sequencing 
both with forward and reverse primers on the ABI 3730 (Applied Biosystems, Foster City, 
CA). Mutation Surveyor software (SoftGenetic) was used for analysis of single nucleotide 
 alterations.
 
Mutational analysis of PRDM1
Individual exons of PRDM1 (1 to 7) were amplified in separate PCRs (primer pairs listed in 
Supplemental Table 2, applying the touch down protocol as described elsewhere15) using 





DNA losses in FOXP1 and the DUSP22 region were analyzed by ligation-mediated PCR (LM-
PCR) as described in detail elsewhere.16 Supplemental Table 3 lists the primers that were 
used and the different primers combinations are described in the Supplemental Materials 
and Methods.
 
PRDM1 and DUSP22 gene expression
mRNA expression of both isoforms of PRDM1, i.e. PRDM1α en PRDM1β was analyzed by 
quantitative RT-PCR (qPCR) as well as expression of DUSP22. Primer efficiencies were 101, 
108, and 88%, respectively. TMEM222, ZDHCC5, and ARF5 were used as reference gene set.15 
The qPCR reactions were run on cDNA in triplicate with the use of iQ SYBR Green Super-
Mix (Bio-Rad) on the CFX384TM Real-Time System (Bio-Rad). The output data were analyzed 
using Bio-Rad CFX Manager software applying the ∆∆Cq method. Relative expression was 
 normalized to the determined reference gene set. Cycle parameters for all transcripts ana-
lyzed were as follows: denaturing for 15 seconds at 95 oC, and annealing and extension for 
20 seconds at 60 oC, for 40 cycles. Specificity of the PCR products was confirmed by melting 
curve analysis. Primer sequences are listed in Supplemental Table 2.
 
FOXP1 promoter methylation assay
The methylation assay was performed as previously described.15 The primers for the FOXP1 
promoter CpG island amplified a 293 bp genomic region near the transcription start site 
and covering the promoter CpG island of FOXP1. 14 CpGs were situated in this amplicon. 
The presence of methylated DNA in the samples was detected through a peak with a higher 
melting curve temperature (78,6 °C) as compared to unmethylated DNA (76,6 °C), using bi-
sulfite converted unmethylated human semen DNA and methylated human DNA (Chemicon, 
Hampshire, UK) as references as described before.17
 
FOXP1 (alternative) transcript analysis
For amplification of FOXP1 tumor sample cDNA, different primer combinations were 
 developed (see Supplemental Table 2) and PCR was performed as described above.
 
Immunohistochemistry
Immunohistochemistry for BCL6, FOXP1 and IRF4 was performed as previously described.12
 
Results
The B-cell activation-related transcription factors BCL6, FOXP1, PRDM1/Blimp1 and IRF4 were 
investigated in PCLBCL, LT, and an overview of the identified aberrations is given in Table 1. 
BCL6
BCL6 immunohistochemistry was considered positive if 30% or more of the tumor cells 
showed nuclear staining.18 Eight out of 10 cases were scored positive, and 6 of these cases 
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showed more than 75% positive tumor cell nuclei. FT-CGH showed no evidence of transloca-
tions or amplifications involving BCL6 that could lead to autonomous upregulation of BCL6 
expression.
Table 1. Overview of transcription factor alterations















1 pos +/+ +/+ isoform 3 +/+ no 0,01 0,31 +/- (loss between 
genes)
2 pos +/+ +/+ no +/+ N/A 0,03 1,00 +/+
3 pos +/+ +/+ no +/- no 2,41 0,12 +/- (loss between 
genes)
4 neg +/+ +/- 
(del ex 4, 5, 6, 7)
isoform 3 +/- no 3,02 0,16 +/+
5 pos +/+ +/- 
(del ex 5, 6, 7)
no +/- no 2,44 0,16 +/+
6 pos +/+ +/+ no +/+ no N/A N/A +/+
7 pos +/+ +/- 
(del ex 3)
no +/+ ex 4 c.843 
C>G (D607E)
3,07 0,22 ampl DUSP22
8 pos +/+ +/+ isoform 3 +/+ no 0,64 0,07 +/+
9 pos +/+ +/+ isoform 3 +/- N/A 16,82 0,05 ampl DUSP22
10 neg +/+ +/+ isoform 3, 
isoform 9
+/- ex 7 c.2376 
G>A (silent)
0,69 0,08 +/- (loss part of 
DUSP22)
a All 10 cases showed immunohistochemical positivity for both FOXP1 and IRF4; b pos = positive; neg = negative; 
c FT-array = high density DNA fine-tiling array;  +/+ = no alteration; +/- = heterozygous DNA loss; ampl = amplifi-




FOXP1 immunohistochemistry showed strong nuclear expression in over 90% of tumor cells 
in all 10 cases. By FT-CGH, there was no evidence of amplification of the FOXP1 gene, as 
a potential explanation for (autonomous) upregulation of FOXP1. Instead, heterozygous 
DNA loss of part of the FOXP1 gene was encountered in 3 out of 10 cases (see Figure 2). As 
these deletions might be part of a translocation/rearrangement, which could also potentially 
lead to upregulation of FOXP1, further exploration by LM-PCR was performed. However, no 
 linkage of the regions flanking these DNA losses to other parts of the genome was detec-
ted. Therefore, most likely, the DNA loss represents a heterozygous deletion rather than a 
break involved in a translocation/rearrangement. The presence of these deletions was con-
firmed by PCR amplification and subsequent sequencing on tumor DNA of the three involved 
cases. All break points were situated in introns, thereby deleting complete exons. Case 4 
showed  heterozygous DNA loss comprising exon 4 to 7 (exon 4 and 5 non-coding, exon 6 
and 7  coding). In case 5 there was DNA loss in exon 5 to 7, and between the rearranged frag-
ments a DNA fragment was inserted containing 6 nucleotides of unknown origin and a 402 
bp fragment of a  repetitive sequence derived from the deleted region. In case 7, the DNA 
102
5
loss was encountered in exon 3 (non-coding), with 2 homologous nucleotides inserted at the 
rearrangement site. To investigate whether the DNA strand with these deletions was actually 
transcribed in these tumors, RNA transcript analysis by PCR using primers located in exon 2 
and exon 8, flanking the deleted regions, with sequencing of the product was performed. In 
two of the three cases showing a deletion in FOXP1, an RNA transcript with concordant de-
letions was encountered, next to normal length transcripts. The promoter methylation assay 
showed no evidence of hypermethylation of the promoter island of FOXP1 that could explain 
the absence of a shorter transcript in the remaining case without a concomitant aberrant 
transcript. Exploring additional alternative transcripts of FOXP1, previously reported alter-
native N-truncated protein coding transcripts with presumed oncogenic potential (isoform 3 
and 9)19 were detected in 5 cases and 1 case, respectively. 
PRDM1
Blimp1 immunohistochemistry was not performed, as previous studies by our group already 
showed complete absence of nuclear staining for this protein in all cases of PCLBCL-LT.12 The 
complete DNA region of PRDM1 covered by the FT-CGH experiment, showed heterozygous 
DNA loss in 5 out of 10 cases, but no homozygous loss was detected that would be explanatory 
for the absence of Blimp1 protein. In order to search for other genetic alterations  explaining 
altered or diminished gene transcription, PCR amplification and subsequent sequencing of 
all exons of PRDM1 was performed. Only one missense mutation was detected, concerning 
a c.843 C>G (D607E) mutation in exon 4 in case 7. However, as this case had two alleles of 
the PRDM1 gene present by FT-CGH, and the mutation was heterozygous, no evidence for 
absence of the Blimp1 protein by genetic inactivation was detected. Of note, one additional 
mutation was found in case 10 (exon 7, c.2376 G>A), this however concerned a silent mu-
tation. Next, we explored whether the absence of the Blimp1 protein was reflected by RNA 
levels and whether RNA levels were lower in cases with heterozygous deletions or mutations 
in PRDM1. qPCR for PRDM1α, the full-length transcript of PRDM1, detected this transcript in 
all cases, and showed substantially varying amounts of mRNA, irrespective of heterozygous 
DNA loss or missense mutation. As the PRDM1 gene has an alternative transcript lacking 
the PR domain, PRDM1β, which has a possible oncogenic potential,20 we also explored this 
transcript by qPCR. Again, amounts varied and were not related to other aberrations in the 
gene. Except for case 1 and 2, PRDM1β levels were lower than levels of PRDM1α and very low 
relative to the expression of the reference genes (see Table 1). 
IRF4 – DUSP22
IRF4 immunohistochemistry was strongly positive in all ten cases. The IRF4 gene showed no 
gains by FT-CGH as a sign of (autonomous) upregulation of the gene, and losses as part of a 
translocation were also not encountered in the IRF4 gene. In the region just upstream of IRF4, 
heterozygous DNA loss or DNA gain was observed in part in the region harboring the DUSP22 
locus. In anaplastic large cell lymphoma, a translocation between DUSP22 and FRAH7 on 
chromosome 7 was recently described.21 However, in our cases LM-PCR of the region flanking 
the deletions did not show linkage of this DNA region to another DNA region, and therefore 
there was no evidence that these deletions were involved in a translocation/rearrangement. 
Furthermore, by performing qPCR analysis, the cases with deletion and/or amplification of 
DUSP22 did not show differences in mRNA expression levels compared to the cases without 
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these genetic alterations. Thereby, the biological significance of these genetic alterations in 
PCLBCL-LT remains unknown.
Figure 2. High-density DNA fine-tiling array chromosome 3
 
(A) The FOXP1 gene locus on chromosome 3 (71,003,865 – 71,633,140) is depicted. The  X-axis represents 
the chromosomal position of the probes, while the y-axis represents the log2-ratio of the read numbers per 
probe relative to control DNA. DNA losses between -0.200 and -0.400 are considered heterozygous losses. (B) 
Sequences of the break points in FOXP1 as assessed by PCR on tumor DNA are represented. While in case 4, 
there was a direct link between intron 3-4 and intron 7-8, case 5 and 7 showed insertions between the break 
points detected by FT-CGH analysis. In case 5, 6 nucleotides of unknown origin and a 402 base pair repetitive 




This study investigated genomic alterations in B-cell activation-related transcription factors 
in PCLBCL-LT. With 8 out of 10 cases showing high levels of the germinal center protein BCL6 
by immunohistochemistry, it is remarkable that the same cases also have high protein levels 
of FOXP1 and IRF4, which are normally downregulated by BCL6, and show absence of Blimp1 
protein, which is upregulated by FOXP1 and IRF4 in a physiological situation (see Figure 1). 
We could not find evidence that BCL6, FOXP1 and/or IRF4 have an autonomous way of protein 
upregulation, as we did not encounter translocations or amplifications involving these genes. 
Moreover, the absence of Blimp1 protein by immunohistochemistry in PCLBCL-LT could not 
be explained by genetic silencing through homozygous deletion of the gene, or heterozy-
gous deletion with concomitant missense or nonsense mutations. These alterations actually 
have been described in ABC-DLBCL, the nodal counterpart of PCLBCL-LT. Especially genetic 
inactivation of PRDM1 is frequently detected in ABC-DLBCL, occurring in approximately one-
third of cases.4,6  Translocations involving IRF4 have only sporadically been described in nodal 
ABC-DLBCL7 and translocations involving FOXP1 are also infrequent, but might preferentially 
be detected in extranodal DLBCL.8
Blimp1 immunohistochemistry was previously reported to be consistently negative in 
 PCLBCL-LT12 using the purified recombinant GST fusion protein encoding N-terminal amino 
acids 1-347 of human BLIMP1 antibody (clone BUR16212), covering exons 2 to 5. The proteins 
of both PRDM1α, the full-length transcript (containing exon 1-7), and PRDM1β, the alternative 
transcript (containing exon 1β and exon 4-7),20 should be detected by this polyclonal antibody. 
Unexpectedly the lack of detectable protein was not reflected by absence or very low levels 
of both transcripts. Blimp1 downregulation might therefore be an epigenetic  phenomenon. 
For example, microRNA let-7 might play a role in nodal ABC-type DLBCL by negatively regu-
lating Blimp1 expression at a posttranscriptional level.22 For IRF4, our results are concordant 
with previous FISH studies in PCLBCL-LT, in which this type of lymphoma has been reported 
to have immunohistochemical (over)expression of IRF4 without gene  rearrangements.23 Al-
ternatively, as IRF4 is a target gene of the nuclear factor (NF)-κB signaling pathway,24 up-
regulation of IRF4 might be related to constitutive activation of the NF-κB pathway. Indeed 
in 70% of PCLBCL-LT, genetic aberrations in NF-κB-activating genes were encountered that 
might lead to aberrant pathway activation.15 No FOXP1 translocations have previously been 
reported in PCLBCL-LT,25 which is in line with our results. However, amplification of FOXP1 as 
detected by fluorescent in situ hybridization was detected in 82% of PCLBCL-LT,25 while this 
was not present in any case of our cohort using the very sensitive FT-CGH method. No genetic 
mechanism underlying consistent upregulation of FOXP1 has been detected, but our study 
revealed that high protein levels of FOXP1 reflect more than merely the presence of the full-
length isoform of FOXP1. As the commonly used JC12 antibody binds in the C-terminal region 
of the protein, various N-truncated proteins will also be detected by this antibody. Next to the 
full-length transcript of FOXP1, in some of our cases we encountered FOXP1 isoforms 3 and 
9. Furthermore, we detected not previously described N-truncated isoforms, based on small 
DNA deletions in the FOXP1 gene. FOXP1 isoform 3 and 9 were suggested to have oncogenic 
potential in nodal ABC-DLBCL,19 which might be due to the related increased expression of 
NF-κB associated genes, as was reported for nodal follicular lymphomas.26 FOXP1 has further-
more been implicated in class switch recombination (CSR). PCLBCL-LT characteristically shows 
intracytoplasmatic expression of IgM, in part combined with IgD, which might imply a defect 
in CSR.27 Although the exact mechanism behind the absence of CSR is not completely under-
stood, in nodal ABC-DLBCL and primary central nervous system DLBCL it has been suggested 
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to be caused by mutations in the switch regions of the constant chain.28,29 In a recent report, 
constitutional expression of FOXP1 led to impairment of switching from IgM to IgG1. It can be 
speculated that FOXP1 might therefore also play a factor in the absence of CSR in PCLBCL-LT, 
leading to a differentiation arrest in the post-germinal center state. 
In summary, high protein levels of transcription factors BCL6, IRF4 and FOXP1 in PCLBCL-LT 
do not seem to be related to autonomous upregulation due to amplification or transloca-
tions involving the genes. However, the high protein levels of FOXP1 represent proteins from 
a variety of FOXP1 transcripts, some not previously described, and others with a presumed 
oncogenic potential. Although protein levels of Blimp1 are undetectable by immunohisto-
chemistry, mRNA levels of PRDM1 (both PRDM1a and PRDM1b) varied substantially between 
the cases, and seemed to be unrelated to heterozygous deletions and/or mutations encoun-
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Supplemental Materials and Methods
Primer combinations used in each DNA sample to characterize FOXP1 deletions
For details of the primers see Supplemental Table 3.
Sample 4: deleted sequence (303,819 bp involving exon 4-7); dna 
range=chr3:71140032-71443850. 
LM-PCR
upstream  1st PCR 3:71,139,678f + AP1 
   2nd PCR 3:71,139,722f + AP2  
downstream 1st PCR  3:71,444,688r + AP1
  2nd PCR 3:71,444,606r + AP2
confirmation PCR
3:71,139,678f + 3:71,444,688r (1192 bp)
Sample 5: deleted sequence (217,427 bp involving exon 5-7); dna range=chr3:71,159,133-  
71,376,559; inserted sequence (402 bp involving intron 4-5); dna range=c
hr3:71,373,433-71,373,834 
LM-PCR
upstream 1st PCR 3:71,158,005f + AP1 
  2nd PCR 3:71,158,509f + AP2  
downstream 1st PCR  3:71,377,299r + AP1 
  2nd PCR  3:71,377,262r + AP2
confirmation PCR
3:71,158,005f + 3:71,377,299r (2169 bp)
Sample 7: deleted sequence (189,514 bp involving exon 3); dna 
range=chr3:71427920-71617433
LM-PCR
upstream 1st PCR 3:71,427,220f + AP1
  2nd PCR 3:71,427,491f + AP2    
downstream 1st PCR  3:71,618,367r + AP1
  2nd PCR  3;71,618,274r + AP2 
confirmation PCR
3:71,427,220f + 3:71,618,367r (1632 bp)
Supplemental Table 1. Coverage high-density DNA fine-tiling array
Position Array coverage
FOXP1 chr3: 71,004,737-71,633,140 chr3: 70,300-72,300
BCL6 chr3: 187,439,165-187,463,475 chr3: 186,400-188,400
IRF4 – DUSP22 chr6: 391,752-411,442 chr6: 0-2000
PRDM1 chr6: 106,534,195-106,557,814 chr6: 104,800-107,800
chr = chromosome.
109











































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 3. List of FOXP1 Primers (5’-3’) for LM-PCR and PCR
Primer Sequence (5’ – 3’) Location
Adaptor-specific
    - AP1 GTAATACGACTCACTATAGGGC
    - AP2 ACTATAGGGCACGCGTGGT
Forward gene-specific
    - 3:71,427,220f GAAAAGGGAATCAATACAGGCCAAGA intron 3-4
    - 3:71,427,491f CTGTTATCCACGGGTTGTGCTTTC intron 3-4
    - 3:71,139,678f TATAATCCATGCTTCCCTTCCCAAC intron 7-8
    - 3:71,139,722f TGAGCATACTCCCTGATCTTCTTTGC intron 7-8
    - 3:71,158,005f GAAGGCAGGGTGTGTATCTTCAACAG intron 7-8
    - 3:71,158,509f CCAAACATAAAGCAGGGAAGTGTGAG intron 7-8
Reverse gene-specific
    - 3;71,618,274r TGGAGCATGTATTAGGGATGAAGTGA intron 2-3
    - 3:71,618,367r CCTTCATACCCCTATTCTGCCCATTA intron 2-3
    - 3:71,444,606r AGCTTGGAAGAGAAGCATTCCAGACT intron 3-4
    - 3:71,444,688r GATGAGGTACCCAGGTAAGGCTTCTC intron 3-4
   - 3:71,377,262r ACACCCAGTCTTTTCAGCTTATCACG intron 4-5
    - 3:71,377,299r GCCAAATTCTTCTGCCTCCTTTAATGT intron 4-5
Supplemental Table 4. Patient characteristics
Sex Age 
(years)
Skin site of 











1 male 84 legs + other RT yes 1 24 D+
2 female 75 both legs PCT + RT yes 12 54 D+
3 female 79 leg RT no 20 21 A0
4 female 81 leg PCT + RT yes 20 39 D+
5 male 81 leg none no 0 2 D+
6 male 53 legs + other PCT yes 6 96 A+
7 male 68 leg PCT yes 17 60 D+
8 female 83 leg PCT + RT yes 34 38 D+
9 male 83 leg RT no 49 50 A0
10 female 76 leg RT no 0 13 D+
PFS = progression free survival; FU = follow-up; RT = radiotherapy; PCT = polychemotherapy; D+ = died of  disease; 
A0 = alive without disease.
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Abstract
Methotrexate (MTX)-associated B-cell lymphoproliferative disorders (B-LPD) may first present 
in the skin, but their clinicopathologic features are still ill defined. Differentiation from primary 
cutaneous follicle center lymphoma (PCFCL) and primary cutaneous diffuse large B-cell lym-
phoma, leg type (PCLBCL-LT) is important, as MTX-associated B-LPD may show spontaneous 
regression after withdrawal of MTX therapy. In the present study, the clinicopathologic and 
phenotypical features of 10 patients with MTX-associated B-LPD first presenting in the skin, 
including 5 EBV+ and 5 EBV- cases, were investigated. Six patients had skin-limited disease. 
Clinically, abrogation of MTX therapy resulted in a complete response in 4 cases and a partial 
response in another 2. The 5-year disease-specific survival was 90%. MTX-associated B-LPD 
differed from PCFCL by the presence of ulcerating and/or generalized skin lesions, an infiltrate 
composed of centroblasts/immunoblasts rather than large centrocytes, reduced  staining 
for CD79a, and  expression of BCL2, IRF4, and FOXP1 in most cases. EBV+ MTX-associated 
B-LPD differed from PCLBCL-LT by the presence ulcerative skin lesions, marked tumor cell poly-
morphism, reduced staining for CD79a, and expression of CD30 and EBV. EBV- cases showed 
 morphologic and immunophenotypical similarities to PCLBCL-LT, but differed by presentation 
with generalized skin lesions in 4 of 5 cases.  The results of this study, showing a relatively 
good clinical outcome and spontaneous disease regression after only withdrawal of MTX  in 
a considerable proportion of patients,  underscores the importance of a careful wait-and-see 
policy before considering more aggressive therapies in patients with MTX-associated B-LPD 
of the skin.
Introduction
In recent years, the incidence and awareness of immunosuppression-related malignancies 
including non-Hodgkin lymphomas (NHLs) has increased. The immunosuppressive state 
 leading to these NHLs might be caused by primary immune disorders, human immunode-
ficiency virus infections, or might be iatrogenic by the use of immunosuppressive agents.1 
The increased chronic use of immunosuppressive drugs for autoimmune diseases is indeed 
associated with higher incidence of NHL, especially of B-cell origin.2 Although the immu-
nosuppressive drug methotrexate (MTX) was first reported to be effective in patients with 
 rheumatoid arthritis and psoriasis in 1951,3 MTX-associated B-cell lymphoproliferative disor-
ders (B-LPD) were not described until 1985.4 Since that time, many reports of MTX-associated 
NHL have been published, particularly in patients with rheumatoid arthritis. Most of these 
lymphomas were B-cell NHL, mainly diffuse large B-cell lymphomas (DLBCL), both Epstein 
Barr virus (EBV) related and unrelated.2 Of interest, there are several reports of spontaneous 
regression of these lymphomas after withdrawal of MTX, underlining the potential pathoge-
netic role of MTX in these lymphomas.5 
Reports of MTX-associated B-LPD presenting in the skin and in particular those presenting 
with only skin lesions are limited.6-10 MTX-associated B-LPD presenting in the skin should 
be differentiated from primary cutaneous follicle center lymphoma (PCFCL) with a diffuse 
growth pattern, from primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT), and 
from  secondary cutaneous manifestation of a primary nodal DLBCL or high grade follicu-
lar lymphoma. The differential diagnosis furthermore comprises EBV+ DLBCL of the elderly 
and lymphomatoid granulomatosis. PCFCL characteristically presents with localized skin le-
sions on the trunk or on the face, most commonly the scalp, are highly responsive to local 
 radiotherapy, and have an excellent prognosis.11,12 PCLBCL-LT characteristically present with 
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skin tumors on the (lower) legs in elderly females, run a much more aggressive course than 
PCFCL, and should be treated primarily with systemic chemotherapy in combination with 
rituximab (R-CHOP).11,12 R-CHOP is also the first choice of treatment in patients with nodal 
DLBCL or high-grade follicular lymphoma secondarily involving the skin.12-14 In contrast, in 
MTX-associated B-LPD the effect of cessation of MTX should first be awaited, before more 
aggressive therapies are considered. Differentiation between these different entities is there-
fore extremely important but may be very difficult, particularly if relevant clinical data are not 
provided.
In the present study we reviewed the clinical, histologic, and immunophenotypical data of 10 
patients with an MTX-associated B-LPD first presenting in the skin. The aim of this study was 
to find out if these MTX-associated B-LPDs show characteristic clinicopathologic features that 
allow their recognition, even in the absence of adequate clinical data, and may be used in the 
differentiation from other DLBCL presenting in the skin. 
 
Table 1. Immunohistochemistry details
Antibody Clone Company AR Dilution Chromogen
CD20 L26 DAKO, Glostrup, Denmark EDTA 1:400 DAB
CD79a JCB117 DAKO EDTA 1:50 DAB
CD3 F7.2.38 DAKO EDTA 1:100 DAB
BCL2 124 DAKO EDTA 1:25 DAB
BCL6 PG-B6p DAKO EDTA 1:40 DAB
CD10 56C6 DAKO EDTA 1:40 DAB
CD35 BERMACD DAKO citrate 1:10 DAB
IRF4/MUM1 MUM1p DAKO EDTA 1:200 DAB
FOXP1 JC12 kind gift of dr. A.H. Banham* citrate 1:400 DAB
MYC Y69 Abcam, Cambridge, UK EDTA 1:100 DAB
heavy chains NA DAKO citrate 1:4000 - 1:8000 DAB+
light chains NA DAKO citrate 1:16000 DAB+
CD30 BerH2 DAKO citrate 1:100 DAB
CD15 Carb-3 DAKO EDTA 1:400 DAB
LMP1 CS1-4 DAKO EDTA 1:40 DAB
* Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK.
AR: antigen retrieval; DAB: 3,3’-diaminobenzidine; DAB+: 3,3’-diaminobenzidine with enhancer; EDTA: 
 ethylenediaminetetraacetic acid; NA: not applicable.
Materials and Methods
Formalin fixed and paraffin embedded skin biopsies of 10 patients with an MTX-associated 
B-LPD were collected from the archive of the Dutch Cutaneous Lymphomas Working Group. 
In all patients adequate staging procedures had been performed, which included complete 
physical examination, total blood count, bone marrow biopsy, and computed tomography 
scans. The diagnosis had been confirmed by a panel of dermatologists and hematopatholo-
gists during one of the quarterly meetings of the Working Group. Details of the immunohis-
tochemical staining procedures are presented in Table 1. Immunohistochemical staining was 
considered positive if ≥ 30% of the tumor cells showed staining with the specific antibody 
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for BCL2, BCL6, CD10, IRF4/MUM1, and FOXP115 or ≥ 40% for MYC.16 CD30 was either scored 
positive or negative depending on whether all tumor cells showed or did not show staining 
for this marker. In situ hybridization for EBV-encoded RNA expression was assessed by hy-
bridization on slides using a fluorescein-conjugated EBER PNA probe (Y5200, Dako, Glostrup, 
Denmark) and scored positive in the case of any nuclear staining in atypical large lymphoid 
cells. DNA was extracted from formalin-fixed and paraffin-embedded sections using standard 
protocols, and clonal rearrangements of the IGH and IGK locus were detected by polymerase 
chain reaction using Identiclone IGH and IGK gene clonality assays (InVivoScribe Technology, 
Carlsbad, CA).17 The potential rearrangements were interpreted in conjunction with a poly-
clonal, monoclonal and blank control. 
After the interpretation of MYC immunohistochemistry in the above-described cases, com-
parison of these results with cases of PCFCL and PCLBCL-LT seemed warranted. As the MYC 
immunohistochemistry in these lymphomas has not been performed before, we selected 
6 cases of PCFCL and 10 cases of PCLBCL-LT from the archive of the Dutch Cutaneous Lym-
phomas Working Group and performed MYC immunohistochemistry as described in Table 1. 
All tissue samples were handled in a coded fashion, according to the Dutch National Ethical 





The clinical patient characteristics, categorized as EBV+ or EBV- as assessed by RNA in situ hy-
bridization, are represented in Figure 1 and Table 2. The study group included 6 females and 
4 males. The median age of presentation was 76 years (range, 57 to 88 y), and the median 
time of MTX treatment was 4 years (range, 1 to 8 y). Five patients had generalized skin lesions 
at presentation, 3 patients presented with multiple skin lesions on 1 leg, whereas 2 patients 
had presented with a solitary lesion. Ulceration was observed in 3 patients, all of them being 
EBV+. Staging procedures revealed extracutaneous localizations in 4 of 10 patients, whereas 
the remaining 6 patients had skin-limited disease. In all 10 patients MTX treatment was dis-
continued, which resulted in complete resolution of the cutaneous and nodal localizations in 
4 of them (cases 4, 5, 6 and 8). In 2 other patients radiation therapy of residual skin lesions 
(cases 9 and 10) also resulted in a complete response. Initial treatment with systemic poly-
chemotherapy (CHOP or R-CHOP) resulted in a complete response in 3 of 4 patients (cases 1, 
2 and 7), whereas 1 patient (case 3) died of cardiac failure during R-CHOP treatment. During 
follow-up, 1 patient (case 10), developed extensive nodal involvement, which was successful-
ly treated with R-CHOP. After a median follow-up of 24 months (range, 6 to 86 mo) 7 patients 
are in complete remission, only 1 died of lymphoma, whereas 2 patients died of unrelated 
disease.  Five year disease-specific survival was 90%.
Histology
A complete overview of tumor characteristics is given in Table 3, and the histology of repre-
sentative EBV+ and EBV- cases is depicted in Figures 2 and 3, respectively. Most cases showed 
a diffuse (n = 7) infiltrate of large B cells, whereas 2 cases showed a perivascular infiltrate and 
1 case a partly follicular infiltrate. The amount of admixed T cells ranged from 5% to 50%. 
Tumor cell morphology was very variable between the different cases. Most of the EBV+ cases 
118
6
showed a predominance of centroblasts and immunoblasts of varying size and were admixed 
with some polymorphic tumor cells with complex nuclear configuration, sometimes with a 
Reed-Sternberg-like appearance (Fig. 2B). EBV- cases showed a more monomorphic infiltrate 
of either centroblasts or immunoblasts (Fig. 3B), or a combination of both, generally without 
tumor cells with complex nuclear configuration. Although cases 1 and 10 showed some ad-
mixture of large centrocytes, these centrocytes were never the predominant cell type of the 
malignant infiltrate. Mitotic figures were easily detected in all cases. Case 7 showed abundant 
apoptosis throughout the whole tumor.
Immunohistochemistry
Immunohistochemistry showed considerable differences between the 5 EBV- and the 5 EBV+ 
cases (Table 3, Figs. 2, 3). Whereas B-cell lineage markers were strongly expressed in all EBV- 
tumors, 4 of 5 EBV+ tumors showed reduced expression of CD79a, combined with complete 
loss of expression of CD20 in case 2. For the cases with loss of 1 or both of these markers, 
B-cell lineage specificity was further confirmed by positive immunohistochemistry for PAX5, 
OCT2, and BOB1 (data not shown). Furthermore, all cases showed clonal rearrangements of 
the B-cell receptor, except for case 6, which showed polyclonal B-cell receptor rearrange-
ments along with intracytoplasmic expression of IgM and λ. 
Figure 1. Clinical manifestation of MTX-associated B-LPD in the skin
Case 1 presented with generalized plaques and small tumors, one of which on the chest showed focal ulceration 
(A). In case 2, extensive lesions on the lower left leg with marked ulceration were encountered (B). Case 4 pre-
sented with 2 deep seated nodules on the right leg clinically resembling erythema nodosum (C). Case 7 showed 
small nonulcerating nodules on the trunk (D) and extensive plaques on the left lower leg (E). In case 8, multiple 
small plaques were encountered on both arms and legs (F). 
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In the EBV- group, all patients showed very strong nuclear expression of FOXP1 and MYC 
in the tumor cells, while FOXP1 and MYC were expressed by only 2 and 1 of 5 EBV+ cases, 
respectively. In contrast, IRF4 and CD30 were strongly expressed in all 5 EBV+ cases, but in 3 
and 1 of 5 cases, respectively, in the EBV- group. LMP1 was expressed in 4 of 5 EBV+ cases but 
in none of the EBV- cases. CD15 was never substantially coexpressed in CD30+ tumors, apart 
from a sporadic (larger) tumor cell in some cases. BCL2 and BCL6 were expressed in 8 and 7 
of 10 cases, respectively, and were not differentially expressed in the EBV+ and EBV- group. Of 
the 8 BCL2+ cases, 7 showed positivity in > 75% of the tumor cells, whereas 1 case (case 4) 
showed positivity of this marker in approximately 30% of the tumor cells. The amount of ex-
pression of BCL6 was more variable, ranging from 30% to 100% of tumor cell positivity. Only 
1 case (case 10) showed remnants of follicular dendritic networks in a CD35 stain, whereas 
all other cases were completely negative for CD35.
 
MYC immunohistochemistry in PCFCL and PCLBCL-LT
The 6 cases of PCFCL all showed only scattered nuclear tumor cell staining and were there-
fore interpreted as negative. The tumor cells of the 10 cases of PCLBCL-LT, however, showed 
virtually all strongly nuclear staining, and all cases were considered positive.
 
Discussion
In the present study, we evaluated the clinicopathologic and immunophenotypical charac-
teristics of 10 patients with MTX-associated B-LPD first presenting in the skin. Recognition 
of these lymphomas is important, as abrogation of MTX therapy may result in spontaneous 
remission and should therefore be considered before more aggressive therapies are used. In 
absence of adequate clinical data, these lymphomas might for example be misinterpreted as 
PCFCL, PCLBCL-LT, or skin localizations of a nodal DLBCL, leading to potential overtreatment 
with radiotherapy and/or chemotherapy. The main goal of the present study was to find 
out whether MTX therapy-associated B-LPDs presenting in the skin show clinical, histomor-
phologic and/or immunophenotypical characteristics that are different from those found in 
 PCFCL and PCLBCL-LT and might be helpful in recognizing these MTX-associated B-LPDs, even 
if crucial clinical information is lacking. Follow-up data of the 10 patients included in this study 
indicate that these MTX-associated B-LPD have a relatively good prognosis, especially when 
compared to PCLBCL-LT. After a median follow-up of 24 months, 7 of 10 patients are still alive 
without disease, including the 4 patients who were withdrawn from MTX therapy  without 
any other additional therapy given. Only 1 patient eventually died of lymphoma despite 
treatment with polychemotherapy. Previous studies suggested that spontaneous regression 
after cessation of MTX is preferentially detected in EBV+ DLBCL.18,19 However, in our series of 
MTX-associated B-LPD first presenting in the skin, the cases showing spontaneous regression 
were equally divided over the EBV+ and EBV- group. 
Differentiation between these MTX-associated B-LPDs and PCFCLs is generally not difficult. 
PCFCL normally presents with localized, nonulcerating skin lesions on the trunk or face, in 
particular the scalp, and uncommonly with lesions on the legs or with generalized skin le-
sions.11 In contrast, most MTX-associated B-LPD in this study presented with generalized skin 
lesions, which often involved the legs and showed ulceration in 3 of them. 
Histologically, PCFCLs show a predominance of large centrocytes with variable numbers 
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of admixed centroblasts, and have a BCL6+, BCL2-, IRF4-, FOXP1- phenotype and do not ex-
press intracytoplasmic immunoglobulins.20,21 Although most cases of PCFCL have a diffuse 
growth pattern, remnants of follicular dendritic cell networks are often found using appro-
priate markers. None of the MTX-associated B-LPDs showed a predominance of centrocytes, 
and most cases strongly expressed BCL2 (8 of 10 cases), IRF4 (8 of 10 cases), FOXP1 (7 of 
10  cases), and monotypic cytoplasmic immunoglobulin heavy and/or light chains (5 of 10 
 cases). Remnants of FDC networks were only found in 1 of 10 cases (case 10). In addition, 
the tumor cells did not express BCL2 and IRF4 in this case. However, the clinical presentation 
 (generalized plaques), tumor cell morphology (a predominance of centroblasts with only few 
admixed centrocytes), and strong expression of FOXP1, MYC and CD30 argue against a diag-
nosis of PCFCL. 
In nodal DLBCLs immunohistochemical expression of MYC is associated with an inferior 
survival.22 To the best of our knowledge reports on MYC expression in CBCL have not been 
 published. For the purpose of this study we therefore performed MYC expression analysis in 
10 well-defined cases of PCLBCL-LT and 6 cases of PCFCL. Strong nuclear expression in virtu-
ally all tumor cells was found in all PCLBCL-LT, whereas PCFCL contained only few scattered 
positive cells (Table 4). It is noteworthy that immunohistochemical double expression of BCL2 
and MYC has been associated with an aggressive clinical course and overall inferior prognosis 
in nodal DLBCL,23 while in our cohort this association was not found. 
There were also major differences between EBV+ MTX-associated B-LPD and  PCLBCL-LT. 
 Clinically, 3 of 5 cases showed (extensive) ulceration, which is uncommon in  PCLBCL-LT. 
 Histologically, the tumor cells in these EBV+ lymphomas often showed marked polymorphism 
and often contained Reed Sternberg-like large tumor cells with complex nuclear configura-
tions, whereas PCLBCL-LTs generally show a more monomorphic infiltrate of centroblasts 
or immunoblasts. In contrast to PCLBCL-LT, EBV+ MTX-associated B-LPD strongly expressed 
CD30, whereas FOXP1 and MYC were expressed by only 2 and 1 of 5 cases, respectively. 
The consistent expression of CD30 is seen in most EBV+ lymphomas due to the induction 
of CD30 in B-cells by EBV.24 In addition, weak or absent expression CD79a in 4 of the cases, 
combined with loss of expression of CD20 in 1 case, has not been reported in PCLBCL-LT. 
Reduced or  absent expression of CD20 was also described in 31% of EBV+ mucocutaneous 
ulcers, an EBV-associated mucocutaneous large B-cell proliferation, usually related to an im-
munosuppressive state,25 which suggests a possible relation between EBV infection and B-cell 
marker loss. Some of the features of EBV+ MTX-associated B-LPDs, including spontaneous 
regression and loss of expression of CD20, show overlap with EBV+ mucocutaneous ulcers. 
However, none of our cases exactly matched the criteria of EBV+ mucocutaneous ulcers, as 
these  characteristically present with solitary sharply circumscribed ulcers.25 Differentiation 
of lymphomatoid granulomatosis from EBV+ MTX-associated B-LPD is based on the clinical 
presentation, for example, skin lesions combined with (bilateral) pulmonary nodules as well 
as the histopathological growth pattern, showing angioinvasion and angiodestruction.26 Dis-
tinction from EBV+ DLBCL of the elderly might be more challenging, especially as our pa-
tients are generally older and have received MTX treatment for several years, and therefore 




Figure 2. EBV+ MTX-associated B-LPD in the skin
Figure 3. EBV- MTX-associated B-LPD in the skin
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* Legend to Figure 2 (previous page): Representative slides from case 2. In overview, the tumor showed a diffuse 
growth pattern (A). The tumor cell morphology was highly variable with some admixed very large and multi-
lobated tumor cells (B). The tumor cells did not show immunohistochemical positivity for B-cell marker CD20 
and showed weak expression of CD79a (C), although the cells were positive for B-cell lineage markers PAX5 (D), 
OCT2, and BOB1, and showed clonal B-cell rearrangements. CD30 showed strong membranous positivity (E) and 
EBER showed positivity in scattered large tumor cells.
* Legend to Figure 3 (previous page): Representative slides from case 8. In overview, the tumor showed a dif-
fuse growth pattern (A). The tumor cells had a predominantly immunoblastic morphology with a large central 
nucleolus and round nuclear contour (B). The tumor cells showed strong immunohistochemical expression of 
B-cell marker CD20 (C). The amount of admixed T-lymphocytes in a CD3 stain was low (D). FOXP1 (E) and MYC 
(F) showed diffuse and very strong nuclear staining in almost all tumor cells.
 
Histologic differentiation between EBV- MTX-associated B-LPD and PCLBCL-LT is much more 
difficult. Both conditions show a rather monotonous proliferation of centroblasts and/or 
immunoblasts and a very similar phenotype including expression of MYC (Table 4). How-
ever,  > 85% of patients with PCLBCL-LT present with skin tumors confined to 1 or both legs.11 
 Presentation with generalized skin lesions is uncommon in this group and should raise sus-
picion that the patient has another type of DLBCL, that is, an MTX-associated or otherwise 
immunodeficiency-associated B-LPD or a secondary cutaneous DLBCL.
In conclusion, in a patient presenting with skin tumors with the histologic features of a DLBCL, 
the presence of ulcerating and/or generalized skin lesions, marked tumor cell polymorphism, 
and reduced staining for CD79a, diagnosis of MTX- or immunodeficiency-associated B-LPD 
should be considered. In such cases EBV and CD30 expression should be performed, if not 
investigated already routinely. The relatively good clinical outcome and spontaneous disease 
regression after only withdrawal of MTX in a considerable proportion of patients warrants 
for a period of careful wait-and-see policy before considering more aggressive therapies in 
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In the WHO-EORTC classification, B-cell lymphomas primarily presenting in the skin are 
 categorized as primary cutaneous marginal zone B-cell lymphoma (PCMZBL), primary cuta-
neous follicle center lymphoma (PCFCL) or primary cutaneous large B-cell lymphoma, leg 
type  (PCLBCL-LT).1 The three subtypes have their own clinicopathologic characteristics, but 
diffe rentiation between PCFCL and PCLBCL-LT can sometimes be challenging. These two lym-
phoma subtypes generally show clinical differences in presentation, i.e. localized skin lesions 
on the head, in particular the scalp, or trunk for PCFCL, and skin lesions on one or both legs 
for PCLBCL-LT, but the distinction between the two entities is primarily based on specific tu-
mor cell morphology, i.e. large cells with cleaved nuclei (centrocytes) in PCFCL and large cells 
with round nuclei (centroblasts and immunoblasts) in PCLBCL-LT.1,2 However this distinction 
based on tumor cell morphology can become challenging when cases of PCFCL have a diffuse 
growth pattern and lack the follicular infiltrate that is distinct from the growth pattern of 
PCLBCL-LT. Accurately separating these two types of lymphoma has large implications for the 
patient, as PCFCL are treated with local radiotherapy (5-year overall survival (OS) 95%), but 
patients with PCLBCL-LT are preferentially treated with polychemotherapy, and still have an 
unfavorable clinical outcome (5-year OS survival 50%).3
Recent guidelines indicate that patients with PCLBCL-LT should be treated with R-CHOP, 
 cyclophosphamide, doxorubicin, vincristine, and prednisone combined with monoclonal anti-
body rituximab, directed at CD20 at the surface membrane of B-lymphocytes.4 However, due 
to the relatively high age at first presentation and concomitant comorbidities, not all patients 
are eligible for this type of chemotherapy. Furthermore, a proportion of patients receiving 
polychemotherapy still show an aggressive clinical course after initial response, leading to a 
challenge in further treatment strategies. Patients might therefore benefit from therapies 
that are less toxic and target more specifically the lymphoma cells, to reduce morbidity and 
increase survival. Molecular and/or genetic characterization of these tumors is thus warran-
ted and might reveal better insight into the pathogenesis of the disease. These insights might 
eventually yield potential targets for therapy directed specifically at these targets.
A rare type of diffuse large B-cell lymphoma (DLBCL) presenting in the skin is methotrexate 
(MTX)-associated B-cell lymphoproliferative disorder (B-LPD). This lymphoma belongs to the 
group of ‘iatrogenic immunodeficiency-associated lymphoproliferative disorders’5 and deve-
lops in patients with autoimmune disorders (mainly rheumatoid arthritis) receiving chronic 
low-dose treatment with MTX. The clinicopathologic features of MTX-associated B-LPD first 
presenting in the skin are still ill-defined, as there are only sporadic reports in literature.6-10 
Differentiation from PCFCL and PCLBCL-LT is nonetheless important, as these lymphomas 
require a different therapeutic approach. It seems warranted to stop MTX treatment and 
follow a careful wait-and-see policy to evaluate potential remission before considering more 
aggressive therapies, as regression of MTX-associated lymphomas after abrogation of MTX 
treatment has been reported.11
The studies presented in this thesis investigated clinicopathologic and genetic aspects of 
 PCFCL and PCLBCL-LT. The main aims of this thesis were (1) to define additional diagnostic 
markers that could aid in the differential diagnosis of PCFCL with a diffuse growth pattern 
from PCLBCL-LT, (2) to investigate molecular and genetic alterations in PCLBCL-LT underlying 
the pathogenesis of this type of lymphoma, and (3) to better define the group of MTX-asso-
ciated B-LPD presenting in the skin, in order to find clinicopathologic and/or immunopheno-
typical characteristics that would allow rapid recognition of these lymphomas. In this final 
chapter, these issues will be discussed based on the data and observations described in the 
preceding chapters and in recent literature.
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Differentiation between PCFCL and PCLBCL-LT
IgM immunohistochemistry
Gene expression profiling studies in PCFCL and PCLBCL-LT have demonstrated different gene 
expression profiles for both lymphoma subtypes, including higher expression of immunoglo-
bulin mu heavy chain enhancer and constant region (IGHM) transcripts in PCLBCL-LT as com-
pared to PCFCL.12 In chapter 2, we explored whether these differences were also reflected 
at protein levels, and performed B-cell heavy and light chain characterization for 53 patients 
with PCFCL and 40 patients with PCLBCL-LT by immunohistochemistry on formalin-fixed and 
paraffin-embedded (FFPE) tumor biopsy specimens. All 40 cases of PCLBCL-LT consistently 
showed cytoplasmic staining for IgM, in 18 of them with coexpression of IgD. In contrast, only 
5 of the PCFCL cases showed cytoplasmic staining for IgM and/or IgD. Not only PCLBCL-LT 
presenting on the leg, but also those cases presenting on the trunk or head, showed strong 
expression of IgM, implying that for lesions on these locations IgM expression might be used 
as an additional marker in differentiating between PCFCL and PCLBCL-LT in clinical pathology 
practice. However, the three PCFCLs that presented on the leg(s) also expressed IgM. There-
fore, IgM expression does not seem to discriminate between both lymphoma subtypes when 
presenting on the leg. Recent studies confirmed our findings, demonstrating expression of 
IgM in 10 out of 10 cases of PCLBCL-LT and only 3 out of 30 cases of PCFCL.13
 
MicroRNA profiling
MicroRNAs can regulate gene expression of their target genes by being able to inhibit transla-
tional initiation by blocking ribosomes and they can also directly target mRNA at the 3 prime 
untranslated region leading to degradation of the molecule.14 Higher expression of a certain 
microRNA might therefore silence a tumor suppressor gene, while loss of expression might 
cause oncogenes to be upregulated. Through these mechanisms, microRNAs are thought to 
contribute in oncogenesis (reviewed in 15).  In chapter 3 we investigated microRNA profiles 
by performing high-throughput sequencing analysis on frozen tumor biopsies from 6 cases of 
PCFCL and 13 cases of PCLBCL-LT. Analogous to previous gene expression profiling studies,12 
we tried to cluster PCFCL and PCLBCL-LT based on their microRNome. In contrast to gene 
expression profiling, cluster analysis of the complete microRNA profile did not discriminate 
the lymphoma subtypes. As gene expression profiles of PCFCL and PCLBCL-LT were concor-
dant with a germinal center B-cell (GCB) and activated B-cell (ABC), respectively, we tried to 
cluster the two cutaneous lymphoma subtypes by three different microRNA profiles of these 
two B-cell subtypes from literature.16-18 These microRNA profiles were reported to be able to 
separate nodal ABC-type from GCB-type DLBCL, but we were not able to separate our two 
groups by one of these methods. Still, the extensive profiling method yielded 16 individual 
mature microRNAs that were differentially expressed between PCFCL and PCLBCL-LT. Single 
microRNA quantitative PCR (qPCR) was conducted for 11 of these 16 microRNAs on FFPE tu-
mor biopsies of 20 additional cases (10 cases of PCFCL and 10 cases of PCLBCL-LT), confirming 
higher expression of miR-9-5p, miR-31-5p, miR-129-2-3p and miR-214-3p in PCFCL as com-
pared to PCLBCL-LT.  This technique can easily be performed on routine biopsy specimens. 
Especially the detection of miR-129-3p by RT-qPCR on FFPE tumor biopsies might be helpful 
in clinical settings, as this microRNA was not expressed in a detectable amount in PCLBCL-LT, 
but showed substantial expression in about half of the cases of PCFCL. This microRNA there-
fore seems a rather specific, yet not highly sensitive, marker for PCFCL. Remarkably, this miR-
129-2-3p was also specifically expressed in substantial amounts in GCB-type nodal DLBCL as 




seems a true germinal center-related microRNA.
Pathogenesis of primary cutaneous diffuse large B-cell lymphoma, leg type
Class switch recombination
In chapter 2 we demonstrated consistent immunohistochemical cytoplasmic expression 
of IgM in 40 cases of PCLBCL-LT, with co-expression of IgD in about half of them. As geno-
typing showed that PCLBCL-LT have the profile of a post-germinal center, activated B-cell,12 
it is expected that class switch recombination (CSR) from IgM (and IgD) to IgG or IgA has 
 occurred. Given this presumed germinal center experience, the absence of CSR in PCLBCL-LT 
is  surprising and might indicate a defect in the CSR mechanism. Although deficiency of the 
 RNA-editing enzyme activation-induced cytidine deaminase (AID) is associated with impair-
ment of CSR,19 relatively high levels of AID have been demonstrated in PCLBCL-LT,20 so the 
absence of CSR cannot be explained by shortage of AID. The expression of IgM is not exclusive 
for PCLBCL-LT. Over 50% of nodal DLBCL also show immunohistochemical expression of IgM 
in the tumor cells,21,22 and high levels of IgM RNA are more frequently encountered in ABC-
type DLBCL than in GCB-type DLBCL.23 IgM expression therefore seems ABC-type related, and 
is indeed also encountered in primary central nervous system (CNS) DLBCL, and primary tes-
ticular  DLBCL, two types of extranodal DLBCL that are also of ABC-type.24,25 In nodal ABC-type 
DLBCL as well as in primary CNS DLBCL it was suggested that CSR was impaired due to the high 
frequency of mutations in the switch regions of the constant chain, comprising both intra-Sµ 
and intra-Sγ deletion/recombination events,26,27 but data concerning these switch regions are 
not  available for PCLBCL-LT. Noteworthy, it was recently described that transcription factor 
forkhead box protein 1 (FOXP1) might also play a role in (blocking) CSR, as constitutio nal 
expression of FOXP1 led to impairment of switching from IgM to IgG1.28 Indeed in  PCLBCL-LT, 
immunohistochemical FOXP1 expression is consistently high, as was shown in chapter 5, al-
though the exact underlying mechanism for this high expression is not yet understood.
 
Nuclear factor-kappa B
Aberrant constitutive activation of the nuclear factor-kappa B (NF-κB) signal transduction 
pathway has been implicated in tumor cell survival of nodal ABC-type DLBCL and other types 
of B-cell lymphomas. Studies on the molecular background of NF-κB pathway activation have 
demonstrated that mutations in multiple genes can cause deregulation of NF-κB signaling in 
nodal ABC-type DLBCL.29 The genes most frequently affected by genetic aberrations are tu-
mor necrosis factor, alpha-induced 3 (TNFAIP3, A20), cluster of differentiation 79B (CD79B), 
caspase recruitment domain-containing protein 11 (CARD11), and myeloid differentiation 
primary response gene 88 (MYD88), which all can contribute to constitutive activation of 
the NF-κB pathway, and in two-third of cases of nodal ABC-type DLBCL, one or more of these 
genes are affected.30 In chapter 4, we investigated NF-κB activating genetic aberrancies in 10 
cases of PCLBCL-LT. Tumor suppressor gene TNFAIP3 was heterozygously deleted in 4 cases. 
No additional promoter hypermethylation was detected that would lead to epigenetic silen-
cing of the non-deleted allele. A CD79B Y196 mutation was found in 2 cases in both DNA 
and cDNA. The coiled-coil domain of CARD11 contained a D415E and a R423W mutation in 
1 sample. At genomic level, the oncogenic MYD88 L265P mutation was found in 4 cases, 3 
of which showed the same mutation at transcriptional level. Combined, 7 out of 10 cases 
of PCLBCL-LT showed genetic alterations in genes that regulate NF-κB activation. Although 
estimation of the real proportion of alterations is difficult in this relatively small study co-
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hort, for pathway activating mutations in CD79B, MYD88, and CARD11 the percentages of 
tumors affected strikingly resemble those present in nodal ABC-DLBCL.30 However, the ho-
mozygous deletion and/or epigenetic silencing of TNFAIP3, as is encountered in 23% of cases 
of  nodal  ABC-DLBCL,30 was not detected in our cases of PCLBCL-LT. The data on the deletion 
of (part of) chromosome 6q, on which TNFAIP3 is located, are in line with previous studies 
in  PCLBCL-LT using conventional array comparative genomic hybridization31 or fluorescent in 
situ hybridization.32 Furthermore, other studies detected MYD88 L265P mutations in 69% of 
PCLBCL-LT cases.32,33
Several molecules in the NF-κB pathway have already been selectively targeted in B-cell NHL 
in vitro and in vivo to explore potential new treatments strategies. For example, sotrastaurin 
can interfere with NF-κB pathway activation, by inhibition of PKC-β, which is required for 
CARD11-dependent activation of the NF-κB pathway.34 Sotrastaurin was shown to be selec-
tively toxic for CD79-mutant DLBCL in a mouse xenograft model35 as compared to unmutated 
DLBCL, but only in presence of wild-type CARD11. An RNA interference screen revealed that 
a BCR signaling component, Bruton’s tyrosine kinase (BTK), is essential for the survival of 
nodal ABC-type DLBCL with wild-type CARD11 and in addition, knockdown of proximal B-cell 
receptor units, i.e. CD79B, was selectively toxic to wild-type CARD11 nodal ABC-type DLBCL, 
but not to other lymphomas.36 Furthermore, in a phase I trial, the BTK-inhibitor ibrutinib was 
well-tolerated and generated a clinical (partial) response in 40% of refractory nodal ABC-type 
DLBCL, both in patients with tumors bearing CD79 mutations or a combination of CD79 and 
MYD88 mutations. However, patients with only MYD88 mutations were refractory to this 
treatment, reflecting the B-cell receptor signaling-independency of these MYD88-mutated 
tumors.37 The potency of ibrutinib in treating nodal ABC-DLBCL has recently been further 
explored, in a high throughput combinatorial screening study, yielding drugs that could co-
operate with ibrutinib in killing ABC-DLBCL cells in vitro.38 Together, these results imply the 
relevance of somatic mutations in CD79B, CARD11 and MYD88 in developing new treatments 
for nodal ABC-DLBCL, and potentially for the treatment of PCLBCL-LT. Especially the impact of 
ibrutinib in the treatment of (several types of) B-cell lymphomas seems promising in treating 
PCLBCL-LT patients who are not eligible for aggressive treatment or who quickly relapse after 
receiving polychemotherapy.39 Therefore, particularly investigating the mutational status of 
MYD88 in PCLBCL-LT might become of clinical relevance, as these patients will potentially not 
benefit from treatment with ibrutinib.
As 70% of PCLBCL-LT shows genetic aberrancies in NF-κB pathway-related genes, our data 
also emphasize the relevance of NF-κB signaling in this type of lymphoma. In nodal ABC-
DLBCL, NF-κB signaling has been recognized as a key feature.40 The lack of genetic  aberrancies 
in the remaining 30% of our cases studied does not necessarily imply physiological NF-κB 
signaling in these cases, as activating mutations in pathway components are not the only 
pathophysiologic mechanism underlying constitutive signaling of this pathway. For example, 
hedgehog signaling is deregulated in DLBCL.41 The dysregulation might partly be due to copy 
number gains involving smoothened (SMO), which is a signal transducer subunit of the hedge-
hog pathway.42 Aberrant hedgehog signaling has been linked to NF-κB pathway activation in 
 DLBCL through SMO, which is able to recruit G-protein subunits that lead to NF-κB pathway 
activation through PKC-β – CARD11 signaling.43 Furthermore, several microRNAs have been 
implicated in NF-κB pathway activation. MiR-155 is able to downregulate IκB kinases, which 
will lead to enhanced NF-κB signaling.44 MiR-21 blocks translation of phosphatase and ten-
sin homolog (PTEN), which is a tumor suppressor inhibiting the activation of NF-κB by AKT 




compared to GCB-DLBCL, concordant with NF-κB being a feature of ABC-DLBCL. However, in 
our cohort explored in chapter 3, we did not encounter differences in expression levels of 
miR-155 and miR-21 between PCLBCL-LT and PCFCL. This might imply that these microRNAs 
do not contribute in aberrant NF-κB signaling in PCLBCL-LT, or that aberrant signaling is also a 
feature of PCFCL. This unclarity warrants for further investigation into this topic.
Transcription factors
In physiologic circumstances, B-cell lymphoma 6 (BCL6) is expressed in germinal center 
B-cells and downregulates Blimp1 expression, the protein encoded by of PR domain con-
taining 1, with ZNF domain (PRDM1).45 After a successful germinal center reaction, BCL6 is 
downregulated, leading to expression of Blimp1. This Blimp1 expression is sufficient to allow 
B-cells to undergo plasma cell maturation, and also induces other transcription factors, such 
as interferon regulatory factor-4 (IRF4), which are also part of the plasma cell program.46 Fur-
thermore, FOXP1 expression is inversely correlated to BCL6 expression, thereby occurring in 
a post germinal center stage, and FOXP1 is also able to upregulate the expression of Blimp1.28 
Noteworthy, the immunohistochemical profile of PCLBCL-LT concerning these transcription 
factors is inconsistent with the profile of activated B-cells, its presumed cell of origin, as BCL6 
is expressed in more than half of the cases, IRF4 and FOXP1 are virtually always expressed by 
the tumor cells, and no substantial expression of Blimp1 is detected.47 The activated B-cell, as 
normal counterpart of PCLBCL-LT, is arrested in differentiation in a transitional stage between 
germinal center B-cell and plasma cell.12 In nodal DLBCL, several mechanisms have been de-
scribed that might (in part) be responsible for this differentiation arrest, for example translo-
cations involving BCL6,48,49 deletion and mutations PRDM1.48,50 Other molecules driving B-cells 
towards plasma cell differentiation include IRF4 and FOXP1, and sporadic genetic alterations, 
such as translocations involving these genes, also occur in nodal DLBCL.51,52 In chapter 5, we 
investigated genetic and immunohistochemical alterations of these B-cell activation-related 
transcription factors in ten cases of PCLBCL-LT. We could not find evidence that BCL6, FOXP1 
and/or IRF4 have an autonomous way of protein upregulation, as we did not encounter trans-
locations or amplifications involving these genes. Moreover, the absence of Blimp1 protein 
by immunohistochemistry in PCLBCL-LT could not be explained by genetic silencing through 
homozygous deletion of the gene, or heterozygous deletion with concomitant missense or 
nonsense mutations. These alterations actually have been described in ABC-DLBCL, the nodal 
counterpart of PCLBCL-LT. Especially genetic inactivation of PRDM1 is frequently detected in 
ABC-DLBCL, occurring in approximately one-third of cases.48,50 Translocations involving IRF4 
have only sporadically been described in nodal ABC-DLBCL51 and translocations involving 
FOXP1 are also infrequent, but might preferentially be detected in extranodal DLBCL.52
 
MYC
In the study described in chapter 6, in which we compared MTX-B-LPD presenting in the skin 
with PCFCL and PCLBCL-LT, we demonstrated that PCLBCL-LT were consistently positive for 
MYC immunohistochemistry, and more than 75% of the tumor cells showed nuclear  staining 
in the 10 cases investigated. In nodal DLBCL, high percentages of MYC-positive tumor cells 
have been linked to MYC rearrangement, gain and/or amplification (53, 54). However, in 
PCLBCL-LT, data concerning translocations involving the MYC gene vary, from occurrence in 
sporadic cases55 to approximately one-third of cases.56 Reports of gains or amplification of 
the MYC gene have to our knowledge not been reported and were not found in the same 
cohort of 10 patients PCLBCL-LT, for which immunohistochemistry was reported, by using fine 
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tiling comparative genomic hybridization (FT-CGH) analysis (Koens et al, unpublished data). 
Above that, in this cohort, FT-CGH analysis did also not reveal evidence of translocations 
involving the MYC gene. MYC protein levels are therefore most likely upregulated by other 
mechanisms. MYC is under physiologic circumstances repressed by B-cell transcription factor 
Blimp-1 in post-germinal center B-cells.57 This protein is however absent in PCLBCL-LT47 and 
this absence might therefore contribute to high levels of MYC protein.
Methotrexate-associated B-cell lymphoproliferative disorder presenting in the skin
In chapter 6 the clinicopathologic and phenotypical features of 10 patients with MTX- 
associated B-LPD first presenting in the skin were studied, including 5 Epstein Barr virus (EBV)- 
positive and 5 EBV-negative cases. 6 patients had skin-limited disease. Clinically, abrogation of 
MTX therapy resulted in a complete response in four cases and a partial response in another 
two. The 5-year disease-specific survival was 90%. MTX-associated B-LPD differed from PCFCL 
by the presence of ulcerating and/or generalized skin lesions, an infiltrate composed of cen-
troblasts/immunoblasts rather than large centrocytes, reduced staining for CD79a, expres-
sion of BCL2, IRF4, FOXP1 in most cases, and monotypic intracytoplasmic immunoglobulin 
expression in half of the cases. EBV-positive MTX-associated B-LPD differed from PCLBCL-LT 
by the presence of ulcerating skin lesions, marked tumor cell polymorphism, reduced staining 
for CD79a, and expression of CD30 and EBV. EBV-negative cases showed morphological and 
immunophenotypical similarities to PCLBCL-LT, but differed by presentation with generalized 
skin lesions in 4 of 5 cases.  The good clinical outcome and spontaneous disease regression 
that occurred after withdrawal of MTX  in a considerable proportion of patients, underscores 
the importance of a careful wait-and-see policy before considering more aggressive therapies 
in patients with  MTX-associated B-LPD of the skin.
Concluding remarks and perspectives
Through the different studies described in this thesis more knowledge is gained about the 
clinicopathologic (and genetic) aspects of PCFCL, PCLBCL-LT and MTX-associated B-LPD 
 presenting in the skin. The results aid in better definition of these separate entities, and 
thereby generate leads for diagnosing these lymphomas in clinical practice. The  differences 
in  microRNA profile further support the notion that PCFCL and PCLBCL-LT are different 
 molecular entities with different biological behavior. An up-to-date overview of clinicopatho-
logic, immunophenotypical and molecular genetic features of PCFCL and PCLBCL-LT is  given 
in Table 1. For PCLBCL-LT therapeutical improvement is much needed and delineation of mo-
lecular or genetic events in the development and/or progression of this type of lymphoma 
might yield potential leads for targeted therapy. Currently known potential genetic events 
and involved molecular pathways in PCLBCL-LT are depicted in Figure 1. In the light of poten-
tial treatments, the studies described in this thesis provide evidence that components of the 
NF-κB pathway might be interesting therapeutical targets. As targeted therapy based on spe-
cific molecular characteristics is extensively explored in nodal DLBCL,58 it will be  important to 
further investigate these specific molecular features in PCLBCL-LT, to find out whether these 
therapies might also be beneficial for patients with this type of lymphoma. The observed 
differences between MTX-associated B-LPD presenting in the skin and PCFCL and  PCLBCL-LT 
might give clinicians clues for diagnosing this rare entity. However, it is still unknown which 
cases will spontaneously resolve after abrogation of MTX therapy and which will show pro-




 molecular and geneti c background of MTX-associated B-LPD presenti ng in the skin are there-
fore required to bett er understand its biological behavior.
Figure 1. Molecular and geneti c pathways and aberrati ons in PCLBCL-LT
The (previously) demonstrated aberrati ons are depicted in red of which the ones represented in bold were 
demonstrated in the studies described in this thesis. The green boxes represent a selecti on of therapeuti cal 
targets that are under current investi gati on in nodal DLBCL.
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    - lesions solitary or multiple tumors solitary or multiple tumors
    - site of primary presentation head and/or trunk one or both leg(s)
    - cutaneous relapse 30% 69%
    - nodal/visceral dissemination 10% 47%
    - 5 year OS/DSS 87% / 95% 37% / 50%
    - first choice treatment local radiotherapy R-CHOP
Histopathology
    - infiltrate diffuse or (partly) follicular diffuse
    - B-cell morphology centrocytes (cleaved) centroblasts/immunoblasts 
round)
    - T-cell admixture abundant sparse
Immunohistochemistry
    - B-cells
* B-cell lineage markers CD20+, CD79a+, PAX5+ CD20+, CD79a+, PAX5+
* germinal center markers BCL2-, BCL6+, CD10- BCL2+, BCL6+/-, CD10-
* activation markers IRF4/MUM1-, FOXP1- IRF4/MUM1+, FOXP1+
* B-cell receptor heavy/light chains- 
(intracytoplasmic)
IgM+, IgD+/-, monotypic light
chain+ (intracytoplasmic)
* cell cycle regulator marker MYC- MYC+
    - background CD21/CD35: (remnants of) 
follicular dendritic networks
CD21/CD35: no (remnants of) 
follicular dendritic networks
Molecular genetics
    - copy number alteration amplification 2p16.1 region, 
deletion 14q11.2-q12
deletion 6q arm, deletion 
9p21.3 region
    - gene expression profiling high expression SPINK2 high expression IGHM, PIM1, 
PIM2, IRF4 and OCT2
   - microRNA profiling miR-129-2-3p present in 50% no miR-129-2-3p present
   - NF-κB pathway mutations not available MYD88 mutations 40%, 
CD79B mutations 20%, 
CARD11 mutations 10%
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Primair cutane lymfomen zijn maligne non-Hodgkinlymfomen (NHL) die zich primair in de 
huid presenteren zonder ziektemanifestaties buiten de huid op het tijdstip dat de diagnose 
gesteld wordt. Primair cutane lymfomen dienen onderscheiden te worden van nodale NHL die 
zich secundair in de huid manifesteren, aangezien het NHL zijn met een specifiek  biologisch 
gedrag en een specifieke prognose. Om deze reden worden ze vaak ook anders behandeld 
dan hun nodale tegenhangers. De verschillende typen primair cutane lymfomen worden ook 
als specifieke entiteiten beschreven in de recentste classificatiesystemen voor lymforeticu-
laire maligniteiten, zoals de World Health Organization (WHO)-European  Organization for 
 Treatment of Cancer (EORTC)-classificatie en de WHO-classificatie (2008).
Terwijl nodale NHL voornamelijk van B-celorigine zijn, behoren de primair cutane 
 B-cellymfomen (CBCL) tot de minderheid (20-25%) van alle primair cutane lymfomen. In de 
WHO- EORTC-classificatie wordt de groep van CBCL ingedeeld in primair cutane marginale 
zone B-cellymfomen (PCMZBL), primair cutane follikelcentrumlymfomen (PCFCL) en primair 
cutane diffuus grootcellige B-cellymfomen – beentype (PCLBCL-LT). PCMZBL toont histolo-
gisch een gemengd infiltraat waarin onder andere kleine maligne B-cellen worden aange-
troffen, die morfologisch variëren van marginalezonecellen tot lymfoplasmacytoïde cellen 
en plasmacellen. De plasmacellen tonen karakteristiek immuunhistochemisch monotypische 
intracytoplasmatische expressie van immunoglobulines. PCMZBL is een indolent type NHL 
met een ziektespecifieke 5-jaarsoverleving van vrijwel 100%. PCFCL toont histologisch hoofd-
zakelijk middelgrote tot grote centrocyten (morfologisch gekliefde cellen), bijgemengd met 
een variabel aantal centroblasten. Het groeipatroon van dit infiltraat is folliculair, folliculair 
en diffuus of, zoals in de meeste gevallen, diffuus. Het histologische groeipatroon is niet ge-
relateerd aan de prognose. De patiënten presenteren zich klinisch met gelokaliseerde huidtu-
moren, die zich voornamelijk op het (behaarde) hoofd of de romp bevinden. De tumoren 
reageren zeer goed op lokale radiotherapie en de ziekte heeft een zeer gunstige prognose 
(5-jaarsoverleving 95%). PCLBCL-LT toont histologisch een diffuus groeiend infiltraat, dat is 
opgebouwd uit  centroblasten en/of immunoblasten (morfologisch ronde cellen) met over 
het algemeen weinig bijgemengde, reactieve T-cellen. Patiënten met PCLBCL-LT presen-
teren zich klinisch met huidtumoren op één of beide benen en hebben veelal een agressief 
 ziektebeloop (5-jaarsoverleving 50%). De voorkeursbehandeling bestaat derhalve uit meer-
dere cycli agressieve immunochemotherapie. 
 
Onderscheid tussen PCFCL en PCLBCL-LT
Het clinicopathologische onderscheid tussen PCFCL met een diffuus groeipatroon en 
 PCLBCL-LT kan soms erg lastig zijn. Deze differentiatie is echter van groot belang, gezien de 
verschillen in klinisch beloop en voorkeursbehandeling. 
 
IgM immuunhistochemie
Bij een eerdere verrichte genexpressiestudie werd veel hogere expressie van immuunglo-
buline zware keten mu (IgM) gevonden in PCLBCL-LT vergeleken met PCFCL. Om uit te  vinden 
of dit verschil zich ook manifesteert op eiwitniveau werden in hoofdstuk 2 immuunhisto-
chemische kleuringen voor zware en lichte ketens verricht op paraffinemateriaal van 53 
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 tumorbiopten van patiënten met PCFCL en 40 van patiënten met PCLBCL-LT. Alle 40 PCLBCL-
LT- biopten toonden intracytoplasmatische expressie van IgM in de tumorcellen, waarbij er 
bij 18 van deze biopten co-expressie was van IgD. Dit betrof zowel PCLBCL-LT met tumoren 
op de benen als met tumoren op andere plaatsen. Daarentegen werd intracytoplasmatische 
expressie van IgM slechts in 5 van de 53 PCFCL-biopten gezien. De 3 patiënten met PCFCL 
die zich presenteerden met tumoren op de benen waren alle 3 positief voor IgM (en IgD). 
Dit betekent dat intracytoplasmatische expressie van IgM (en IgD) vooral goed kan differen-
tiëren tussen PCFCL en PCLBCL-LT met tumoren die zich op het tijdstip van de diagnose niet 
op de benen bevinden. Aangezien het simpel uit te voeren immuunhistochemische kleurin-
gen  betreft die op paraffinebiopten kunnen worden verricht, kunnen deze kleuringen in de 




MicroRNA’s kunnen de genexpressie van hun doelgenen reguleren. Dit kan onder andere 
middels het inhiberen van de translationele initiatie van het doelgen door het blokkeren van 
ribosomen. MicroRNA’s kunnen ook direct binden aan het reeds gevormde messenger RNA 
van het doelgen, wat leidt tot directe degradatie van dit molecuul. Als een bepaald microRNA 
in hoge mate tot expressie komt, zou dit derhalve kunnen leiden tot het onderdrukken van 
expressie van een tumorsupressorgen, terwijl verlies van expressie van een bepaald micro-
RNA zou kunnen zorgen voor hogere expressie van oncogenen. Middels deze mechanismen 
zouden microRNA’s bij kunnen dragen aan de oncogenese van tumoren. 
In hoofdstuk 3 werd het complete microRNA-profiel bepaald op vriesmateriaal van 
 huidtumoren van 6 patiënten met PCFCL en 13 patiënten met PCLBCL-LT met behulp van 
high-throughput sequencing. Overeenkomstig de clusteranalyses van eerdere genexpressie-
studies werd geprobeerd de casus PCFCL en PCLBCL-LT te clusteren op basis van de gegene-
reerde microRNA-profielen. In tegenstelling tot de genexpressiestudies kon deze cluster-
analyse echter geen evident onderscheid maken tussen PCFCL en PCLBCL-LT. Aangezien 
eerder op basis van genexpressieprofielen was aangetoond dat PCFCL en  PCLBCL-LT 
 gelijkenissen vertonen met respectievelijk kiemcentrum-B-cellen (GCB) en geactiveerde 
B-cellen (ABC), werd vervolgens geprobeerd clusteranalyse te verrichten op basis van 3 gese-
lecteeerde microRNA- profielen, waarvan in de literatuur beschreven is dat deze onderscheid 
kunnen maken tussen nodale diffuus grootcellige B-cellymfomen (DLBCL) van het GCB- en 
het ABC-type. Ook middels cluster analyse volgens deze profielen was het echter niet moge-
lijk de PCFCL en PCLBCL-LT evident te onderscheiden. Er werd echter wel van 16 indi viduele 
microRNA’s aangetoond dat deze differentieel tot expressie kwamen tussen PCFCL en PCLB-
CL-LT. Van 11 van deze 16 individuele microRNA’s werd een quantitatieve PCR  (qPCR)-analyse 
verricht op in formaline gefixeerd en in paraffine ingebed (FFPE) tumorweefsel van 20 additio-
nele patiënten (10 PCFCL en 10 PCLBCL-LT). Hiermee werd de hogere expressie van miR-9-5p, 
miR-31-5p, miR-129-2-3p en miR-214-3p in PCFCL in vergelijking met PCLBCL-LT bevestigd. 
Deze techniek kan  gemakkelijk worden verricht op routinematig verwerkte biopsiespecimens. 
Vooral het detecteren van miR-129-3p door middel van qPCR op FFPE tumorweefsel zou mo-
gelijk in de kliniek van aanvullende waarde kunnen zijn, aangezien dit microRNA in geen enkel 
PCLBCL-LT-biopt gedetecteerd werd, maar wel in ongeveer de helft van de PCFCL-biopten. 
Alhoewel de sensitiviteit niet erg hoog is, lijkt dit microRNA derhalve wel een zeer specifieke 
marker voor PCFCL. Het is bovendien opvallend dat microRNA-129-2-3p in de controlegroep 
van 20 nodale DLBCL ook duidelijk hoger tot expressie kwam in de GCB-biopten dan in de 
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ABC-biopten. Mogelijkerwijs betreft het dus een kiemcentrumgerelateerde microRNA.
 
Pathogenese van PCLBCL-LT
Alhoewel een deel van de PCLBCL-LT-patiënten langdurige remissie toont na behandeling 
met agressieve immunochemotherapie, treden bij een deel van de patiënten ook snelle reci-
dieven op met hierop volgende progressieve ziekte. Omdat een groot deel van de patiënten 
oudere mensen betreft die vaak comorbiditeit tonen, zal ook niet elke patiënt agressieve 
chemotherapie lichamelijk kunnen verdragen. Zowel het vaak niet afdoende zijn van de hui-
dige chemotherapeutische behandeling, als het klinisch niet in aanmerking komen voor che-
motherapie, dwingt tot het zoeken naar additionele behandelingsopties voor PCLBCL-LT. Het 
zou vooral voordelig zijn strategieën te vinden die minder toxich zijn en die direct gericht 
zijn op alleen de maligne cellen. Hiervoor is het van belang een beter inzicht te krijgen in de 




In hoofdstuk 2 werd consistente immuunhistochemische expressie van IgM aangetoond in 
40 PCLBCL-LT-biopten, waarbij de helft co-expressie van IgD toonde. Aangezien genexpres-
siestudies hebben aangetoond dat PCLBCL-LT het profiel heeft van een post-kiemcen-
trum, geactiveerde B-cel, zou echter verwacht worden dat de maligne B-cellen van dit 
lymfoom class-switchrecombinatie (CSR) van IgM (en IgD) naar IgG of IgA zouden heb-
ben ondergaan. De afwezigheid van CSR in PCLBCL-LT zou derhalve kunnen wijzen op 
een defect in het CSR- mechanisme. Eerder is deficiëntie van activatie-geïnduceerde cy-
tidine deaminase (AID) gelinkt aan onvolkomen CSR. Van PCLBCL-LT is echter bekend dat 
het AID relatief hoog tot expressie brengt, dus een tekort aan AID is in dit type lymfoom 
geen verklaring voor de afwezigheid van CSR. De expressie van IgM wordt niet exclusief 
gezien in PCLBCL-LT, maar onder andere ook in andere DLBCL, zowel nodaal als extra-
nodaal. Het betreft dan voornamelijk DLBCL die ook van het ABC-type zijn, zoals  nodale 
ABC-DLBCL, primaire centraal zenuwstelsel DLBCL en primair testiculaire DLBCL. Bij  nodale 
ABC-DLBCL en primaire centraal zenuwstelsel DLBCL is eerder gesuggereerd dat CSR 
in deze lymfomen afwezig zou zijn door mutaties in de switch-regio van het immuunglo-
buline-zwareketengen. Data over deze regio in PCLBCL-LT zijn echter niet beschikbaar. 
Nuclear factor-kappa B
Aberrante constitutieve activatie van de nuclear factor kappa B (NF-κB) signaaltransductier-
oute is betrokken bij tumorceloverleving van onder andere nodale ABC-DLBCL. Op moleculair 
niveau is van afwijkingen in meerdere genen aangetoond dat deze kunnen bijdragen aan de 
aberrante activatie in dit type lymfoom. In tweederde van de gevallen betreft dit afwijkingen 
in tumor necrosis factor-alpha induced-protein 3 (TNFAIP3), cluster of differentiation 79B 
(CD79B), caspase recruitment domain-containing protein 11 (CARD11) en/of myeloid differ-
entiation primary response gene 88 (MYD88). In hoofdstuk 4 onderzochten we een selectie 
van NF-κB-activerende genafwijkingen in 10 PCLBCL-LT-biopten. Er werd een heterozygote 
deletie van tumorsupressorgen TNFAIP3 aangetoond in 4 biopten. Er werd geen additionele 
hypermethylatie van de promoterregio van dit gen aangetoond die zou kunnen leiden tot 
epigenetische downregulatie van het niet-gedeleteerde allel. Een CD79B Y196-mutatie werd 
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in 2 casus aangetoond in zowel DNA als cDNA. Eén tumor toonde zowel een D415E- als een 
R423W-mutatie in CARD11. In het DNA van 4 tumoren werd een L265P-mutatie aangetrof-
fen in MYD88, waarbij 3 van deze tumoren dezelfde mutatie in het cDNA toonden. In totaal 
werden in 7 van de 10 PCLBCL-LT-biopten afwijkingen aangetroffen in de onderzochte genen 
die NF-κB-activatie reguleren. Alhoewel het een kleine groep betreft, komen de percentages 
genetische afwijkingen in CD79B, CARD11 en MYD88 opvallend overeen met die in nodale 
ABC-DLBCL.  Daarentegen tonen nodale ABC-DLBCL in ongeveer een kwart van de gevallen 
homozygote deletie en/of epigenetische downregulatie van TNFAIP3, waarvoor in PCLBCL-LT 
geen aanwijzingen werden gevonden. 
Het selectief inhiberen van meerdere moleculen van de NF-κB-signaaltransductieroute wordt 
reeds onderzocht als mogelijke therapie voor B-cel NHL. Zo kan sotrastaurin met activatie 
van de NF-κB-signaaltransductieroute interfereren door inhibitie van PKC-β, een molecuul 
dat vereist is voor CARD11-afhankelijke NF-κB-activatie en in een muis xenograftmodel was 
sotrastaurin alleen effectief in CD79B-gemuteerde DLBCL. Middels RNA-interferentiescree-
ning werd aangetoond dat Brutons tyrosine kinase (BTK), een component van B-celreceptor-
signalering, essentieel is voor tumorceloverleving in nodale ABC-DLBCL als er sprake is van 
wildtype CARD11. Bovendien was het uitschake len van proximale onderdelen van de B-cel-
receptor, zoals CD79B, selectief toxisch in nodale ABC-DLBCL, maar niet in andere lymfomen. 
In een fase I-onderzoek werd de BTK-inhibitor ibrutinib goed getolereerd en genereerde dit 
medicijn een klinische (partiële) respons in 40% van de refractaire nodale ABC-DLBCL. Deze 
(partiële) respons werd zowel in patiënten met tumoren met CD79-mutaties als in tumoren 
met CD79- en MYD88-mutaties gezien. Als er alleen MYD88-mutaties in de tumoren werden 
aangetroffen, toonden deze patiënten echter geen klinische respons op ibrutinib. De poten-
tie van ibrutinib in de behandeling van nodale ABC-DLBCL werd recent verder onderzocht in 
een high throughput- combinatiestudie, waarin medicijnen werden ontdekt die zouden kun-
nen samenwerken met ibrutinib om ABC- DLBCL-cellen in vitro te doden. Samengevat laten 
deze resultaten de relevantie van somatische mutaties in CD79B, CARD11 en MYD88 zien bij 
het ontwikkelen van nieuwe medicijnen tegen nodale ABC-DLBCL en mogelijk ook voor de be-
handeling van PCLBCL-LT. Met name de impact van behandeling met ibrutinib op (verschillen-
de soorten) B-cellymfomen lijkt beloftevol voor de behandeling van patiënten met PCLBCL-LT 
die niet in aanmerking komen voor agressieve behandeling of die een snel recidief tonen na 
behandeling met conventionele chemotherapie. Met name onderzoek naar de mutatiestatus 
van MYD88 in patiënten met PCLBCL-LT zou klinisch belangrijk kunnen worden, omdat deze 
patiënten mogelijk geen baat zouden hebben bij behandeling met ibrutinib.
Aangezien 70% van de tumoren genetische afwijkingen tonen in NF-κB-signaaltransductie-
routegerelateerde genen, benadrukken onze data ook de relevantie van NF-κB-signalering in 
PCLBCL-LT. In nodale ABC-DLBCL wordt NF-κB-signalering als essentiële eigenschap beschou-
wd. Dat 30% van onze casus geen genetische afwijkingen in deze genen toont, betekent niet 
zonder meer dat er geen afwijkende NF-κB-signalering is in deze casus. Er is namelijk een 
beperkt aantal onderdelen van de route bestudeerd, de canonical en niet de non-canonical 
route is onderzocht en ten derde zijn de verschillende activerende mutaties in componen-
ten van de signaaltransductieroute niet de enige pathofysiologische mechanismen die ten 
grondslag kunnen liggen aan constitutieve activatie van deze route. Hedgehogsignalering is 
bijvoorbeeld ontregeld in DLBCL. Deze ontregeling is waarschijnlijk gedeeltelijk veroorzaakt 
door gain/amplificatie van smoothened (SMO). SMO is een transductiesubunit van hedge-
hogsignalering. In DLBCL is ontregelde hedgehogsignalering gelinkt aan de NF-κB-signaal-
transductieroute via SMO, aangezien SMO in staat is G-eiwitsubunits te recruteren die tot 
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NF-κB-activatie leiden middels PKC-β – CARD11-signalering. Tot slot zijn waarschijnlijk ook 
meerdere microRNA’s  betrokken in NF-κB-activatie. MiR-155 kan IκB-kinases downregule-
ren, wat vervolgens leidt tot verhoogde NF-κB-activatie. MiR-21 kan translatie van phospha-
tase and tensin homolog (PTEN) blokkeren. PTEN is een tumorsuppressor die normaalgespro-
ken NF-κB-activatie inhibeert door middel van AKT-signalering. Van beide microRNA’s wordt 
relatief frequent gerapporteerd dat ze hoger tot expressie komen in nodale ABC-DLBCL dan 
in GCB-DLBCL, overeenkomstig het feit dat NF-κB-signalering een essentiële eigenschap is 
van ABC-DLBCL. Wij troffen in ons cohort dat is onderzocht in hoofdstuk 3 echter geen sig-
nificante verschillen in expressie van miR-155 en/of miR-21 aan tussen PCLBCL-LT en PCFCL. 
Dit zou kunnen betekenen dat deze microRNA’s niet bijdragen aan afwijkende NF-κB-signale-
ring in PCLBCL-LT of dat afwijkende signalering ook een kenmerk zou kunnen zijn van PCFCL. 
Aangezien dit niet duidelijk is, is meer onderzoek op dit gebied gewenst.
Transcriptiefactoren
Onder fysiologische omstandigheden wordt B-cell lymphoma 6 (BCL6) tot expressie ge-
bracht in kiemcentrum-B-cellen en onderdrukt dit eiwit expressie van Blimp1, het eiwit dat 
gecodeerd wordt door PR domain containing 1, with zinc finger domain (PRDM1). Na een 
succesvolle kiemcentrumreactie vermindert de expressie van BCL6, wat leidt tot expressie 
van Blimp1. Deze expressie van Blimp1 is in principe voldoende om B-cellen plasmaceldiffe-
rentiatie te laten ondergaan en induceert ook de expressie van andere transcriptiefactoren 
die betrokken zijn bij het plasmacelprogramma, zoals interferon regulatory factor-4 (IRF4). 
Daarnaast is de expressie van forkhead box P1 (FOXP1) omgekeerd evenredig met de ex-
pressie van BCL6 en komt FOXP1-expressie dus voor in B-cellen na de kiemcentrumreactie. 
Ook FOXP1 kan de expressie van Blimp1 induceren. Het immuunhistochemische profiel van 
 PCLBCL-LT betreffende deze transcriptiefactoren is echter niet consistent met het profiel van 
de geactiveerde B-cellen, de veronderstelde normale tegenhanger van dit lymfoom. BCL6 
komt namelijk in meer dan de helft van de casus tot expressie, IRF4 en FOXP1 worden vrijwel 
altijd gedetecteerd in de tumorcellen en van Blimp1 is nooit substantiële expressie in tumor-
cellen aangetoond.  
De geactiveerde B-cel, als veronderstelde normale tegenhanger van PCLBCL-LT, toont een 
differentiatiestop in de transitionele fase tussen kiemcentrum-B-cel en plasmacel. Er zijn 
in nodale DLBCL meerdere mechanismen beschreven die (gedeeltelijk) verantwoordelijk 
kunnen zijn voor deze stop, zoals bijvoorbeeld translocaties met betrokkenheid van BCL6 
en deleties van en mutaties in PRDM1. IRF4 en FOXP1 zijn andere transcriptiefactoren die 
B-cellen richting plasmaceldifferentiatie kunnen drijven. Sporadische genetische afwijkingen 
met betrokkenheid van deze genen, zoals translocaties, kunnen ook voorkomen in nodale 
DLBCL. In hoofdstuk 5 onderzochten we genetische en immuunhistochemische afwijkingen 
van deze B-celactivatiegerelateerde transcriptiefactoren in 10 PCLBCL-LT-biopten. Er werden 
geen aanwijzingen gevonden dat BCL6, FOXP1 en/of IRF4 een autonome manier van ver-
hoogde expressie toonden, aangezien geen translocaties of amplificaties in de genen werden 
aantroffen. Daarnaast kon de afwezigheid van het eiwit Blimp1 door middel van immuun-
histochemie niet verklaard worden door genetische inactivatie, dat wil zeggen door homo-
zygote deletie van PRDM1 of door heterozygote deletie met bijkomende relevante mutatie 
in het niet-gedeleteerde allel. Deze genetische inactivatie van PRDM1 is wel beschreven in 
ABC-DLBCL, de nodale tegenhanger van PCLBCL-LT, waarbij het in ongeveer eenderde van de 
gevallen voorkomt. Translocaties die IRF4 betreffen zijn slechts sporadisch gerapporteerd in 
nodale ABC-DLBCL en ook FOXP1 is in deze lymfomen niet vaak betrokken in een translocatie, 
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alhoewel deze mogelijk vaker voorkomen in extranodale DLBCL.
MYC
In de studie die is beschreven in hoofdstuk 6, waarin we methotrexaat (MTX)-geassocieerde 
B-cellymfoproliferatieve aandoeningen (B-LPD) die zich in de huid manifesteren vergeleken 
met PCFCL en PCLBCL-LT, toonden we aan dat in alle 10 onderzochte PCLBCL-LT in meer 
dan 75% van de tumorcellen het MYC-eiwit tot expressie werd gebracht. In nodale DLBCL 
zijn hoge percentages MYC-positieve tumorcellen geassocieerd met MYC-herschikking, -gain 
en/of -amplificatie. In PCLBCL-LT variëren de data over translocaties met betrokkenheid van 
MYC nogal, van sporadisch tot eenderde van de gevallen. Publicaties over gain of amplificatie 
van MYC in PCLBCL-LT zijn er echter niet en wij troffen dit ook middels DNA array niet aan 
in de tumoren van ons cohort van 10 patiënten, waarop tevens de immuunhistochemische 
kleuring was verricht. Bovendien werden middels deze methode in de tumoren ook geen 
aanwijzingen gevonden voor translocaties met betrokkenheid van MYC. Het MYC-eiwit komt 
derhalve waarschijnlijk middels andere mechanismen verhoogd tot expressie in PCLBCL-LT. 
Onder fysiologische omstandigheden wordt de expressie van MYC in geactiveerde B-cellen 
onderdrukt door B-celtranscriptiefactor Blimp1. Dit eiwit lijkt echter afwezig in PCLBCL-LT en 
mogelijk draagt deze afwezigheid bij aan de hoge expressie van het MYC-eiwit in dit lymfoom.
Methotrexaatgeassocieerde B-cellymfoproliferatieve aandoeningen van de huid
In hoofdstuk 6 werden de clinicopathologische en fenotypische kenmerken van 10 patiënten 
met MTX-geassocieerde B-LPD van de huid in kaart gebracht, waaronder 5 Epstein-Barrvirus 
(EBV)-positieve en 5 EBV-negatieve gevallen. Bij 6 patiënten was de aandoening beperkt tot 
de huid. Klinisch leidde het stoppen met de MTX-behandeling tot complete remissie bij 4 
patiënten en tot partiële remissie in 2 andere patiënten. De 5-jaars ziektespecifieke over-
leving was 90%. Het verschil tussen MTX-geassocieerde B-LPD en PCFCL lag met name in de 
aanwezigheid van ulcererende en/of gegeneraliseerde huidlaesies, een infiltraat dat meer 
bestaat uit centroblasten/immunoblasten dan uit grote centrocyten, verminderde immuun-
histochemische aankleuring voor CD79a, expressie van BCL2, IRF4 en FOXP1 in de meeste 
MTX-geassocieerde B-LPD-gevallen en monotypische aankleuring voor intracytoplasmatische 
immuunglobulines in de helft van deze gevallen. EBV-positieve MTX-geassocieerde B-LPD ver-
schilden van PCLBCL-LT wat betreft ulcererende huidlaesies, uitgesproken tumorcelpolymor-
fisme, verminderde immuunhistochemische aankleuring voor CD79a en expressie van CD30 
en EBV. EBV-negatieve gevallen toonden morfologisch en immuunhistochemisch duidelijke 
overeenkomsten met PCLBCL-LT, maar verschilden met name in klinische presentatie, waar-
bij 4 van de 5 gevallen zich presenteerden met gegeneraliseerde huidlaesies. Het relatief 
gunstige klinische beloop en de spontane ziekteregressie na slechts het stoppen van de be-
handeling met MTX in een aanzienlijk deel van deze patiënten benadrukt het belang van een 
zorgvuldig ‘wait-and-see’-beleid alvorens een meer agressieve behandeling te overwegen.
 
Concluderende opmerkingen
Door de verschillende studies die in dit proefschrift zijn beschreven is er meer inzicht ver-
kregen in de clinicopathologische (en genetische) aspecten van PCFCL, PCLBCL-LT en MTX-ge-
associeerde B-LPD van de huid. De resultaten zijn behulpzaam in het beter definiëren van 
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deze aparte entiteiten en leveren daarmee aanknopingspunten voor het diagnosticeren van 
deze lymfomen in de klinische praktijk. De verschillen in microRNA-profielen tussen PCFCL 
en PCLBCL-LT ondersteunen nogmaals de opvatting dat PCFCL en PCLBCL-LT verschillende 
moleculaire entiteiten zijn met een verschillend biologisch gedrag. Op het moment is ver-
betering van de behandeling van PCLBCL-LT dringend gewenst. Het in detail in kaart brengen 
van moleculaire en/of genetische afwijkingen in de ontwikkeling en/of progressie van dit lym-
foom zou potentiële aanknopingspunten voor doelgerichte behandeling kunnen opleveren. 
In het licht hiervan heeft de studie beschreven in hoofdstuk 4 van dit proefschrift aange-
toond dat componenten van de NF-κB-signaaltransductieroute interessante therapeutische 
aangrijpingspunten zouden kunnen zijn. Doelgerichte behandeling op basis van specifieke 
moleculaire kenmerken wordt uitgebreid onderzocht in nodale DLBCL en daarom is het van 
belang om dezelfde moleculaire karakteristieken ook in PCLBCL-LT te onderzoeken. Op die 
manier kan vastgesteld worden of deze therapieën ook toegepast kunnen worden bij de be-
handeling van patiënten met PCLBCL-LT.
De geobserveerde verschillen tussen MTX-geassocieerde B-LPD van de huid en PCFCL en 
PCLBCL-LT zouden clinici goede aanknopingspunten kunnen geven om deze zeldzame aan-
doening te kunnen diagnosticeren. Het is echter nog onbekend welke patiënten spontane 
remissie zullen tonen na het stoppen van de behandeling met MTX en welke een progressief 
ziektebeloop zullen tonen en daarom agressievere behandeling behoeven. Verder onderzoek 
naar de moleculaire en genetische achtergrond van MTX-geassocieerde B-LPD in de huid is 




Lianne Koens werd geboren op 29 juli 1982 te Delft. Zij groeide op in Pijnacker en doorliep 
haar middelbare school aan het Stanislascollege te Delft. Na het behalen van het eindexamen 
gymnasium in 2000, begon zij in datzelfde jaar met de studie Biomedische Wetenschappen 
aan de Rijksuniversiteit Leiden. Dit jaar werd afgerond met een propedeuse en in 2001 volgde 
de overstap naar de studie Geneeskunde aan dezelfde universiteit. Aan het eind van haar co-
schappen volgde zij gedurende 10 weken een keuzecoschap Hematopathologie in het Leids 
Universitair Medisch Centrum. In 2007 werd het artsexamen behaald. Vanaf oktober 2007 
was zij werkzaam als AIOSKO (arts in opleiding tot specialist en klinisch onderzoeker) op de af-
deling Pathologie van het Leids Universitair Medisch Centrum met in eerste instantie prof. dr. 
G.J. Fleuren en later prof. dr. V.T.H.B.M. Smit als opleider. In 2009 werd officieel aangevangen 
met een promotieonderzoek naar primair cutane grootcellige B-cellymfomen onder bege-
leiding van prof. dr. R. Willemze (afdeling Dermatologie, Leids Universitair Medisch Centrum). 
Als verdiepingsstage in de opleiding tot patholoog bezocht zij in 2014 drie maanden de af-
deling Hematopathologie van het UCLA Medical Center in Los Angeles onder begeleiding 





Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid 
arthritis. 
Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM. 
Acta Dermato Venereologica 2009; 89(6): 653-654.
IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, 
leg type from primary cutaneous follicle center lymphoma. 
Koens L, Vermeer MH, Willemze R, Jansen PM.
The American Journal of Surgical Pathology 2010; 34(7): 1043-1048.
MicroRNA profiling of primary cutaneous large B-cell lymphomas.
Koens L, Qin Y, Leung WY, Hageman L, Corver WE, Jansen PM, Willemze R, Vermeer MH, 
Tensen CP.
(Abstract) Journal of Hematopathology 2012; 5: 256-257.
Impact of the microenvironment on the prognosis of primary bone diffuse large B-cell 
 lymphoma.
Szepesi A, Rajnai H, Tímár B, Heyning FH, Koens L, Csomor J, Matolcsy A. 
(Abstract) Journal of Hematopathology 2012; 5: 267.
Nuclear factor-κB activation in primary lymphoma of bone. 
Koens L, Heyning FH, Szepesi A, Matolcsy A, Hogendoorn PC, Jansen PM. 
Virchows Archiv: an International Journal of Pathology 2013; 462(3): 349-354.
MicroRNA Profiling of Primary Cutaneous Large B-Cell Lymphomas. 
Koens L, Qin Y, Leung WY, Corver WE, Jansen PM, Willemze R, Vermeer MH, Tensen CP. 
Public Library of Science ONE 2013; 8(12): e82471.
The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary 
diffuse large B-cell lymphoma of bone. 
Rajnai H, Heyning FH, Koens L, Sebestyén A, Andrikovics H, Hogendoorn PC, Matolcsy A, 
 Szepesi A. 
Virchows Archiv: an International Journal of Pathology 2014; 464(2): 229-239.
Programmed death-1 expression in cutaneous B-cell lymphoma. 
Cetinozman F, Koens L, Jansen PM, Willemze R. 
Journal of Cutaneous Pathology 2014; 41(1): 14-21.
154
Nuclear Factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell 
 lymphoma, leg type. 
Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, Vermeer MH, Willemze R, 
 Jansen PM, Schmidt CA, Tensen CP. 
Journal of Investigative Dermatology 2014; 134(1): 290-292.
Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a 
 clinicopathologic and immunophenotypical study of ten cases. 
Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM.
The American Journal of Surgical Pathology 2014; 38(7): 999-1006.
Genetic alterations in B-cell activation-related transcription factors in primary cutaneous 
large B-cell lymphoma, leg type.
Koens L, Zoutman WH, Winkler P, Przybylski GK, Vermeer MH, Willemze R, Jansen PM, 
Schmidt CA, Tensen CP.
Submitted.
Acute eosinophilic pneumonia.












Medewerkers onderzoekslaboratium Huidziekten 
(met name Qin, Wim, Coby en Leslie)
Leden Landelijke Werkgroep Cutane Lymfomen




Wim Corver en Jan Oosting
Stéphanie Boonk en Fatoş Çetinözman
Franziska Pfau en Lois Hageman
Medeonderzoekers kamer P3-35
Pathologen en AIOS LUMC
Medewerkers afdeling pathologie LUMC
Paranimfen Marloes en Suzanne
Dinomar Daal
Liesbeth, Eveline, Katja en Marinke
Dacia, Rosanne, Jennifer, Esther en Esther
Dorottya, Marjan, Femke en Ellen
Toos, Wendy en Martijn 
Bedankt voor de prettige begeleiding, samenwerking en/of ondersteuning in de  
periode dat dit proefschrift tot stand is gekomen!



